


Renata Annual Report

2021-2022





Syed Humayun Kabir
Founder Chairman
(1931 - 2015)



Renata Limited

PABX : 8001450-54
Fax : 880-2-8001446
Email : renata@renata-ltd.com
Website : www.renata-ltd.com

Corporate Headquarters: Plot No. 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh

TRANSMITTAL LETTER

The Shareholders
Bangladesh Securities and Exchange Commission
Registrar of Joint Stock Companies & Firms
Dhaka Stock Exchange Ltd.

Sub: Annual Report for the year ended June 30, 2022

Dear Sir/Madam (s)

We are pleased to enclose a copy of our Annual Report and Audited Accounts including a Statement of Financial Position, a Statement of Comprehensive Income, and notes and annexes as needed for the year that ended June 30, 2022. We hope you enjoy reviewing the Report and seeing how Renata has grown as a company over the past year.

Yours sincerely,

Md. Jubayer Alam
Company Secretary
October 22, 2022

RENATA LIMITED

Corporate Headquarters: Plot # 1, Milk Vita Road
Section-7, Mirpur, Dhaka-1216

October 22, 2022

NOTICE

NOTICE is hereby given that the 49th Annual General Meeting of Renata Limited will be held on Saturday, December 17, 2022 at 11.30 am through Digital Platform Link- <https://agmbd.live/renata2022> (in pursuance with BSEC Order SEC/SRMRC/04-231/25 dated 08 July 2020) to transact the following business :

AGENDA

Agenda-1: To receive, consider and adopt the Audited Accounts of the Company for the year ended June 30, 2022 together with Reports of the Auditors and the Directors.

Agenda-2: To declare dividend for the year which ended on June 30, 2022 (See note ii).

Agenda-3: To elect Directors, in accordance with the relevant provisions of the Articles of Association of the Company.

Agenda-4: To appoint Auditors for the year 2022-23 and to fix their remuneration.

Agenda-5: To appoint Compliance Auditors for the year 2022-23 and to fix their remuneration.

By Order of the Board



(Md. Jubayer Alam)
Company Secretary

NOTES:

- i) The 'Record Date' (in lieu of Book Closure) is Thursday, November 10, 2022. The Shareowners whose name will appear in the Share Register of the Company and in the Depository Register on that Date will be eligible to attend the meeting and qualify for the Dividend to be declared at the AGM.
- ii) The Directors have recommended @ 140% cash dividend for year 2021-2022 and stock dividend (bonus share) @ 7% for the year ended June 30, 2022.
- iii) A member entitled to attend and vote at the Annual General Meeting may appoint a proxy to attend and vote on his/her behalf. The Proxy Form, duly completed, must be deposited at the Registered Office of the Company at Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216 or sent through e-mail at aunikfarid@renata-ltd.com not later than 48 hours before the time fixed for the Meeting.
- iv) Members are requested to notify change of address, if any, to the Company. For BO A/C holders, the same to be rectified through their respective Depository Participants.
- v) In Compliance with the BSEC Notification No.BSEC/CMRRCD/2006-158/208/Admin/81 dated 20 June 2018, Annual Report 2021-2022 will be duly sent in soft copy to the respective shareholders e-mail addresses available in their Beneficial Owner (BO) Accounts maintained with the DP. These will also be available in Company's website: www.renata-ltd.com
- vi) Full login/participation process Digital Platform Meeting will also be available in the Company's website: www.renata-ltd.com
- vii) For any IT related guidance in this regard Members may contact cell number **01811-415502**

TABLE OF CONTENTS

1	Company Profile
3	Our Values
4	Our Mission and Vision
7	Chairman's Statement
21	Board of Directors
26	Corporate Governance
27	Directors' Report
56	Financial Highlights
57	Financial Trend
61	Statement of Value Addition
62	Corporate Social Responsibility
65	Product Portfolio



Renata (UK) Limited and Renata Pharmaceuticals (Ireland) Limited

139	Renata (UK) Limited and Renata Pharmaceuticals (Ireland) Limited
-----	---



Financial Statements of Renata Limited

81	Auditors' Report
91	Statement of Financial Position
92	Statement of Profit or Loss & Other Comprehensive Income
93	Statement of Changes in Equity
94	Cash Flow Statement
99	Notes to the Financial Statements

140	Corporate Directory
-----	---------------------

141	Proxy Form
-----	------------

Company Profile

**Year of Incorporation**

1972 as Pfizer Laboratories (Bangladesh) Limited, subsidiary of Pfizer Corporation, USA

Change of Name

1993 Renamed as Renata Limited after divestment of shareholdings by Pfizer Corporation, USA

Field of Business

Manufacturing, Marketing & Distribution of Human Pharmaceuticals,
Animal Health Medicines, Nutritionals, and Vaccines

Contract Manufacturing

General products for UNICEF and SMC

Certification:**MHRA Certificate**

Medicines and Healthcare products Regulatory Agency, UK has issued a Certificate of GMP Compliance of a Manufacturer to Renata Limited for our Potent Products Facility at section 7, Mirpur, Dhaka & Rajendrapur General Facility, Rajendrapur, Gazipur, Bangladesh

ANVISA Certificatie

The Brazilian Health Regulatory Agency (ANVISA) has issued a Certificate of GMP to Renata Limited at Plot 1, Milk Vita Road, Section 7, Mirpur, Dhaka & Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, Bangladesh

Marketing & Distribution Rights

- Evans Vanodine International (UK): Animal farm disinfectants
- Zinpro Corporation (USA)
- Biomin Holding GmbH (Austria): Animal nutritional products
- Elanco(New Zealand): Animal health products
- Novus (USA): Animal health products
- Natural Herbs Ltd., India
- Syva, Spain
- Huve Pharma, SEA, Bulgaria
- Vaxxinova International BV, Netherland
- Intron Life Sciences, Thailand
- Nutrex, Belgium
- AHC, Netherlands
- SILVA TEAM, Italy

Investment in Subsidiaries

- 100% Shareholding in Renata (UK) Limited
- 100% Shareholding in Renata Pharmaceuticals (Ireland) Limited



BANKERS

Agrani Bank Limited
Bank Asia Limited
Brac Bank Limited
Commercial Bank of Ceylon
Citibank, N.A.
Eastern Bank Limited
Standard Chartered Bank
Sonali Bank Limited
The City Bank Limited
The Hongkong and Shanghai Banking
Corporation Limited (HSBC)

AUDITOR

ACNABIN, Chartered Accountants

LEGAL ADVISORS

Dr. M. Zahir and Associates
Vertex Chambers
Hoque & Associates

CORPORATE HEADQUARTERS


Plot # 1, Milk Vita Road, Section-7
Mirpur, Dhaka-1216, Bangladesh

MANUFACTURING SITES

Plot # 1, Milk Vita Road, Section-7
Mirpur, Dhaka-1216, Bangladesh

Noyapara, Bhawal Mirzapur
Rajendrapur, Gazipur, Bangladesh

Kashor Herbal Facility, Kashor
Hobirbari, Bhaluka, Mymensingh



Our Values



Customer Focus

Customer satisfaction is the main reason behind all our activities.



Integrity

We conform to the highest ethical standards.



Social Responsibility

We make active efforts to improve the welfare of our community.



Building Leaders

Renata cannot grow without leadership in all spheres of our activities. Therefore creating leaders is a key priority.



The Corporate Family

We recognise that people are the cornerstone of Renata's success. We are one big family where each of us expects to be treated fairly and with dignity.




Our Mission

To provide maximum value to our customers,
and communities where we live and work.



Approach to Quality

The endurance of a company's reputation depends upon
the quality of work it does rather than the quantity.
Hence, the appreciation of quality must be instinctive,
and our commitment to quality must be total.



Our Vision


To establish Renata permanently among the best of
innovative branded generic companies.

Renata Limited for being recognized in credit rating as a

AAA
RATED COMPANY
for consecutive three years



ICMAB BEST CORPORATE AWARD-2020



**TAX PAYER AWARD AMONG
PHARMACEUTICAL & CHEMICAL INDUSTRY**





Dr. Sarwar Ali
Chairman

Chairman's Statement

Welcome to the 49th Annual General Meeting of Renata Limited.

The Company results in FY 2021-22 did not maintain traditional growth rates essentially for external reasons. Net Profit and Sales grew by only 1.51% and 6.22% respectively. Two factors explain this performance: First, there was no Government procurement of birth control pills in the last fiscal year. As a result, our contract-manufacturing business suffered a significant setback. Second, the Taka depreciated by more than 20% against the US Dollar within a very short period. The ensuing exchange rate loss adversely affected our fourth quarter performance.

The fall in the value of the Taka is of course related to a variety of inauspicious developments around the world. Just as the global economy was recovering from a pandemic-induced recession, the war in Ukraine plunged almost all non-oil producing countries into stagflation. Moreover, in the fight against domestic inflation, the Federal Reserve Bank in America raised interest rates which sent the value of the dollar soaring against all currencies.

Since the pharmaceutical business in Bangladesh is primarily an import-substituting activity, a precipitous fall of the Taka creates challenging conditions. In addition, the global oil shock has led to uncertainties in terms of pricing and availability of energy.

Companies such as ours that are financially robust can ride out such turbulent times. The accumulated strength from 25 years of steady growth provides confidence that we shall eventually emerge relatively unscathed from this difficult period.

It is therefore essential to affirm that we do not intend on making any alterations to our long-term strategies. However, we must undertake certain steps to ensure that we remain in sync with our broader goals. These measures must be implemented over both the short and longer term:

Short-Term Measures

Protection Against further Depreciation of the Taka: The common sense approach is not have any foreign- currency denominated loans for the foreseeable future. Therefore, whenever feasible, all our UPAS positions should be converted into short-term Taka loans.

Presently, it is proving difficult to obtain forward-coverage against import LCs. However, we must avail opportunities that arise periodically.

Improving Liquidity: In 2021-22, capital expenditure carried out by Renata was a historical high. We created two state-of-the-art factories in Kashor, Bhaluka, expanded production capacity and capabilities of factories on all our four sites, and augmented R&D facilities in Mirpur.

About 70% of this capital expenditure was financed through retained earnings. The remainder needs to be converted into long-term loans to improve our cash-flow.

Investment expenditure in 2022-23 is expected to be considerably lighter. Therefore, all other things remaining the same, cash flow should improve simply because of lower spending on capital items.

Restoring Profitability: Depreciation of the Taka has raised the effective cost of raw materials. Realistically, the only way of neutralising the extra cost is by raising product prices. We have therefore, as other members of the Industry begun the process of modestly increasing prices on selected products.

Longer-Term Measures

Regular Improvement in Manufacturing Productivity: Adoption of newer technology, larger batch sizes, and optimisation of production processes increase yields and also reduce costs. These productivity measures must be reviewed regularly and alternations made as and when needed. The ground floor of the newly built Kashor General Facility (KGF) has been especially designed for large volume production. Rajendrapur General Facility (RGF) is customised for mid-size operations, while Mirpur General Facility (MGF) is ideal for small batch manufacturing. In addition, there are ten factories for manufacturing specialised products.

It should also be emphasised, that within each factory, considerable investments have been made to improve product-handling and batch turnaround times.

New Dosage Forms: New factories and upgradation of existing factories shall enable us to introduce new dosage forms in respiratory care, hormone therapy, and oncology. By the time this report is published, Renata would have launched Inhalers. Moreover, in early 2023, we expect to launch injectable products in hormones and oncology.

Invest Heavily in Product Development and R&D: In earlier reports, I have emphasised the need for a large portfolio of products for competing in generic markets. In addition, there is a pressing need for moving up the value-chain through patent challenges and novel products.

As such, Renata has been making heavy investments in product development and R&D for the last few years. I am happy to note that our progress has been impressive. Table No. 1 provides an idea about our development capabilities. In Fiscal Year 2021-22, Renata carried out 18 bioequivalent studies, of which 14 were successful.

During this period, we have also filed three products in UK, Ireland, Malta, and Germany. In addition, we have filed patent-challenges (NCE-1) for two products in the USA. These products are awaiting litigation. Biostudies for two more NCE-1 products are being prepared. (NB: NCE-1 products seek the first opportunity for generic drug filing into branded drug markets. Generic launch is dependent on many factors, including FDA approval and patents)

Set Benchmark Quality for the Bangladesh Market: In the 1970s, our predecessor company, Pfizer (Bangladesh) Limited set the benchmark for product-quality, which became its primary comparative advantage. However, over the years, local companies upgraded their production processes, and product-quality became standardised

TABLE NO. 1 Product Development Activity for Stringently Regulated Markets during 2021-22

				Study Outcome	
BCS Classification	PRODUCT CODE	Type	Study Condition	PASS	FAIL
III	Drug No. 1	Pivotal	Fasting	Pass	
IV	Drug No. 2	Pivotal	Fed	Pass	
IV	Drug No. 3	Pivotal	Fasting	Pass	
Not Established	Drug No. 4	Pivotal	Fasting	Pass	
III	Drug No. 5	Pivotal	Fasting	Pass	
II	Drug No. 6	Pivotal	Fed	Pass	
IV	Drug No. 7	Pivotal	Fed	Pass	
NA	Drug No. 8	Pivotal	Fasting	Pass	
II	Drug No. 9	Pivotal	Fasting		Fail
SUBTOTAL A	9	9		8	1
IV	Drug No. 7	Pilot	Fasting	Pass	
II	Drug No. 10	Pilot	Fasting	Pass	
I	Drug No. 11	Pilot	Fasting	Pass	
II	Drug No. 12	Pilot	Fasting	Pass	
II	Drug No. 13	Pilot	Fasting	Pass	
Not Established	Drug No. 14	Pilot	Fasting	Pass	
II	Drug No. 15	Pilot	Fasting		Fail
II	Drug No. 16	Pilot	Fasting		Fail
IV	Drug No. 17	Pilot	Fasting		Fail
SUBTOTAL B	9	9		6	3
TOTAL	17	18		14	4

NB: Two products are considered to be bioequivalent **when they are equal in the rate and extent to which the active pharmaceutical ingredient (API) becomes available at the site(s) of drug action.** For registration in markets such as US and EU, more often than not, a generic drug must be bioequivalent to the inventor product.

TABLE NO. 2 Bioequivalent Products of Renata Limited

Generic	Renata Brand	Generic	Renata Brand
1. Amantadine HCl capsules	Mantadin	25. Imatinib FC tablets	Tyrokin
2. Apixaban FC tablets	Apilyte	26. Letrozole FC tablets	Letrol
3. Azithromycin tablets	Zithrin	27. Levonorgestrel 0.15mg + EE 0.03mg sugar coated tablets	Generic only
4. Bempodoic Acid tablets	Generic only	28. Levonorgestrel 1.5mg tablets	Emcon 1
5. Cabergoline 0.5mg tablets	Cabolin	29. Levothyroxine sodium tablets	Thyrox
6. Cabergoline 2mg tablets	Generic only	30. Memantine tablets	Generic only
7. Carbimazole tablets	Generic only	31. Meropenem Injection	Meropen
8. Clindamycin capsules	Qcin	32. Metolazone tablets	Generic only
9. Clomifene citrate tablets	Ovulet	33. Metoprolol Tartrate tablets	Generic only
10. Colchicine 500mcg tablets	Generic only	34. Naratriptan FC tablets	Generic only
11. Cyproterone Acetate 2mg + Ethinylestradiol 0.035 mg tablets	Giane	35. Nefopam HCl FC tablets	Generic only
12. Desogestrel 0.15 mg + Ethinylestradiol 0.03 mg tablets	Desolon	36. Olmesartan tablets	Rezor
13. Desogestrel tablets	Bredicon	37. Pazopanib tablets	Pazoren
14. Dicycloverine HCl tablets	Generic only	38. Pregabalin capsules	GABA-P
15. Dipyridamole MR capsules	Generic only	39. Propylthiouracil tablets	PTU
16. Doxepin Capsules	Generic only	40. Rifampicin 300 mg capsules	Generic only
17. Drospirenone 3 mg + Ethinylestradiol 0.03 mg tablets	Novelon	41. Risperidone tablets	Sperid
18. Escitalopram tablets	Escilex	42. Rivaroxaban FC tablets	Roxolyte
19. Esomeprazole MUPS tablets	Maxpro MUPS	43. Rosuvastatin Calcium tablets	Rolip
20. Febuxostat FC tablets	Feburen	44. Sertraline tablets	Seronex
21. Fludrocortisone tablets	Generic only	45. Sildenafil FC tablets	Performax
22. Frovatriptan tablets	Generic only	46. Tadalafil FC tablets	Durevolis
23. Glycopyrronium tablets	Generic only	47. Telmisartan tablets	Telpro
24. Hydrocortisone tablets	Generic only	48. Terbinafine tablets	Terbimax
		49. Topiramate 200 mg tablets	Topmate
		50. Upadacitinib tablets	Generic only

TABLE NO. 3 Farm Prices for Poultry Products

	Eggs		Day Old Chicks			Live Broiler
	Red	White	Broiler	Layer	Sonali	per Kg
July 2021	8.42	8.00	30.50	23.24	11.80	115.00
August 2021	8.40	8.02	28.60	22.50	12.30	124.00
September 2021	8.30	7.95	27.40	23.00	11.90	118.00
October 2021	8.26	7.96	25.40	23.50	16.20	112.00
November 2021	8.20	7.90	24.00	23.00	14.50	124.00
December 2021	8.16	7.90	28.50	22.50	18.00	115.00
January 2022	8.26	7.94	43.50	26.00	11.00	126.00
February 2022	8.45	8.02	54.20	35.00	15.00	122.00
March 2022	8.46	8.03	52.00	24.00	22.50	118.00
April 2022	8.45	8.02	35.00	22.00	10.50	110.00
May 2022	8.50	8.05	16.50	23.00	9.00	115.00
June 2022	8.56	8.12	15.50	11.00	8.50	116.00

across the larger companies. In other words, “Quality” was no longer a distinguishing feature.

However, as a direct result of our investment in R&D and product-development, Renata now has 50 bioequivalent products – far more than any of our competitors. This feature of our product portfolio has once more brought forth the opportunity to set Industry standards for “Quality.”

In all stringently regulated markets, generics cannot be registered unless clinical tests on healthy volunteers demonstrate bioequivalence with the inventor product. *(NB: There are limited exceptions to this rule)*

While bioequivalence is not a regulatory requirement in Bangladesh, because of the efforts of our young scientists, Renata is pre-empting harmonisation of domestic regulatory standards with those of the best.

This emphasis on product development is undoubtedly improving our prospects in Bangladesh and elsewhere. In the meantime, the earlier drive to enhance exports through global institutional markets is showing promising results. Exports grew by 49%, primarily due to orders from such institutions.

I now take a very brief look at our constituent businesses:

Pharmaceutical: The market grew at 15.15%. Our growth of 15.24% was therefore only slightly above par. However, we should not read too much into this comparative performance because Covid-19 had distorted the pharmaceutical market in 2020-21, which led to absurd level of push-sales, completely unrelated to actual demand. So, the comparison of 2021-22 with an unusual year is not meaningful.

In an encouraging development for long-term growth, the share of chronic care and OTC products in total sales rose significantly. Our sales rank remained unchanged at No. 4.


Animal Health: Recessionary conditions (Table No. 3) in the poultry market depressed the overall growth for Animal Health products. Renata grew at 5.28% against market growth of only 2.37%.

Almost all of the miniscule growth in the Industry can be attributed to farms rearing large animals.

Renata retained its market leadership position.

Contract-Manufacturing: The public vaccination programme against Covid-19 understandably diverted time and resources from other programmes. As such, there was no procurement of birth-control pills by the Government last year. Instead, the national Family Programme operated by running down existing stocks. Predictably therefore, our fast growing contract-manufacturing business suffered a serious setback. Sales fell by –57.36%. On a positive note, we expect procurement to resume in the current fiscal year.

Outlook for 2022-23: The Pandemic and fallout from the Ukraine war have created debilitating conditions that have not been witnessed by more than one generation. I shall therefore refrain from making customary predictions for the next fiscal year except for saying that historical evidence suggests that the strong not only survive Black Swan events, but also emerge stronger. With history on our side, Renata shall continue to deliver strong performances.



Dr. Sarwar Ali
Chairman
October 22, 2022

চেয়ারম্যানের প্রতিবেদন

রেনাটা লিমিটেডের ৪৯তম বার্ষিক সাধারণ সভায় স্বাগতম।

২০২১-২২ অর্থবছরে কোম্পানীর প্রথাগত প্রবৃদ্ধির হার বজায় রাখতে পারিনি মূলত বৈশ্বিক কারনে। নীট মুনাফা ও বিক্রয়ের প্রবৃদ্ধি হয়েছে যথাক্রমে ১.৫১% এবং ৬.২২%। মূলতঃ দুটি কারনে এই ফলাফল হয়েছে। প্রথমতঃ গত অর্থ বছরে সরকার কোন জন্ম নিয়ন্ত্রণ বড়ি ক্রয় করে নাই। যার ফলে আমাদের কন্ট্রোল ম্যানুফ্যাকচারিং ব্যবসায় ব্যাপক ধাক্কা লেগেছে। দ্বিতীয়তঃ খুব অল্প সময়ের মধ্যে মার্কিন ডলারের বিপরীতে টাকার ২০% এর বেশী অবমূল্যায়ন হয়েছে, যাহা ৪র্থ কোয়ার্টারে ডলারের এই বিনিময় হার আমাদের পারফরম্যান্সে বিরূপ প্রভাব ফেলে।

টাকার এই মূল্য পতন অবশ্যই বিশ্বের বিভিন্ন অঞ্চল প্রভাবের সাথে সম্পর্কিত। বৈশ্বিক অর্থনীতি যেমন মহামারী প্ররোচিত মন্দা থেকে পুনরুদ্ধার হয়েছিল, ইউক্রেনের যুদ্ধে তেল অনুৎপাদনকারী সকল দেশগুলোকে অচলাবস্থায় নিমজ্জিত করেছে। অধিকন্তু, আভ্যন্তরীণ মুদ্রাস্ফীতির বিরুদ্ধে লড়াইয়ে আমেরিকার ফেডারেল রিজার্ভ ব্যাংক সুদের হার বাড়িয়ে ছিল, ফলে সমস্ত মুদ্রার বিপরীতে ডলারের মূল্য বৃদ্ধি পায়।

যেহেতু বাংলাদেশে ফার্মাসিউটিক্যাল ব্যবসা প্রাথমিক ভাবে আমদানি নির্ভর, তাই টাকার এই দ্রুত পতন চ্যালেঞ্জিং পরিস্থিতি তৈরী করে। অধিকন্তু বিশ্বব্যাপী তেলের এই ধাক্কার কারনে উপকরনের মূল্য ও প্রাপ্যতার ক্ষেত্রে অনিশ্চয়তার দিকে পরিচালিত করেছে।

আমাদের মত আর্থিক ভাবে শক্তিশালী কোম্পানীগুলো এই ধরনের খারাপ পরিস্থিতিতে কার্যক্রম চালাতে পারে। পর্চিশ বছর ধারাবাহিক ভাবে প্রবৃদ্ধি অর্জন থেকে অর্জিত শক্তি আমাদের আত্মবিশ্বাস প্রদান করে যে, এই কঠিন সময়ে আমরা তুলনামূলক ভাবে অক্ষত থাকব। তাই এটা নিশ্চিত করা অপরিহার্য যে আমরা আমাদের দীর্ঘ মেয়াদী পরিকল্পনাগুলিতে কোন পরিবর্তন আনতে চাই না। যাই হোক, আমাদের বৃহত্তর লক্ষ্যগুলির সাথে সুসংগত থাকা নিশ্চিত করতে হবে। এই ব্যবস্থাগুলি স্বল্প এবং দীর্ঘমেয়াদী উভয় ক্ষেত্রেই প্রয়োগ করা আবশ্যিক।

স্বল্পমেয়াদী ব্যবস্থাঃ

টাকার আরও অবমূল্যায়নের বিরুদ্ধে সুরক্ষাঃ টাকার আরও অবমূল্যায়নের ফলে লোকসান থেকে বাঁচার সাধারণ কৌশল হল অদূর ভবিষ্যতে কোন বৈদেশিক মুদ্রার লোন না থাকা। অতএব, যখনই সম্ভব আমাদের সমস্ত ইউ-পাস ঋণগুলোকে স্বল্পমেয়াদী ঋণে (টাকাতে) রূপান্তরিত করা। বর্তমানে আমদানী এলসির বিপরীতে ফরোয়ার্ড কভারেজ পাওয়া বেশ কঠিন হচ্ছে। যাই হোক, আমাদের অবশ্যই পর্যায়ক্রমে প্রাপ্ত সুযোগগুলোর ব্যবহার নিশ্চিত করতে হবে।

তারল্যের উন্নতিঃ ২০২১-২২ সালে রেনাটার মূলধন ব্যয় একটি ঐতিহাসিক মাইলফলক। আমরা কাশর ও ভালুকায় দুটি অত্যাধুনিক কারখানা তৈরী করেছি, আমাদের চারটি সাইটের কারখানায় উৎপাদন ক্ষমতা ও সক্ষমতা বৃদ্ধি করেছি এবং মিরপুরে R&D সুবিধা বৃদ্ধি করেছি।

আমাদের মূলধন ব্যয়ের ৭০% অর্থায়ন করা হয়েছে পূর্বের সঞ্চিত আয় থেকে। আমাদের নগদ প্রবাহের উন্নতির জন্য অবশিষ্ট ব্যয়কে দীর্ঘ মেয়াদী ঋণে রূপান্তর করতে হবে।

২০২২-২৩ সালে বিনিয়োগ ব্যয় হবে তুলনামূলক সীমিত পরিমাপের। সুতরাং অন্যান্য জিনিসগুলো অপরিবর্তিত থাকবে এবং মূলধন ব্যয় কম হওয়ার কারনে নগদ প্রবাহের উন্নতি হবে।

মুনাফার পুনরুদ্ধারঃ টাকার অবমূল্যায়নের কারনে কাঁচামালের জন্য খরচ বেড়ে গেছে। প্রকৃতপক্ষে অতিরিক্ত খরচ সময়ের একমাত্র উপায় হলো পনের দাম বাড়িয়ে দেওয়া। তাই এই শিল্পের অন্যান্য সদস্যদের ন্যায় আমরাও কিছু পনের যুক্তিসংগত দাম বাড়ানো শুরু করেছি।

দীর্ঘমেয়াদী ব্যবস্থাঃ

উৎপাদনশীলতার নিয়মিত উন্নতিঃ নতুন প্রযুক্তি, বৃহৎ ব্যাচের আকার এবং উৎপাদন প্রক্রিয়ার অপটিমাইজেশনে উৎপাদন বৃদ্ধি পায় এবং খরচ কমে। তাই উৎপাদনশীলতা নিয়মিত পরিমাপ করা এবং প্রয়োজনে পরিবর্তন করতে হবে। বড় আকারের উৎপাদনশীলতার জন্য কাশরের নতুন জেনারেল ফেসিলিটির (KGF) নীচ তলা বিশেষ ভাবে ডিজাইন করা হয়েছে। রাজেন্দ্রপুর জেনারেল ফেসিলিটি (RGF) মাঝারী আকারের অপারেশন এর জন্য কাষ্টমাইজ করা হয়েছে। অন্যদিকে মিরপুর জেনারেল ফেসিলিটি (MGF) ছোট ব্যাচের উৎপাদনের জন্য আদর্শ হবে। এ ছাড়াও বিশেষায়িত পন্য তৈরীর জন্য দশটি কারখানা রয়েছে। প্রতিটি কারখানার মধ্যে পন্য-হ্যান্ডলিং এবং টার্ন-এরাউন্ড সময় উন্নত করার জন্য যথেষ্ট বিনিয়োগ করা হয়েছে।

নতুন ডোজ ফর্মঃ নতুন কারখানা এবং বিদ্যমান কারখানাগুলোর আপগ্রেডেশনের ফলে আমরা শ্বাসতন্ত্র, হরমোন এবং ক্যান্সারের নতুন ডোজ ফর্ম চালু করতে সক্ষম হব। এই রিপোর্ট প্রকাশিত হওয়ার মধ্যে রেনাটা ইনহেলার বাজারজাত করবে। তদুপরি ২০২৩ সালের প্রথম দিকে আমরা হরমোন এবং ক্যান্সারের ইনজেকশন চালু করার আশা করছি।

গবেষণা এবং উন্নয়নে প্রচুর বিনিয়োগঃ পূর্ববর্তী প্রতিবেদনগুলোতে আমি জেনেরিক বাজারে প্রতিযোগিতা করার জন্য একটি বড় পোর্টফোলিও প্রয়োজনীয়তার উপর জোর দিয়েছিলাম। উপরন্তু, লান্ডের পরিমাণ বাড়াতে গেলে পেটেন্ট এবং নতুন মলিকিউলে বিনিয়োগ আবশ্যকীয়। যেমন, রেনাটা গত কয়েক বছর ধরে পণ্য উন্নয়ন এবং গবেষণায় ব্যাপক বিনিয়োগ করেছে। আমি খুশি যে আমাদের অগ্রগতি বেশ ভাল। টেবিল নং-১ আমাদের উন্নয়ন সক্ষমতার একটি ধারণা প্রদান করে। ২০২১-২২ অর্থবছরে রেনাটা ১৮টি বায়ো-ইকুইভেলেন্ট পরীক্ষা করে, যার মধ্যে ১৪টি সফল হয়েছে।

এই সময়ের মধ্যে আমরা যুক্তরাজ্য, আয়ারল্যান্ড, মাল্টা এবং জার্মানিতে তিনটি প্রোডাক্ট ফাইল করেছি। উপরন্তু আমরা মার্কিন যুক্তরাষ্ট্রে দুটি পনের জন্য পেটেন্ট-চ্যালেঞ্জ (NCE-1) ফাইল করেছি। এই পন্যগুলো পাওয়ার অপেক্ষায় রয়েছি। আরও দুটি পনের NCE-1 এর জন্য বায়োেস্টাডি তৈরী করা হচ্ছে (বিদ্রঃ NCE-1 পন্যগুলি ব্রান্ডেড ওষুধের বাজারে জেনেরিক ড্রাগ ফাইল করার প্রথম সুযোগ পায় যাহা জেনেরিক লাঞ্চিং এ FDA অনুমোদন এবং পেটেন্টসহ অনেক কারনের উপর নির্ভরশীল)।

বাংলাদেশের বাজারের জন্য মানদণ্ড নির্ধারণ করাঃ ১৯৭০ এর দশকে আমাদের পূর্বসূরী কোম্পানী, ফাইজার (বাংলাদেশ) লিমিটেড পন্য মানের জন্য একটি মানদণ্ড নির্ধারণ করে, যাহা তার প্রাথমিক তুলনামূলক সুবিধা হয়ে উঠে। যাইহোক, বছরের পর বছর ধরে স্থানীয় কোম্পানীগুলো তাদের উৎপাদন প্রক্রিয়াগুলোকে আপগ্রেড করেছে ফলে পনের গুণমান, বড় কোম্পানীগুলোতে মান সম্পন্ন হয়ে উঠেছে। অন্য কথায়, শুধুমাত্র কোয়ালিটি দিয়ে প্রোডাক্টকে আলাদা করা যাচ্ছে না।

টেবিল নং-১

প্রোডাক্ট ডেভোলাপমেন্ট এন্টিভিটি ফর স্ট্রিনজেন্টলি রেগুলেটেড মার্কেট ২০২১-২২

				স্টাডি আউটকাম	
বিসিএস ক্লাসিফিকেশন	প্রোডাক্ট কোড	টাইপ	স্টাডি কন্ডিশন	পাশ	ফেইল
৩	ড্রাগ নং ১	পাইভোটাল	ফাষ্টিং	পাশ	
৪	ড্রাগ নং ২	পাইভোটাল	ফেড	পাশ	
৪	ড্রাগ নং ৩	পাইভোটাল	ফাষ্টিং	পাশ	
প্রতিষ্ঠিত না	ড্রাগ নং ৪	পাইভোটাল	ফাষ্টিং	পাশ	
৩	ড্রাগ নং ৫	পাইভোটাল	ফাষ্টিং	পাশ	
২	ড্রাগ নং ৬	পাইভোটাল	ফেড	পাশ	
৪	ড্রাগ নং ৭	পাইভোটাল	ফেড	পাশ	
প্রযোজ্য না	ড্রাগ নং ৮	পাইভোটাল	ফাষ্টিং	পাশ	
২	ড্রাগ নং ৯	পাইভোটাল	ফাষ্টিং		ফেইল
সাব টোটাল	৯	৯		৮	১
৪	ড্রাগ নং ৭	পাইলট	ফাষ্টিং	পাশ	
২	ড্রাগ নং ১০	পাইলট	ফাষ্টিং	পাশ	
১	ড্রাগ নং ১১	পাইলট	ফাষ্টিং	পাশ	
২	ড্রাগ নং ১২	পাইলট	ফাষ্টিং	পাশ	
২	ড্রাগ নং ১৩	পাইলট	ফাষ্টিং	পাশ	
প্রযোজ্য না	ড্রাগ নং ১৪	পাইলট	ফাষ্টিং	পাশ	
২	ড্রাগ নং ১৫	পাইলট	ফাষ্টিং		ফেইল
২	ড্রাগ নং ১৬	পাইলট	ফাষ্টিং		ফেইল
৪	ড্রাগ নং ১৭	পাইলট	ফাষ্টিং		ফেইল
সাব টোটাল - বি	৯	৯		৬	৩
মোট	১৭	১৮		১৪	৪

বিঃদ্রঃ কোন প্রোডাক্ট বায়ো-ইকুইভেলেন্ট হিসাবে তখনই বিবেচিত হয় যখন API এর মানব দেহের অভ্যন্তরে কার্যকারিতার হার এবং পরিমাণ উদ্ভাবকের সমান হয়। US এবং EU এর মতো বাজারে নিবন্ধনের জন্য প্রায়শই নয়, একটি জেনেরিক ওষুধ অবশ্যই উদ্ভাবক পণ্যের বায়ো-ইকুইভেলেন্ট হতে হবে।

টেবিল নং - ২

বায়ো-ইকুইভেলেন্ট প্রোডাক্টস অব রেনাটা লিমিটেড

জেনেরিক নাম	রেনাটা ব্রান্ড	জেনেরিক নাম	রেনাটা ব্রান্ড
১ আমান্টাডিন এইচসিআই ক্যাপসুল	মানটাজিন	২৫ ইমটিনিব এফসি ট্যাবলেটস্	টাইরোকিন
২ এপিপ্রাব্যান ট্যাবলেটস্	এপিলাইট	২৬ লেট্রেল এফসি ট্যাবলেটস্	লেট্রেল
৩ এজিপ্তোমাইসিন ট্যাবলেটস্	জিপ্রিন	২৭ লিভোনরজেসট্রিল ০.১৫এমজি +	
৪ বিন্সোডাইক এসিড ট্যাবলেটস্	জেনেরিক মাত্র	ইই ০.০৩৩এমজি সুগার কোটেড ট্যাবলেটস্	জেনেরিক মাত্র
৫ ক্যাবেরগোলিন ০.৫এমজি ট্যাবলেটস্	ক্যাবোলিন	২৮ লিভোনরজেসট্রিল ১.৫এমজি ট্যাবলেটস্	ইমকন-১
৬ ক্যাবেরগোলিন ২এমজি ট্যাবলেটস্	জেনেরিক মাত্র	২৯ লিভোথাইরক্সিন সোডিয়াম ট্যাবলেটস্	থাইরক্স
৭ কারবিমাজোল ট্যাবলেটস্	জেনেরিক মাত্র	৩০ মিমাস্টিন ট্যাবলেটস্	জেনেরিক মাত্র
৮ ক্লিনভামাইসিন	কিউসিন	৩১ মেরোপিন্যাম ইনজেকসন্	এ্যারোপেন
৯ ক্রোমিফেন সাইট্রেট ট্যাবলেটস্	ওভুলেট	৩২ মেটোলাজোন ট্যাবলেট	জেনেরিক মাত্র
১০ কোলহিসাইন সাইট্রেট ট্যাবলেটস্	জেনেরিক মাত্র	৩৩ মেটোপ্রোলোল টারট্রেড ট্যাবলেটস্	জেনেরিক মাত্র
১১ সাইপ্রোটারোন এসিটেট ২এমজি +		৩৪ নেরাট্রিপটিন এফসি ট্যাবলেট	জেনেরিক মাত্র
ইথিনাইলেসট্রাডিওল ০.০৩৫এমজি ট্যাবলেটস্	গায়ান	৩৫ নেফোপাম এইচসিআই এফসি ট্যালেটস্	জেনেরিক মাত্র
১২ ডিসোজেসট্রিল ০.১৫এমজি +		৩৬ ওলম্যাসারট্যান ট্যাবলেট	রেজর
ইথিনাইলেসট্রাডিওল ০.০৩এমজি ট্যাবলেটস্	ডেসোলন	৩৭ প্যাজোপানিব ট্যাবলেট	পাজোরেন
১৩ ডিসোজেসট্রিল ট্যাবলেটস্	ব্রেডিকন	৩৮ প্রিগাবালিন ক্যাসুলস্	গাবা-পি
১৪ ডাইসিক্লোভারিন এইচসিআই ট্যাবলেটস্	জেনেরিক মাত্র	৩৯ প্রোপাইলথিওরাসিল ট্যাবলেট	পিটিইউ
১৫ ডাইপিরাইডামোল এমঅর ক্যাপসুলস্	জেনেরিক মাত্র	৪০ রিফামপিসিন ৩০০এমজি ক্যাসুলস্	জেনেরিক মাত্র
১৬ ডক্সিপিন ক্যাপসুলস্	জেনেরিক মাত্র	৪১ রিসপিরিডোন ট্যাবলেট	এ্যাসপিরিওড
১৭ ড্রসপিরিনোন ৩এমজি +		৪২ রিভারোব্রাবান এফসি ট্যাবলেট	রক্সেলাইট
ইথিনাইলেসট্রাডিওল ০.০৩এমজি ট্যাবলেটস্	নভেলন	৪৩ রোসুভাসটাটিন ক্যালসিয়াম ট্যাবলেট	রোলিপ
১৮ ইসছিটালোথ্রাম ট্যালেটস্	এসসিল্যাক্স	৪৪ সারট্রালাইন ট্যাবলেট	সিরোনেক্স
১৯ ইসোমিপ্রাজল মাল্গ ট্যালেটস্	ম্যাক্সপ্রো মাল্গ	৪৫ সিলডিনাফিল এফসি ট্যাবলেট	পারফরম্যাক্স
২০ ফিবোব্রস্টাট এফসি ট্যাবলেটস্	ফেবুরেন	৪৬ টাডালাফিল এফসি ট্যাবলেট	ডিউরিভোলিন
২১ ফ্লুডোকোরটিসন ট্যাবলেটস্	জেনেরিক মাত্র	৪৭ টেলিমিসারটান ট্যাবলেট	টেলপ্রো
২২ ফ্রোভাট্রিপট্যান ট্যাবলেটস্	জেনেরিক মাত্র	৪৮ টারবিনাফাইন ট্যাবলেট	টারবিম্যাক্স
২৩ গ্লাইকোপিপেরোনাম ট্যাবলেটস্	জেনেরিক মাত্র	৪৯ টাপিরাম্যাট ২০০এমজি ট্যাবলেট	টপমেট
২৪ হাইড্রোকোরটিসোন ট্যাবলেটস্	জেনেরিক মাত্র	৫০ উপাডাসাইটিনিব ট্যাবলেট	জেনেরিক মাত্র

টেবিল নং- ৩ পোল্ট্রি খামারের জন্য খাদ্য মূল্য

মাস	ডিম		দৈনিক পুরানো বাচ্চা			জীবন্ত ব্রয়লার
	লাল	সাদা	ব্রয়লার	লেয়ার	সোনালী	প্রতি কে.জি.
জুলাই ২০২১	৮.৪২	৮.০০	৩০.৫০	২৩.২৪	১১.৮০	১১৫.০০
আগস্ট ২০২১	৮.৪০	৮.০২	২৮.৬০	২২.৫০	১২.৩০	১২৪.০০
সেপ্টেম্বর ২০২১	৮.৩০	৭.৯৫	২৭.৪০	২৩.০০	১১.৯০	১১৮.০০
অক্টোবর ২০২১	৮.২৬	৭.৯৬	২৫.৪০	২৩.৫০	১৬.২০	১১২.০০
নভেম্বর ২০২১	৮.২০	৭.৯০	২৪.০০	২৩.০০	১৪.৫০	১২৪.০০
ডিসেম্বর ২০২১	৮.১৬	৭.৯০	২৮.৫০	২২.৫০	১৮.০০	১১৫.০০
জানুয়ারী ২০২২	৮.২৬	৭.৯৪	৪৩.৫০	২৬.০০	১১.০০	১২৬.০০
ফেব্রুয়ারী ২০২২	৮.৪৫	৮.০২	৫৪.২০	৩৫.০০	১৫.০০	১২২.০০
মার্চ ২০২২	৮.৪৬	৮.০৩	৫২.০০	২৪.০০	২২.৫০	১১৮.০০
এপ্রিল ২০২২	৮.৪৫	৮.০২	৩৫.০০	২২.০০	১০.৫০	১১০.০০
মে ২০২২	৮.৫০	৮.০৫	১৬.৫০	২৩.০০	৯.০০	১১৫.০০
জুন ২০২২	৮.৫৬	৮.১২	১৫.৫০	১১.০০	৮.৫০	১১৬.০০

যাই হোক, পল্ট্রির গবেষণা ও উন্নয়নে আমাদের বিনিয়োগের প্রত্যক্ষ ফল হিসাবে রেনাটা-এর কাছে এখন ৫০টি বায়ো-ইকুইভেলেন্ট পন্য রয়েছে, যাহা আমাদের প্রতিযোগীদের থেকে অনেক বেশী। আমাদের প্রোডাক্ট পোর্টফোলিওর এই বৈশিষ্ট্যটি এই শিল্পে আরও একবার কোয়ালিটি প্রোডাক্ট এর কোম্পানী হিসাবে পরিচিত করার সুযোগ এনে দিয়েছে।

কঠোর ভাবে নিয়ন্ত্রিত বাজারে, স্বাস্থ্যবান স্বেচ্ছাসেবকদের উপর ক্লিনিক্যাল পরীক্ষাগুলি, উদ্ভাবক প্রোডাক্টের সাথে বায়ো-ইকুইভেলেন্ট প্রদর্শন না করা পর্যন্ত জেনেরিকগুলি নিবন্ধিত করা যায় না (বি.দ্রঃ এই নিয়মের সীমিত ব্যতিক্রম আছে)।

যদিও বাংলাদেশের জন্য বায়ো-ইকুইভেলেন্ট কোন বাধ্যতামূলক নয়, আমাদের তরুণ বিজ্ঞানীদের প্রচেষ্টার কারণে দেশের বাজারেও রেগুলেটরী বাজারের মানসম্পন্ন পন্য স্থানীয় বাজারে দিচ্ছি।

প্রোডাক্ট ডেভেলপমেন্ট এর উপর এই জোড় নিঃসন্দেহে বাংলাদেশ ও অন্যত্র আমাদের সম্ভাবনাকে উন্নত করেছে। ইতিমধ্যে, বৈশ্বিক প্রতিষ্ঠানিক বাজারের মাধ্যমে রপ্তানী বাড়ানোর পূর্বের প্রচেষ্টা আশাব্যঞ্জক ফলাফল দেখাচ্ছে। রপ্তানী ৪৯% বৃদ্ধি পেয়েছে মূলতঃ প্রাথমিক ভাবে এই ধরনের প্রতিষ্ঠানের অর্ডারের কারণে।

আমি এখন আমাদের মূল ব্যবসার একটি সংক্ষিপ্ত আলোকপাত করবো-

ফার্মাসিউটিক্যালঃ বাজার প্রবৃদ্ধি ছিল ১৫.১৫%। আমাদের প্রবৃদ্ধি ১৫.২৪% তাই সমমানের থেকে সামান্য উপরে ছিল। যাইহোক, আমাদের এই তুলনামূলক পারফরমেন্স খুব বেশী বলা উচিত নয়, কারণ কোভিড-১৯, ২০২০-২১ সালে ফার্মাসিউটিক্যাল বাজারকে ধ্বংস করেছিল। যেখানে প্রকৃত চাহিদার সাথে সম্পূর্ণ ভাবে সম্পর্কহীন পুশ-সেলকে অযৌক্তিকতার দিকে পরিচালিত করেছিল। সুতরাং, একটি অস্বাভাবিক বছরের সাথে ২০২১-২২ এর তুলনা অর্থবহ নয়।

দীর্ঘ মেয়াদী প্রবৃদ্ধির জন্য আশার ব্যাপার হলো, ক্রনিক কেয়ার এবং ওটিসি পল্ট্রির বিক্রয় তাৎপর্যপূর্ণ ভাবে বেড়েছে। বিক্রির দিক থেকে আমাদের র‍্যাংক-৪ এ অপরিবর্তিত আছে।

পশুস্বাস্থ্যঃ ৩নং টেবিল থেকে ধারণা পাওয়া যায় যে, পোল্ট্রি বাজারে মন্দা পরিস্থিতির জন্য পশুস্বাস্থ্য ব্যবসার প্রবৃদ্ধিকে ব্যাহত করেছে। ২.৩৭% বাজার প্রবৃদ্ধির বিপরীতে রেনাটার প্রবৃদ্ধি হয়েছে ৫.২৮%।

এই শিল্পের ছোট যে প্রবৃদ্ধি হয়েছে তার পুরোটাই গবাদিপশুর খামারিদের থেকে এসেছে। রেনাটা তার মার্কেট লিডারশিপ পজিশন ধরে রেখেছে।

চুক্তিভিত্তিক উৎপাদনঃ কোভিড-১৯ এর বিরুদ্ধে জনসাধারণের জন্য টিকাদান কর্মসূচী, সরকারের অন্যান্য কর্মসূচী থেকে তার সময় ও সম্পদগুলো দূরে সরিয়ে নিয়েছে। সেই হিসেবে গত বছর সরকার কোন জন্ম নিয়ন্ত্রণ বাড়ি ক্রয় করেনি। পরিবর্তে, জাতীয় পরিবার পরিকল্পনা কর্মসূচী বিদ্যমান স্টক নিয়েই পরিচালিত হয়েছে। বলা যায় যে, এর ফলে আমাদের চুক্তিভিত্তিক উৎপাদন ব্যবসা একটি মারাত্মক ধাক্কা খায়। বিক্রয় কমেছে ৫৭.৩৬%। ইতিবাচক দিক হলো, আমরা আশা করি চলতি অর্থবছরে এই ক্রয় পুনরায় শুরু হবে।

প্রেক্ষাপট ২০২২-২৩ঃ

মহামারী এবং ইউক্রেন যুদ্ধের বিপর্যয় যে দুর্বল পরিস্থিতি তৈরী হয়েছে তাহা প্রজন্মের পর প্রজন্ম দেখে নাই যা একের অধিক প্রজন্ম স্বাক্ষরী হতে পারবে না। আমি তাই আগামী অর্থবছরের জন্য প্রথাগত ভবিষ্যৎবানী করা থেকে বিরত থেকে শুধু এইটুকু বলতে চাচ্ছি যে, ঐতিহাসিক প্রমাণগুলি ইঙ্গিত করে যে শক্তিশালীরা কেবল ব্ল্যাক সোয়ান ইভেন্টে বেঁচে থাকে না বরং আরও শক্তিশালী হয়ে উঠে। ইতিহাস আমাদের পাশে আছে বলে, বলতে পারি রেনাটার শক্তিশালী পারফরমেন্স অব্যাহত থাকবে।



ডাঃ সারওয়ার আলী
চেয়ারম্যান
অক্টোবর ২২, ২০২২



Capital Expenditure





Capital Expenditure





Capital Expenditure





Capital Expenditure





Capital Expenditure





Capital Expenditure





R & D





Environment

The Board of Directors



Dr. Sarwar Ali, Chairman

Current Responsibilities

Chairman, Board of Directors, Renata Limited
Trustee, Liberation War Museum
Executive President, Chhayanaut
Vice President, Bangladesh Diabetic Association

Past Responsibilities

Director, Renata Limited
Managing Director, Renata Limited
Medical Director, Pfizer (Bangladesh) Limited
President Bangladesh Employers' Federation
International Councilor of IPPNW
Secretary General, Bangladesh Medical Association
Member, Dhaka University Senate
Chairman, Board of Management, BIRDEM Hospital

Education

MBBS, Dhaka Medical College

Kaiser Kabir, CEO & Managing Director

Current Responsibilities


CEO & Managing Director, Renata Limited
Member, Sajida Foundation
Executive Member, Bangladesh Aushad Shilpa Samity

Past Responsibilities

Chairman, Renata Agro Industries Limited
Chairman, Purnava Limited
Director, BRAC Bank Limited
Board Member, BRAC
Board of Directors, GAIN
Member, Finance & Audit Committee
Member, Nominations Committee
Managing Director, BRAC-Renata Agro Industries Limited
Executive Director, Sajida Foundation
National Macroeconomist, Financial Sector Reform Project
Consultant, The World Bank, RMB
Vice President, Bangladesh Association of Pharmaceutical Industries
Research Officer, Institute of Economics & Statistics, University of Oxford

Education

MPhil in Economics, University of Oxford, UK
Postgraduate Diploma in Economics with Distinction,
University of East Anglia, UK
Bachelor of Arts in Economics and International Relations,
Claremont McKenna College, USA





Zahida Fizza Kabir, Director

Current Responsibilities

Director, Renata Limited
 CEO, Sajida Foundation
 Trustee, Valor of Bangladesh
 Chairman, Psychological Health & Wellness Clinic (PHWC)
 Chairman, Inner Circle Private Limited (ICPL)
 Chairman, Home and Community Care Limited (HCCL)

Past Responsibilities

Executive Director, Sajida Foundation
 Director of Programs, Sajida Foundation
 Board Member, ActionAid Bangladesh
 General Body Member, INAFI Bangladesh

Education

Post Graduate Diploma, Organizational Leadership,
 Said Business School, University of Oxford
 Master's Degree, International and Intercultural Management,
 School for International Training, Vermont, USA
 Bachelor's Degree, Social Work, University of the Philippines
 Diliman

Sajeda Farisa Kabir, Director

Current Responsibilities

Director, Renata Limited
 Safeguarding, Internal Communication & Legal Consultant, Sajida
 Foundation

Past Responsibilities

Associate Director, Human Rights and Legal Services Program, BRAC
 Senior Regional Manager, Human Rights and Legal Services Program,
 BRAC
 Founding Partner, Vertex Chambers, Dhaka, Bangladesh

Education

Post Graduate Diploma in Professional Legal Skills, City University,
 London, UK
 LLB (Honours), Cardiff Law School, University of Wales, UK
 Professional Qualifications
 Barrister (of Lincoln's Inn), UK
 Advocate, Supreme Court of Bangladesh
 Solicitor (New South Wales), Australia





Mridul Chowdhury, Director

Current Responsibilities

Director, Renata Limited
 Founder and CEO, mPower Social Enterprises Limited
 Co-Founder and Chairperson, Jeeon Limited
 Co-Founder and Chairperson, TraumaLink

Past Responsibilities

Founder and CEO, ClickDiagnostics, Inc., USA
 ICT4D Consultant, UNDP, Bangladesh
 Executive Director, Development Research Network (D.Net), Bangladesh
 ICT Consultant, Bangladesh Enterprise Institute, Bangladesh
 e-Governance Consultant, Ministry of Planning, Government of Bangladesh

Education

MPA in International Development, Development Economics – Kennedy School of Government, Harvard University, USA
 BA in Economics, Mathematics, Political Science – The University of Texas at Austin, USA
 Executive Education in Social Entrepreneurship – Stanford University, USA
 Executive Education in Social Entrepreneurship – INSEAD Business School, France

Tanya Tazeen Karim, Director

Current Responsibilities

Director, Renata Limited
 Architect Partner, Tanya Karim NR Khan & Associates
 Member, Bangladesh Womens' Chamber of Commerce & Industry(BWCCI)
 Director, Vantage Engineering & Construction Ltd.
 Managing Director, Urban Bangla Ltd.
 Chairperson, Center for Elderly Support Initiatives (CESI)
 Director, Green Infrastructure Services Ltd. (GISL)
 Director, Vantage Engineering & Construction Ltd. (VEC)
 Chairman, Rupos Agro Tech Ltd. (RATL)

Past Responsibilities

Board Member, Bangladesh Womens' Chamber of Commerce & Industry(BWCCI)
 EC Member: Women Architects, Engineers, Planners Association(WAEPA)
 Founder Member, UW2SDA (Urban Water, Wastelands Society & Design Alliance), presently ISUS (Institute for Sustainable Urban Studies)also attached to the 'Swaraswati Program' for exchange program of Environmental Expertise among selected universities of USA, India and Bangladesh.

Education

B. Arch from Bangladesh University of Engineering & Technology(BUET) Management Course for Women Entrepreneurs from IBA





Nehal Ahmed, Independent Director

Current Responsibilities

Director, Renata Limited
 Director, A-CUBED PTE Ltd., Singapore
 Advisor, SHEBA.XYZ
 Advisor, Amartaka.com
 Advisor, Xenious International (Pvt) Ltd.

Past Responsibilities

Senior Director (Head of Communications), Grameenphone
 Director (Marketing), Grameenphone
 Executive Vice President, Robi Axiata Limited
 Chief Marketing Officer, AUGERE Wireless Broadband Bangladesh Limited (QUBEE)
 Global Marketing Manager, BACARDI Global Brands Ltd., London, UK
 European Brand Director, MARS Snackfoods Europe, Slough, UK
 Global Marketing Manager, MARS Drinks Global, Basingstoke, UK
 International Brand Marketing Manager, British American Tobacco PLC, London, UK
 Group Brand Manager, British American Tobacco Bangladesh Ltd.,

Education

Innovation – Strategy to Execution, INSEAD Business School, Singapore
 Strategic Marketing Program, London Business School (LBS), London
 Bachelor of Science in Industrial Engineering and Operations,
 The University of Massachusetts, USA

Ejaj Ahmad, Independent Director

Current Responsibilities

Director, Renata Limited
 President and Founder, Bangladesh Youth Leadership Center
 Global Council Member, Asia Society, USA
 Global Network Council Member, Eisenhower Fellowships, USA
 Ashoka Fellow, USA

Past Responsibilities

Honorary Teaching Fellow, School of Management, University of St Andrews
 Principal Consultant, National Youth Policy 2017; appointed by Bangladesh Government and Commonwealth Secretariat in London
 Economist, Unnayan Shammunay; served as researcher in World Bank/Ministry of Commerce funded Bangladesh Export Diversification Project and as assistant technical editor in UNDP funded People's Report on Bangladesh Environment

Education

Master in Public Policy, Harvard University, USA
 MA (Hons) in Economics, University of St. Andrews, Scotland
 Executive Education in Venture Capital, University of Pennsylvania, USA
 Executive Education in Art and Practice of Leadership Development, Harvard University, USA





Md. Jubayer Alam, Company Secretary

Current Responsibilities

Company Secretary, Renata Limited

Past Responsibilities

Director, Renata Agro Industries Limited

Human Resources Manager, Renata Limited

Training Manager, Renata Limited

Regional Sales Manager, Novartis (BD) Limited

Education

LLB from Atish Dipankar University of Science and Technology

MBA (Major in HRM) from Stamford University

MBA (Major in Marketing) from Stamford University

Masters in Psychology from University of Dhaka

THE AUDIT COMMITTEE

Mr. Nehal Ahmed - Independent Director • Chairman, Audit Committee

Mrs. Tanya Tazeen Karim - Director • Member, Audit Committee

Mr. Mridul Chowdhury - Director • Member, Audit Committee

Management Team

Chief Executive Officer &
Managing Director

Director, Manufacturing

Director, Animal Health

Director, Marketing Pharmaceutical

General Manager, International Regulatory Affairs

General Manager, Finance

General Manager, Projects

General Managers, Sales Pharma

General Manager, International & Institutional Business

General Manager, Human Resources Division

Heads of Quality Assurance

Head of Information Technology

Corporate Governance



Directors' Report



TO THE SHAREHOLDERS

The Directors of Renata Limited are pleased to present to the Shareholders their report along with the audited financial statements of the Company for the year ended on 30 June 2022. This report has been prepared in compliance with section 184 of the Companies Act 1994 and Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated 03 June 2018.

PRINCIPAL ACTIVITIES

The principal activities of the Company are manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products, consumer products and so on.

OPERATIONS AND STATE OF AFFAIRS

Renata Limited's turnover from operations was Taka 31,070.6 million for the year ended 30 June 2022 as compared to Taka 29,250.9 million of previous year, registering a growth of 6.2%. Net profit after tax increased by 1.5% to Taka 5,111.0 million for the year under review compared to Taka 5,034.8 million of previous year. Earnings per Share (EPS) of the Company stood at Taka 47.68 during 2021-2022 against Taka 46.97 of 2020-2021.

During the year under review, export sales amounted to Taka 1,208.1 million as against Taka 798.6 million of previous year, a 51.3% increase. Exports are expected to rise in the coming years.

Furthermore, Renata Limited and its subsidiaries' consolidated turnover from operations was Taka 31,070.6 million for the year ended 30 June 2022 as compared to Taka 29,970.7 million of previous year, registering a growth of 3.7%. Consolidated net profit after tax increased by 1.0% to Taka 5,110.9 million for the year under review compared to Taka 5,061.6 million of previous year. Earnings per Share (EPS) of the Group stood at Taka 47.68 during 2021-2022 against Taka 47.22 of 2020-2021.

PRODUCT DEVELOPMENT

The following table provides details of the 76 new formulations introduced by Renata Limited during the year 2021-2022:

Sl.	Brand Name	Generic	Division	Developed by
1	Elazol 50mg Tablet	Voriconazole USP	Pharmaceutical	Renata
	Elazol 200mg Tablet		Pharmaceutical	Renata
2	Ferium 10ml Injection	Ferric Carboxymaltose	Pharmaceutical	Renata
3	Gefiren 250mg Tablet	Gefitinib INN	Pharmaceutical	Renata
4	Metirox 5 tablet	Methimazole	Pharmaceutical	Renata
	Metirox 10 tablet		Pharmaceutical	Renata
5	Rolip 20mg Tablet	Rosuvastatin	Pharmaceutical	Renata
6	Stark 60ml Oral Solution	Rupatadine	Pharmaceutical	Renata
7	Ursoren 150mg Tablet	Ursodeoxycholic Acid BP	Pharmaceutical	Renata
	Ursoren 300mg Tablet		Pharmaceutical	Renata
8	Decaren 60mg Soft Gelatin Capsule	Ubidecarenone USP	Pharmaceutical	Renata
9	Furoclav 70ml Dry Powder for Suspension	Cefuroxime+Clavulanic Acid	Pharmaceutical	Renata
10	Xiomox 400mg Tablet	Moxifloxacin	Pharmaceutical	Renata
11	Cipran 40mg Capsule	Levomilnacipran	Pharmaceutical	Renata
	Cipran 80mg Capsule		Pharmaceutical	Renata
12	Nexdex 30mg Capsule	Dexlansoprazole	Pharmaceutical	Renata
	Nexdex 60mg Capsule		Pharmaceutical	Renata
13	Carmustine 100mg Powder for solution for infusion 100mg/vial	Carmustine	Pharmaceutical	Renata
14	Renapine 25mg Tablet	Quetiapine Fumarate USP	Pharmaceutical	Renata
	Renapine 100mg Tablet		Pharmaceutical	Renata

Sl.	Brand Name	Generic	Division	Developed by
15	Telpro 40mg Tablet	Telmisartan BP	Pharmaceutical	Renata
	Telpro 80mg Tablet		Pharmaceutical	Renata
16	Telpro Max 40mg Tablet	Telmisartan BP + Amlodipine BP	Pharmaceutical	Renata
	Telpro Max 80mg Tablet		Pharmaceutical	Renata
17	Rivaren 1.5mg Capsule	Rivastigmine Tartrate USP	Pharmaceutical	Renata
	Rivaren 3mg Capsule		Pharmaceutical	Renata
18	Betatin 8mg Tablet	Betahistine Dihydrochloride BP	Pharmaceutical	Renata
	Betatin 16mg Tablet			
19	Exicof 100ml Syrup	Guaifenesin BP, Levomenthol BP & Diphenhydramine HCL BP	Pharmaceutical	Renata
20	Opexa 20mg Tablet	Bilastine INN	Pharmaceutical	Renata
21	Orcef 21ml Pediatric Drop	Cefixime	Pharmaceutical	Renata
22	Rolac MDT 10mg Tablet	Ketorolac	Pharmaceutical	Renata
23	Temixil 10mg Tablet	Temazepam BP 10mg	Pharmaceutical	Renata
24	Trop T Sensitive	Troponin T Test Kit	Pharmaceutical	Renata
25	Vomiren 0.075mg/1.5ml Injection	Palonosetron	Pharmaceutical	Renata
	Vomiren 0.25mg/5ml Injection			
26	Lupravis 200mg Capsule	Molnupiravir INN	Pharmaceutical	Renata
27	Nitroren SR 2.6mg tablet	Nitroglycerine	Pharmaceutical	Renata
28	Renacid 200mL Suspension	Sodium Alginate 500mg + Potassium Bicarbonate 100mg	Pharmaceutical	Renata
29	Rezor Plus 20mg Tablet	Olmesartan Medoxomil BP and Hydrochlorothiazide USP	Pharmaceutical	Renata
	Rezor Plus 40mg Tablet		Pharmaceutical	Renata
30	Sitacret 50mg tablet	Sitagliptin Phosphate USP	Pharmaceutical	Renata
31	Terbimax 250mg tablet	Terbinafine	Pharmaceutical	Renata
32	Valporin 100ml Syrup	Sodium Valporate BP	Pharmaceutical	Renata
33	Valporin CR 200mg Tablet	Sodium Valproate BP & Valporic Acid BP	Pharmaceutical	Renata
	Valporin CR 300mg Tablet		Pharmaceutical	Renata
	Valporin CR 500mg Tablet		Pharmaceutical	Renata
34	Lupravis 200mg Capsule	Molnupiravir INN	Pharmaceutical	Renata
35	Renacid 200mL Suspension	Sodium Alginate + Potassium Bicarbonate	Pharmaceutical	Renata
36	Rezor Plus 20mg Tablet	Olmesartan Medoxomil BP and Hydrochlorothiazide USP	Pharmaceutical	Renata
	Rezor Plus 40mg Tablet		Pharmaceutical	Renata
37	Sitacret 50mg tablet	Sitagliptin Phosphate USP	Pharmaceutical	Renata
38	Terbimax 250mg tablet	Terbinafine	Pharmaceutical	Renata
39	Valporin 100ml Syrup	Sodium Valporate BP	Pharmaceutical	Renata
40	Valporin CR 200mg Tablet	Sodium Valproate BP& Valporic Acid BP	Pharmaceutical	Renata
	Valporin CR 300mg Tablet		Pharmaceutical	Renata
	Valporin CR 500mg Tablet		Pharmaceutical	Renata
41	Epiket 500mg XR	Levetiracetam USP	Pharmaceutical	Renata
	Epiket 750mg XR		Pharmaceutical	Renata
	Epiket 1000mg XR		Pharmaceutical	Renata
42	Epiket 500/5 Injection		Pharmaceutical	Renata
43	Nitroren 2.6mg tablet	Nitroglycerine	Pharmaceutical	Renata
44	Sperid 100ml Syrup	Risperdone USP	Pharmaceutical	Renata
45	Benazin 12.5mg Tablet	Tetrabenazine INN	Pharmaceutical	Renata
	Benazin 25mg Tablet		Pharmaceutical	Renata
46	Bendopa 50mg Dispersible Tablet	Levodopa USP and Benserazide Hydrochloride Ph. Eur.	Pharmaceutical	Renata
	Bendopa 100mg Dispersible Tablet		Pharmaceutical	Renata

Sl.	Brand Name	Generic	Division	Developed by
47	Caparen 500mg Tablet	Capecitabine USP	Pharmaceutical	Renata
48	Mitapro 7.5mg Tablet	Mirtazapine USP	Pharmaceutical	Renata
	Mitapro 15mg Tablet		Pharmaceutical	Renata
	Mitapro 30mg Tablet		Pharmaceutical	Renata
49	Esodip 1.25 mg Tablet	Levamlodipine Maleate INN	Pharmaceutical	Renata
	Esodip 2.50 mg Tablet		Pharmaceutical	Renata
	Esodip 5 mg Tablet		Pharmaceutical	Renata
50	Melphalan 50mg Powder and Solvent for Solution for Injection	Melphalan Hydrochloride Equivalent to Melphalan INN 50mg	Pharmaceutical	Renata
51	Novelip 180mg Tablet	Bempezoic Acid INN	Pharmaceutical	Renata
52	Oragon FC 150mg Tablet	Elagolix	Pharmaceutical	Renata
53	Renapine 50mg XR Tablet	Quetiapine Fumarate USP	Pharmaceutical	Renata
	Renapine 200mg XR Tablet		Pharmaceutical	Renata
54	Renasone Cream	Econazole Nitrate & Triamcinolone Acctonide	Pharmaceutical	Renata
55	Bricet 25mg Tablet	Brivaracetam INN	Pharmaceutical	Renata
	Bricet 50mg Tablet		Pharmaceutical	Renata
	Bricet 75mg Tablet		Pharmaceutical	Renata
	Bricet 100mg Tablet		Pharmaceutical	Renata
56	Relupros 120mg Tablet	Relugolix INN	Pharmaceutical	Renata
57	Reluren Tablet	Relugolix INN , Estradiol BP and Norethindrone Acetate	Pharmaceutical	Renata
58	R-Pag 12.5mg Tablet	Eltrombopag	Pharmaceutical	Renata
	R-Pag 25mg Tablet		Pharmaceutical	Renata
	R-Pag 50mg Tablet		Pharmaceutical	Renata
59	Terbimax Cream	Terbinafine	Pharmaceutical	Renata
60	Maxpro Mups 40mg Tablet	Esomeprazole	Pharmaceutical	Renata
61	Renapine 300mg XR Tablet	Quetiapine Fumarate USP	Pharmaceutical	Renata
62	Pazoren 200mg Tablet	Pazopanib 200mg INN	Pharmaceutical	Renata
63	Alkanon 500mg Tablet	Nabumeton USP	Pharmaceutical	Renata
	Alkanon 750mg Tablet		Pharmaceutical	Renata
64	Copnat N Cream & Ointment	Clobetasol Propionare+ Neomycin Sulphate + Nystatin	Pharmaceutical	Renata
65	Renazyme CS 500ml	Liquid Multienzyme	Animal Health	Renata
66	Utoren 500ml	Ecobic	Animal Health	Renata
67	Renalyte 20gm	Electrolyte	Animal Health	Renata
68	Natuphos E 5000G 4G	Phytase	Animal Health	Renata
	Natuphos E 5000G 4GL	Phytase	Animal Health	Renata
	Natuphos E 5000 CombiG	Plytase, Xylanase, Glucanase	Animal Health	Renata
69	Marbosyva inj. 100ml	Marbofloxacin	Animal Health	Renata
70	Flumixine inj. 10ml	Flunixin Meglumine	Animal Health	Renata
71	Renaflo Vet	Florfenicol INN	Animal Health	Renata
72	Renamox inj. 1gm	Amoxicillin	Animal Health	Renata
	Renamox inj. 2gm	Amoxicillin	Animal Health	Renata
73	Renatrim 500ml	Sulfadiazine & Trimethoprim	Animal Health	Renata
74	Endoban Powder	Red Algae, Silicates	Animal Health	Renata
75	Renazyme Powder	NSP enzymes	Animal Health	Renata
76	Natugrain TS 20kg	Xylanase & Glucanase	Animal Health	Renata

QUALITY CONTROL

The Company is strongly focused on maintaining and improving the quality of its products following strictly laid down criteria at every level of production and handling. It also continuously follows-up withdrawal of expired products from the market through close inspection and surveillance.

CAPITAL EXPENDITURES

Renata Limited incurred substantive capital expenditures funded from internally generated cash and bank loans to improve its operational efficiency during the year 2021-2022 as detailed below:

(Taka in millions)

	2021-22
Freehold land	582.4
Buildings	2,520.3
Plant and machinery	6,622.7
Automobiles	236.8
Office equipment, furniture & fixtures and others	137.2
Total	10,099.4

Current production capacity, actual production and utilization for major product groups are provided in Note No. 42.2 of the financial statements of Renata Limited.

RISKS AND CONCERNS

Operating in a dynamic and competitive market exposes the Company to various risks from time to time that may affect its business. Decrease in purchasing power of customers, competition in domestic market, international trade barriers, dependency on import for APIs, uncertainties arising from significant changes in the pharmaceutical policy and regulations, tax regime, variable fiscal and monetary policies, etc. can impose regressive impact on the growth potential of the pharmaceutical sector.

Management of the Company is vigilant in identifying any such risks associated with operating activities of the business, and assessing and determining effective solutions to those risks to ensure smooth performance and progress of the Company. The Company envisages that transition of Bangladesh to a middle-income country is likely to improve the standard of living, purchasing power and health awareness of its population, which in turn is expected to trigger the demand for healthcare products in the coming years. With long-term strategic plans in place and with a strong marketing and sales team, Renata Limited expects to retain and expand its existing market share and keep up with the changing demand of the market by adding new products to its portfolio. The Company makes investment decisions only after considering all related risks and return on investment. Furthermore, to ensure uninterrupted operation with

Financial Results

The Directors take pleasure in reporting the following financial results of the Company for the year 2021-2022:

	2021-22 Taka	2020-21 Taka
Profit before tax	6,122,668,298	6,733,532,035
Less: Provision for tax	1,011,711,088	1,698,711,125
Net profit after tax	5,110,957,210	5,034,820,910
Add/(Less): Other comprehensive income	1,990,825	27,074,401
Total comprehensive income	5,112,948,035	5,061,895,311
Add: Unappropriated profit brought forward	22,811,518,067	19,259,433,444
Add: Depreciation adjustment on revalued assets	635,885	635,885
Add: Adjustment for merger of Renata Agro Industries Limited and Purnava Limited	262,402,968	-
	28,187,504,955	24,321,964,640
APPROPRIATION RECOMMENDED		
Dividend proposed:		
a) Cash dividend @ 140% per share of Taka 10 each	1,500,701,748	1,412,998,407
b) Stock dividend (bonus share) @ 7% of Taka 10 each	75,035,087	97,448,166
	1,575,736,835	1,510,446,573
Balance of unappropriated profit carried forward	26,611,768,128	22,811,518,067
	28,187,504,955	24,321,964,640

competitive edge, Renata Limited sources its raw materials at competitive prices from different suppliers from across the world to reduce dependency. The Company also expects to expand its global presence in the coming years and is investing heavily in people, factories, and R&D.

DIVIDEND

While there is reasonable profit available for distribution, the investment pipeline is also rich. Hence the Directors deem it necessary to retain adequate funds to finance the capital expenditures for capacity building to sustain the growth of the Company.

The Board of Directors is pleased to recommend a cash dividend @ 140% per share of Taka 10 each. This dividend will entail a payment of Taka 1,500,701,748. The Board of Directors also recommend for declaration of stock dividend (bonus shares) @ 7% of Taka 10 each aggregating a payment of Taka 75,035,087.

Information on unclaimed dividend as on 30 June 2022 are disclosed in Note No. 24 of the financial statements of Renata Limited.

Renata Limited committed that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.

CONTRIBUTION TO NATIONAL EXCHEQUER

During the year under review, Renata Limited paid Taka 7,108 million to the National Exchequer in the form of Corporate Income Tax, Import Duties and Value Added Tax (VAT) compared to Taka 6,890 million of previous year. The contribution constitutes 20.0% of gross turnover of 2021-2022 as against 20.8% of previous year.

EMPLOYEES

The Company engaged 10,380 employees as at 30 June 2022 compared to 8,957 employees as at 30 June 2021. In order to improve productivity of human input, the Company continuously provides formal and informal training to the employees at every echelon of operation and management. The Company is also committed to providing a healthy and risk-free environment for its employees. It is worth mentioning that along with other benefits, the Company also provides 5% of profit before charging such expense to employees as workers' participation and welfare fund in accordance with Bangladesh Labour Act 2006 (as amended in 2013).

RELATED PARTY TRANSACTIONS

The Company carried out a number of transactions with related parties in the normal course of business. Details of the related party transactions are disclosed in Note No. 44 of the financial statements of Renata Limited.

CONSOLIDATION OF ACCOUNTS

The Company prepares its financial statements in accordance with the applicable International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and adopted by the Institute of Chartered Accountants of Bangladesh (ICAB). The consolidated financial statements of Renata Limited and its subsidiaries have been prepared in accordance with IFRS 10, 'Consolidated financial statements'. The Board has duly protected the interests of minority Shareholders in the Company.

RETIREMENT AND RE-ELECTION OF DIRECTORS

The Directors retiring by rotation under Articles 109, 115 and 116 of the Articles of Association of the Company are Dr. Sarwar Ali and Mr. Mridul Chowdhury, who have been longest in the office since election and constitute one-third of the Directors who are to retire by rotation. Being eligible, they offer themselves for re-election.

Brief profile of Dr. Sarwar Ali and Mr. Mridul Chowdhury is depicted under the Board of Directors profile in the Annual Report.

REMUNERATION PAID TO THE DIRECTORS

During the year, the Company has paid Taka 420,000 as Board Meeting attendance fees and Taka 150,000 for Audit Committee Meeting attendance fees. The remuneration of the Directors has been mentioned in Note No. 37 of the financial statements of Renata Limited.

APPOINTMENT OF STATUTORY AUDITORS

The Company's Auditor Messrs. ACNABIN, Chartered Accountants retire at the 49th Annual General Meeting. As per order of Bangladesh Securities and Exchange Commission the issuer Company shall not appoint any firm of chartered accountants as its statutory auditors for a consecutive period exceeding three years. As such they are not eligible for reappointment. Therefore, the Board of Directors is pleased to recommend Messrs. S. F. Ahmed & Co., Chartered Accountants as auditor of the Company for the year 2022-2023 and fix their remuneration. The Audit Committee and Board recommended Auditor's remuneration of Taka 1,000,000 (ten lac fifty thousand) only for the year 2022-2023 subject to the approval of the Shareholders in the 49th Annual General Meeting of the Company.

ADDITIONAL STATEMENTS

The Directors are pleased to make the following additional statements in respect of this Report prepared under section 184 of the Companies Act 1994.

- a) The financial statements for the year ended 30 June 2022 together with the notes thereon have been drawn up in conformity with the Companies Act 1994 and Securities and Exchange Rules 1987. These statements present fairly the Company's state of affairs, the result of its operations, cash flow and changes in equity.
- b) Proper books of accounts have been maintained by the Company as required by applicable laws, rules and standards.
- c) Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment.
- d) The International Accounting Standards (IASs)/ Bangladesh Accounting Standards (BASs)/ International Financial Reporting Standards (IFRSs)/ Bangladesh Financial Reporting Standards (BFRSs), as applicable in Bangladesh, have been followed in preparation of the financial statements.
- e) The Company maintains a sound internal control system that gives a reasonable assurance against any material misstatement. The internal control system is regularly monitored by the Audit Committee in each meeting on a quarterly basis.
- f) Based on the available information on the future, the Company has the plans and resources to manage its business risks successfully and remain financially strong. The Company has adequate resources to continue its operations for the foreseeable future and there is no significant doubt about the ability of the Company to continue as a going concern.
- g) There is no significant deviation from the operating result of the last year.
- h) The key operating and financial data of last five years have been presented in summarized form in the annexed Financial Highlights.
- i) The Directors have recommended cash dividend @ 140% per share of Taka 10 each and stock dividend (bonus share) @ 7% of Taka 10 each.
- j) During the year 2021-2022, total 6 (six) Board meetings, 5 (five) Audit Committee meetings and 1 (one) NRC meeting were held and the attendance by each Director is given below:

Board Meeting:

1. Dr. Sarwar Ali Chairman of the Board	6 times
2. Mr. Syed S. Kaiser Kabir CEO & Managing Director	6 times
3. Ms. Zahida Fizza Kabir Director	6 times
4. Ms. Sajeda Farisa Kabir Director	6 times
5. Mr. Mridul Chowdhury Director	6 times
6. Ms. Tanya Tazeen Karim Director	6 times
7. Mr. Nehal Ahmed Independent Director	6 times
8. Mr. Ejaj Ahmad Independent Director	6 times

Audit Committee Meeting:

1. Mr. Nehal Ahmed Chairman	5 times
2. Mr. Mridul Chowdhury Member	5 times
3. Ms. Tanya Tazeen Karim Member	5 times

NRC Committee Meeting:

- | | |
|-------------------------------------|--------|
| 1. Mr. Nehal Ahmed
Chairman | 1 time |
| 2. Ms. Tanya Tazeen Karim
Member | 1 time |
| 3. Ms. Zahida Fizza Kabir
Member | 1 time |
- k) The pattern of shareholding as at 30 June 2022 are as follows:

(i) Parent/ Subsidiary / Associated companies:

The shareholding information as at 30 June 2022 and other related information are set out in Note No. 14 of the financial statements of Renata Limited.

(ii) **Name of the Directors** **No. of Shares**

Dr. Sarwar Ali	5,924
Mr. Syed S. Kaiser Kabir	148,527
Ms. Zahida Fizza Kabir	34,821
Ms. Sajeda Farisa Kabir	15,588
Mr. Mridul Chowdhury	-
Ms. Tanya Tazeen Karim	-
Mr. Nehal Ahmed	-
Mr. Ejaj Ahmed	2,867

(iii) **Company Secretary**

Mr. Jubayer Alam	2,675
------------------	-------

(iv) **Chief Financial Officer (CFO)**

Mr. Khokan Chandra Das	12,000
------------------------	--------

(v) **Head of Internal Audit**

Mr. ATM Muniruzzaman	522
----------------------	-----

(vi) **Executives:**

Dr. Sayma Ali	16,500
Mr. Monowarul Islam	-
Mr. Sirajul Hoque	-
Mr. Zaki Chowdhury	-
Mr. Shamsur Rahman Bhuyian	2,181

(vii) **Shareholders holding 10% or more voting interest:**

Sajida Foundation	54,764,954
Business Research International Corp.	23,307,989

ENVIRONMENTAL ROLE

Renata Limited is committed to protecting the environment and maintains a high standard of pollution free environment as required by the regulators. It carries out its operations in an environmentally friendly manner and ensures continuous improvement in the utilization of resources and prevention of pollution or degradation of the environment. Renata Limited strictly complies with local and national legislations and regulations, ensures appropriate treatment of all effluents prior to discharge, ensures waste management in an environmentally responsible manner and consistently creates awareness on environmental issues among its employees to conserve natural resources like water and energy for sustainable development.

CORPORATE SOCIAL RESPONSIBILITY

Renata Limited continues to contribute to the welfare of the local communities through its CSR activities, details of which has been annexed to the Annual Report.

STATUS OF COMPLIANCE

Compliance status of the conditions imposed by Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated 03 June 2018, issued under section 2CC of the Securities Exchange Ordinance 1969 is shown in Annexure-C.

ACKNOWLEDGEMENT

Renata Limited and its Board of Directors wishes to thank the Shareholders and other stakeholders of the Company for their continuous support and guidance. The Board also expresses their appreciation to the Government of Peoples Republic of Bangladesh, National Board of Revenue (NBR), Registrar of Joint Stock Companies and Firms (RJSC), Bangladesh Securities and Exchange Commission (BSEC), Central Depository Bangladesh Limited (CDBL), Dhaka Stock Exchange Ltd. (DSE), Officials of the Drug Administration and other Government Officials, Doctors, Chemists, Medical Institutions, Consumers, Creditors, the Company's Employees, Banks, Insurance Companies, Utility Providers and all other business partners and well-wishers for their continued cooperation and support.

On behalf of the Board of Directors,



Dr. Sarwar Ali
Chairman
October 22, 2022



Renata Limited

Corporate Headquarters: Plot No. 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh

PABX : 8001450-54
Fax : 880-2-8001446
Email : renata@renata-ltd.com
Website : www.renata-ltd.com

The CEO and CFO's certification to the Board

October 22, 2022

The Board of Directors
Renata Limited

Subject: Declaration on Financial Statements for the year ended on June 30, 2022

Dear Sirs,

Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 Dated June 3, 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

- (1) The Financial Statements of Renata Limited for the year ended on June 30, 2022 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
- (2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
- (3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;

- (4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
- (5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed ; and
- (6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:-

- (i) We have reviewed the financial statements for the year ended on June 30, 2022 and that to the best of our knowledge and belief:
 - (a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) these statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,



Syed S. Kaiser Kabir
CEO & Managing Director
October 22, 2022



Khokan Chandra Das
Chief Financial Officer
October 22, 2022

ANNEXURE-B

[(Certificate as per condition No. 1(5)(xxvii)]



ক. এম. হাসান এন্ড কো.
K. M. HASAN & CO.
Chartered Accountants

Chartered Accountants (CPA & CA) Firm
27, New Commerce Road, Dhaka-1000
Phone: 8800211094, 8800211097, 8800211098
Fax: 8800211099
E-mail: info@khasan.com.bd
Website: www.khasan.com.bd



McMillan Woods
International
Incorporation in the Bahamas

Report to the Shareholders of Renata Limited on compliance on the Corporate Governance Code

We have examined the compliance status to the Corporate Governance Code by Renata Limited for the year ended on 30 June 2022. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/ Admin/80, dated 03 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any conditions of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission except those mentioned in the statement of compliance status;
- The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- Proper books and records have been kept by the company as required under the Companies Act, 1994, the Securities Laws and other relevant laws; and
- The governance of the company is satisfactory.

Place: Dhaka
Dated: 02 November 2022



For K. M. HASAN & CO.
Chartered Accountants

Md. Amirul Islam FCA, FCS
Senior Partner
Enrollment No. 331

ANNEXURE-C

[(As per condition No. 1(5)(xxvii)]

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Status of compliance with the conditions imposed by the Commission's Notification No. BSEC/CMRRCD/2006-158/207/ Admin/80, dated 03 June, 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9.00)

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1	Board of Directors			
1(1)	Size of the Board of Directors			
	The total number of members of a company's Board of Directors (hereinafter referred to as "Board") shall not be less than 5 (five) and more than 20 (twenty).	✓	-	-
1(2)	Independent Directors			
1(2)(a)	At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s);	✓	-	-
1(2)(b)(i)	Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company;	✓	-	-
1(2)(b)(ii)	Who is not a sponsor of the company and is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid-up shares of the company on the basis of family relationship and his or her family members also shall not hold above mentioned shares in the company.	✓	-	-
1(2)(b)(iii)	Who has not been an executive of the company in immediately preceding 2 (two) financial years;	✓	-	-
1(2)(b)(iv)	Who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies;	✓	-	-
1(2)(b)(v)	Who is not a member or TREC (Trading Right Entitlement Certificate) holder, director, or officer of any stock exchange;	✓	-	-
1(2)(b)(vi)	Who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓	-	-
1(2)(b)(vii)	Who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code;	✓	-	-
1(2)(b)(viii)	Who is not an independent director in more than 5 (five) listed companies;	✓	-	-
1(2)(b)(ix)	Who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI);	✓	-	-
1(2)(b)(x)	Who has not been convicted for a criminal offence involving moral turpitude.	✓	-	-
1(2)(c)	The independent director(s) shall be appointed by the board of directors and approved by the shareholders in the Annual General Meeting (AGM).	✓	-	-
1(2)(d)	The post of independent director(s) cannot remain vacant for more than 90(ninety) days.	✓	-	-
1(2)(e)	The tenure of office of an independent director shall be for a period of 3(three) years, which may be extended for 1(one) term only.	✓	-	-
1(3)	Qualification of Independent Director			

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(3)(a)	Independent director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial, regulatory and corporate laws and can make meaningful contribution to business.	✓	-	-
1(3)(b)(i)	Business Leader who is or was a promoter or director of an unlisted company having minimum paid-up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association;	-	-	-
1(3)(b)(ii)	Corporate Leader who is or was a top-level executive not lower than Chief Executive officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company;	✓	-	-
1(3)(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor's degree in economics or commerce or business or law;	-	-	-
1(3)(b)(iv)	University Teacher who has educational background in Economics or Commerce or Business Studies or Law;	-	-	-
1(3)(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	-	-	-
1(3)(c)	The independent director(s) shall have at least 10 (ten) years of experiences in any field mentioned in clause (b);	✓	-	-
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission.		-	No such event occurred
1(4)	Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer			
1(4)(a)	The positions of the Chairperson of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) of the company shall be filled by different individuals;	✓	-	-
1(4)(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed company shall not hold the same position in another listed company;	✓	-	-
1(4)(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the company;	✓	-	-
1(4)(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and/ or Chief Executive officer;	✓	-	
1(4)(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	-	-	No such event occurred
1(5)	The Directors' Report to the Shareholders			
1(5)(i)	An industry outlook and possible future developments in the industry;	✓	-	-
1(5)(ii)	The Segment-wise or product-wise performance;	✓	-	-
1(5)(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓	-	-
1(5)(iv)	A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable;	✓	-	-

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(5)(v)	A discussion on continuity of any extraordinary activities and their implications (gain or loss);	-	-	No such event occurred
1(5)(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	✓	-	-
1(5)(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or through any other instruments;	-	-	Not applicable
1(5)(viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc;	-	-	Not applicable
1(5)(ix)	An explanation on any significant variance that occurs between Quarterly Financial Performance and Annual Financial Statements;	-	-	Not applicable
1(5)(x)	A statement of remuneration paid to the directors including independent directors;	✓	-	-
1(5)(xi)	A statement that the financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓	-	-
1(5)(xii)	A statement that proper books of account of the issuer company have been maintained;	✓	-	-
1(5)(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓	-	-
1(5)(xiv)	A statement that International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed;	✓	-	-
1(5)(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓	-	-
1(5)(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓	-	-
1(5)(xvii)	A statement that there is no Significant doubt upon the issuer company's ability to continue as going concern, if the issuer company is not considered to be a going concern, the fact along with reasons thereof shall be disclosed;	✓	-	-
1(5)(xviii)	An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained;	-	-	No such event occurred
1(5)(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓	-	-
1(5)(xx)	An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year;	-	-	Declared Dividend
1(5)(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	-	-	Not applicable
1(5)(xxii)	The total number of Board meetings held during the year and attendance by each director;	✓	-	-
1(5)(xxiii)	A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:-			

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(5)(xxiii)(a)	Parent or Subsidiary or Associated Companies and other related parties (name-wise details);	✓	-	-
1(5)(xxiii)(b)	Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance their spouses and minor children (name-wise details);	✓	-	-
1(5)(xxiii)(c)	Executives;	✓	-	-
1(5)(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details).	✓	-	-
1(5)(xxiv)	In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders: -			
1(5)(xxiv)(a)	a brief resume of the director	✓	-	-
1(5)(xxiv)(b)	nature of his/her expertise in specific functional areas;	✓	-	-
1(5)(xxiv)(c)	Names of companies in which the person also holds the directorship and the membership of committees of the board.	✓	-	-
1(5)(xxv)	A management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in financial statements, among others, focusing on:			
1(5)(xxv)(a)	Accounting policies and estimation for preparation of financial statements;	✓	-	Discussed in the Chairman's Statement
1(5)(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	✓	-	Do
1(5)(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediately preceding five years explaining reasons thereof;	✓	-	Do
1(5)(xxv)(d)	compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	-	-	Will be complied
1(5)(xxv)(e)	briefly explain the financial and economic scenario of the country and the globe;	✓	-	Discussed in the Chairman's Statement
1(5)(xxv)(f)	risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and	✓	-	Do
1(5)(xxv)(g)	future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM;	✓	-	Do
1(5)(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A; and	✓	-	-
1(5)(xxvii)	The report as well as certificate regarding compliance of conditions of this code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	✓	-	-
1(6)	Meetings of the Board of Directors			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	✓	-	-
1(7)	Code of Conduct for the Chairperson, other Board Members and Chief Executive Officer			
1(7)(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC), for the Chairperson of the Board, other board members and Chief Executive Officer of the company;	✓	-	-

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
1(7)(b)	The code of conduct as determined by the NRC shall be posted on the website of the company	✓	-	-
2	Governance of Board of Directors of Subsidiary Company			
2(a)	Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company;	✓	-	-
2(b)	At least 1 (one) independent director of the Board of the holding company shall be a director on the Board of the subsidiary company;	✓	-	-
2(c)	The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company.	-	-	Not applicable
2(d)	The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also;	-	-	Not applicable
2(e)	The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company.	-	-	Not applicable
3	Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	✓	-	-
3(1)(b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	✓	-	-
3(1)(c)	The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time;	✓	-	-
3(1)(d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓	-	-
3(1)(e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	-	-	No such event occurred
3(2)	Requirement to attend Board of Director's Meetings			
	The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board:	✓	-	-
3(3)	Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)			
3(3)(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:			
3(3)(a)(i)	These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	✓	-	-
3(3)(a)(ii)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws;	✓	-	-
3(3)(b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent illegal or violation of the code of conduct for the company's Board or its member;	✓	-	-
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	✓	-	-
4	Board of Director's Committee. For ensuring good governance in the company, the Board shall have at least following sub-committees:			

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
4(i)	Audit Committee;	✓	-	-
4(ii)	Nomination and Remuneration Committee	✓	-	-
5	Audit Committee			
5(1)	Responsibility to the Board of Directors			
5(1)(a)	The company shall have an Audit Committee as a sub-committee of the Board;	✓	-	-
5(1)(b)	The Audit Committee shall assist the Board of Directors in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business;	✓	-	-
5(1)(c)	The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing.	✓	-	-
5(2)(a)	The Audit Committee shall be composed of at least 3 (three) members;	✓	-	-
5(2)(b)	The Board shall appoint members of the audit committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	✓	-	-
5(2)(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓	-	-
5(2)(d)	When the term of service of any Committee members expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	✓	-	-
5(2)(e)	The company secretary shall act as the secretary of the Committee.	✓	-	-
5(2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	✓	-	-
5(3)(a)	The Board of Directors shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an Independent director;	✓	-	-
5(3)(b)	In the absence of the Chairperson of the audit committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular chairperson shall be duly recorded in the minutes.	✓	-	-
5(3)(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM):	✓	-	-
5(4)(a)	The Audit Committee shall conduct at least its four meetings in a financial year. Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	✓	-	-
5(4)(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓	-	-
5(5)	The Audit Committee shall:			
5(5)(a)	Oversee the financial reporting process;	✓	-	-
5(5)(b)	Monitor choice of accounting policies and principles;	✓	-	-

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
5(5)(c)	Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance plan and review of the Internal Audit and Compliance Report;	✓	-	-
5(5)(d)	Oversee hiring and performance of external auditors.	✓	-	-
5(5)(e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓	-	-
5(5)(f)	Review along with the management, the annual financial statements before submission to the board for approval;	✓	-	-
5.5(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the board for approval;	✓	-	-
5.5(h)	Review the adequacy of internal audit function;	✓	-	-
5(5)(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report;	✓	-	-
5(5)(j)	Review statement of all related party transactions submitted by the management;	✓	-	-
5(5)(k)	Review Management Letters or Letter of Internal Control weakness issued by statutory auditors.	-	-	Not applicable
5(5)(l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	✓	-	-
5(5)(m)	Oversee whether the proceeds raised through Initial public Offering (IPO) or Repeat public Offering (RPO) or Rights Share offer have been utilized as per the purpose stated in relevant offer document or prospectus approved by the Commission:	-	-	Not applicable
5(6)	Reporting of the Audit Committee			
5(6)(a)	Reporting to the Board of Directors			
5(6)(a)(i)	The Audit Committee shall report on its activities to the Board.	✓	-	-
5(6)(a)(ii)	The Audit Committee shall immediately report to the Board of Directors on the following findings, if any: -			
5(6)(a)(ii)(a)	report on conflicts of interests;	-	-	No such event occurred
5(6)(a)(ii)(b)	suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements; control system;	-	-	No such event occurred
5(6)(a)(ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;	-	-	No such event occurred
5(6)(a)(ii)(d)	any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately;	-	-	No such event occurred
5(6)(b)	Reporting to the Authorities: -			
	If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier.	-	-	No such event occurred
5(7)	Reporting to the Shareholders and General Investors			

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
	Report on activities carried out by the Audit Committee, including any report made to the Board under condition 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	✓	-	-
6	Nomination and remuneration Committee (NRC).			
6(1)	Responsibility to the Board of Directors			
6(1)(a)	The company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	✓	-	-
6(1)(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top-level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	✓	-	-
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	✓	-	-
6(2)	Constitution of the NRC			
6(2)(a)	The Committee shall comprise of at least three members including an independent director;	✓	-	-
6(2)(b)	All member of the Committee shall be non-executive directors;	✓	-	-
6(2)(c)	Members of the Committee shall be nominated and appointed by the Board;	✓	-	-
6(2)(d)	The Board shall have authority to remove and appoint any member of the Committee;	✓	-	-
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	-	-	Not applicable
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	-	-	No such event occurred
6(2)(g)	The company secretary shall act as the secretary of the Committee;	✓	-	-
6(2)(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	✓	-	-
6(2)(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company.	✓	-	-
6(3)	Chairperson of the NRC			
6(3)(a)	The Board shall select 1(one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓	-	-
6(3)(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	✓	-	No such event occurred
6(3)(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders;	✓	-	-
6(4)	Meeting of the NRC			
6(4)(a)	The NRC shall conduct at least one meeting in a financial year;	✓	-	-

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	-	-	No such event occurred
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	✓	-	-
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	✓	-	-
6(5)	Role of the NRC			
6(5)(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	✓	-	-
6(5)(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board:	✓	-	-
6(5)(b)(i)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:	✓	-	-
6(5)(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;	✓	-	-
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	✓	-	-
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;	✓	-	-
6(5)(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	✓	-	-
6(5)(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	✓	-	-
6(5)(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;	✓	-	-
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	✓	-	-
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies;	✓	-	-
6(5)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓	-	-
7	External or Statutory Auditors			
7(1)	The issuer shall not engage its external or statutory auditors to perform the following services of the company, namely:			
7(1) (i)	Appraisal or valuation services or fairness opinions;	✓	-	-
7(1) (ii)	Financial information system design and implementation;	✓	-	-
7(1) (iii)	Book-keeping or other services related to the accounting records or financial statement;	✓	-	-
7(1) (iv)	Broker –dealer services;	✓	-	-
7(1) (v)	Actuarial services;	✓	-	-
7(1) (vi)	Internal audit services or special audit services;	✓	-	-

STATUS OF COMPLIANCE

OF THE CORPORATE GOVERNANCE GUIDELINE (CGG), 2018

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (if any)
		Complied	Not Complied	
7 (1) (vii)	Any services that the Audit Committee determines.	✓	-	-
7 (1) (viii)	Audit or certification services on compliance of corporate governance as required under condition No.9(1);	✓	-	-
7 (1) (ix)	Any other service that creates conflict of interest	✓	-	-
7(2)	No Partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company.	✓	-	-
7(3)	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓	-	-
8	Maintaining a website by the Company			
8(1)	The Company shall have an official website linked with the website of the stock exchange.	✓	-	-
8(2)	The company shall keep the website functional from the date of listing.	✓	-	-
8(3)	The company shall make available the detailed disclosures on its website as required under the regulations of the concerned stock exchange(s)	✓	-	-
9	Reporting and Compliance of Corporate Governance			
9(1)	The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report.	✓	-	-
9(2)	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the Shareholders in the annual general meeting.	✓	-	-
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not.	✓	-	-



CEO & Managing Director

AUDIT COMMITTEE REPORT FOR THE YEAR ENDED JUNE 30, 2022

The Audit Committee consists of the following members:

Mr. Nehal Ahmed	Independent Director	Chairman, Audit Committee
Mrs. Tanya Tazeen Karim	Director	Member
Mr. Mridul Chowdhury	Director	Member

The scope of Audit Committee was defined as under:

- a) To review the quarterly, half yearly and the audited financial statements and management letter if any;
- b) To recommend to the Board of Directors the quarterly, half yearly and the audited financial statements for approval;
- c) To review the internal audit findings and monitor the progress of potential issues;
- d) To review the statement of all related party transactions submitted by the management; and
- e) To recommend the appointment of Messrs S. F. Ahmed & Co., Chartered Accountants as External Auditors of the Company for the year 2022-2023.

Activities carried out during the period

The committee reviewed the internal audit reports, financial statements and the external audit report. The committee didn't find any material deviation, discrepancy or any adverse finding / observation in the area of reporting.



Nehal Ahmed
Chairman
Audit Committee

RENATA LIMITED

DIVIDEND DISTRIBUTION POLICY

Policy Statement

The Dividend Policy of the Company aims to strike a balance between the dual objectives of rewarding shareholders through Dividends and ploughing back earnings to support sustained growth.

Bangladesh Companies Act 1994 empowers the Board of Directors to make dividend decisions that must be approved by shareholders at the Annual General Meeting. Shareholders, on the other hand, cannot approve a higher dividend than the Board of Directors recommends.

The Dividend Distribution Policy was developed and implemented in accordance with the rules of the Bangladesh Securities and Exchange Commission's (BSEC) Directive No. BSEC/CMRRCD/2021-386/03 dated 14 January 2021 on dividend declaration, payment, disbursement, and compliance.

Companies that fail to report at least 30% of their net profits for the year as dividends are subject to a penalizing tax provision under Bangladeshi Tax regulation, Income Tax Ordinance 1984. The rule also states that if a company declares both a cash and a stock dividend, the amount of stock dividend cannot be greater than the cash dividend. Thus, the Company shall endeavor to maintain the Dividend Payout Ratio of at least 30% of the net earnings for the year as dividend.

When declaring or proposing a dividend on behalf of the Company, the Board of Directors (the Board) will take the directive into account. The Policy shall not be an alternative to the Board's decision to make/recommend dividend taking into account all relevant conditions listed below or other determinations by the Board.

Scope

The dividend is the proportion of the profit to be distributed among its shareholders by a Company in relation to the amount of paid-up shares they hold in the form of Cash and/or Stock (Bonus). The Company's profits might either be retained in the business or dispersed as dividends among shareholders.

The Policy set out herein relate to Boards report in accordance with the provisions of Section 184 1(c) of the Companies Act, 1994. This Policy is also in compliance with section 16G of Income Tax Ordinance 1984. The Policy generally relate to Final Dividend recommended by the Board of Directors of the Company; however, it also applies to Interim Dividend declared by the Board of Directors of the Company, when they consider it fit.

Dividend Classifications

The Act covers two dividend classifications – Interim and Final

- ❑ The interim dividend is the dividend declared by the Board of Directors between two Annual General Meetings (AGMs), as and when it is deemed appropriate. The Board is authorized by the Act to declare interim dividends during any financial year from the earnings for the financial year in which the dividend is requested to be declared and/or the profit and loss account surplus.
- ❑ At the time of approval of the annual financial accounts as well as profit appropriation, the final dividend for the fiscal year is recommended. The Board of Directors shall have the authority to recommend a final dividend to the shareholders for approval at the Company's AGM. The dividend recommended by the Board cannot be altered before the AGM takes place.

Objectives

- a) To define the Policy and Procedures of the Company in relation to the calculation, declaration and settlement of Dividends.
- b) To create a transparent and methodological Dividend policy, clearly identified and promptly communicated to appropriate stakeholders.

Dividend Declaration

Dividends are declared and paid out of the following accounts, subject to the Act's provisions:

- i. Company profit in respect of the year for which, after set-off, the dividend is to be paid in respect of prior losses and depreciation not given in the preceding year(s);
- ii. Profits from prior financial years that were left undistributed after accounting for depreciation in line with the law.
- iii. Both i and ii come from the same source.

Prior to dividend declaration, the Company may, in its sole discretion, move a part of its profit to the Company's reserves.

In case of a lack of profit in any year, the Company may, according to the Act and Rules, issue dividend out of free reserves.

Parameters / Factors to be considered

It is a vital choice to decide whether the shareholders should get a dividend payment, and if the profit should be maintained in the firm.

Dividend pay-out decision conditions depend on many external and internal variables and financial considerations that the Board of Directors takes into account while recommending/declaring dividends including:

1. External Factors

- ☐ In the event of an Adverse Economic Scenario, the Board should strive to maintain a bigger part of its earnings to build up reserves.
- ☐ In order to save resources, the Board should assess the market trends for technological advances that need investments, competitive profitability, etc.
- ☐ In order to guarantee compliance with relevant regulations, the Board shall, when appropriate, examine the limits imposed by Acts and other applicable laws as regards the declaration of dividends.
- ☐ The choice on the dividend declaration may have an influence on the dividend distribution tax or any tax deduction from sources, as required by tax act, which applies at the time of the dividend declaration.
- ☐ Other events that are beyond management control, such as natural disasters, fire, etc., that affect the Company's activities, may influence the decision on a dividend declaration.

2. Internal Factors

- ☐ Possibility of earning consisting profit
- ☐ Global Market Conditions
- ☐ Tax Policy
- ☐ Fund availability and liquidity
- ☐ Capital expenditure requirements for established companies
- ☐ Business expansion / upgrade
- ☐ Further investment in subsidiaries/company partners
- ☐ Cost of collecting resources from other sources
- ☐ Cost of maintenance of debts remaining
- ☐ Contingent liability funds
- ☐ Acquisitions and Mergers
- ☐ Any other criteria that the Board deems acceptable.

In addition to the aforementioned factors, the Board analyzes the prior payout history and the sense of shareholders' expectations when establishing the dividend rate. In exceptional situations, the Board may also recommend a special dividend.

3. Financial Factors

The Company is devoted to providing its shareholders with sustainable value. The Company will seek to deliver an optimal and suitable amount of earnings in the form of dividends to its shareholders.

The Board will make every effort to sustain a dividend pay-out, taking into account the aforementioned considerations. While recommending / declaring dividend, the Board will consider financial parameters, including but not limited to,

- ☐ Operating results and overall financial position
- ☐ Working capital
- ☐ Capital expenditure requirement including for inorganic growth, if any

- ❑ Debt servicing requirements of the Company, its Subsidiaries, its Associates and Joint Ventures ('Group').

Dividend Expectations

The recommendation of Dividend will always be at the sole discretion of the Board. The Board will recommend and/or declare Dividend after reviewing this Policy keeping in mind the business environment and requirements of the Group.

Utilization of Retained Earnings

The Company will endeavor to utilize Retained Earnings for business requirements including, but not limited to, working capital, investments, expansions, acquisitions, etc.

Thus, the retained earnings may be used in accordance with, subject to the provisions of the Act and other applicable laws, as set forth in:

- ❑ Bonus shares that are completely paid up are issued;
- ❑ Interim or Final Dividend Declaration;
- ❑ Increase internal resources;
- ❑ Capital expenditure/expansion plans/procurement funding;
- ❑ Debt Repayment;
- ❑ Any other purpose that the Board deems appropriate.

Criteria for Different Share Classes

The company currently has only one share class: Equity Shares. In terms of dividend distribution, there is no special treatment for the Company's Equity Shareholders.

General Procedure

All resolutions relating to the declaration and payment of dividends will be generated by the Board of Directors of the Company.

The Board of Directors shall have the authority to recommend a final dividend to the shareholders for approval at the Company's Annual General Meeting. The Board of Directors shall have the exclusive authority to issue an interim dividend at any time throughout the fiscal year as they see fit.

The Board of Directors' decision on the Final Dividend shall be communicated to the Shareholders in the form of a recommendation.

At the AGM, the decision on whether or not to declare and pay dividends will be a separate item on the agenda.

The Board of Directors will decide on the Dividend amounts due and the payment method at a meeting when the directors will vote on the distribution of the Company's net profit for the fiscal year and recommend it to the Shareholders.

Any declaration to pay Dividends may provide the following:

- The type and class of shares on which the Dividends have been declared;
- The amount of Dividends per share of each type and class;
- The period for payment; and
- The form of payment.

Persons entitled to receive Dividends

- The list of persons entitled to receive Dividends will be prepared by the Company's Registrar in accordance with the record date determined by the Company for such purpose.
- Such list will contain registered shares, and the people on behalf of whom the nominal holders own the shares as on the record date.
- Nominal shareholders will submit information on the individuals for whom they hold shares in order to compile a list of those entitled to dividends.

Paying Declared Dividends

- The date on which annual Dividends are paid will be chosen by the Directors and announced in the Notice convening the AGM in the case of a Final Dividend. The Board of Directors will decide when interim dividends will be paid.
- No interest shall accrue on unclaimed Dividends.

- c) Any issues pertaining to the payment of Dividends that are not covered by the Law, the Company's Articles of Association, or policies shall be decided by the Board of Directors in a way that respects and protects the rights and legitimate interests of shareholders.

Disclosure of Policy

This policy is to be disclosed in the company's annual report and on the website of the company, www.renata-ltd.com.

In cases where, apart from the criteria referred to in the policy, the Company proposes or intends to amend the parameters included in this Policy to make a dividend, the Company should announce such amendments together with the rationale for them in the Annual Report and through the Website.

Board Approval

The Board of Directors of the Company at its meeting held on October 23, 2021 has approved this Dividend Distribution Policy.

Applicability and Effective Date

This Policy shall be applicable to the Company for dividend, if any, with effect from the Financial Year 2020-21 onward.

Policy Amendments

Any or all provisions of this Policy may be amended, revoked, modified, or revised by the Board. Amendments to the Act or the Listing Regulations, however, will be binding even if they are not included in this Policy.

On behalf of the Board of Directors,



Dr. Sarwer Ali
Chairman

RENATA LIMITED

REPORT OF THE NOMINATION & REMUNERATION COMMITTEE (NRC)

The Board of Directors of Renata Limited has duly constituted a Nomination and Remuneration Committee (NRC), in accordance with the requirements of the BSEC Code of Corporate Governance. .

The NRC at Renata provides guidance to the management in identifying the Company's needs for employees at different levels and determining their selection, transfer or replacement and promotion criteria.

The NRC aid the Board in the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of Directors and other top-level executives. The NRC also assists the Board to formulate policy for formal and continued process of considering remuneration/honorarium of Directors and top-level executives.

The Report of Nomination and Remuneration Committee is prepared in compliance with the Corporate Governance Code issued by the Bangladesh Securities and Exchange Commission (BSEC).

This Report describes the nomination and remuneration policies, evaluation criteria and activities of the NRC at Renata Ltd.

Roles, Responsibilities, Constitution and Evaluation Criteria of the Committee:

a) Executive Directors

The respective line authority of the Executive Director(s) sets the performance measurement criteria based on the respective role profile and responsibilities through a Company appraisal process at the beginning of each calendar year. The Executive Director(s) prepare the performance document (half-year and year end). The respective line authority then evaluates the performance of the Executive Director(s) according to the measurement criteria.

b) Independent Director & Non-Executive Director

The evaluation of performance of the Independent Directors (IDs) and Non-Executive Directors are carried out at least once a year by the Board of Directors, according to the following criteria:

- a) Attendance at the Board meetings and committee meetings
- b) Participation in the Board meetings and committee meetings
- c) Contribution to improving the corporate governance practices of the Company

c) Top-level Executives & other Employees

The respective line authority of top-level executives and other employees sets the performance measurement criteria based on the respective roles and responsibilities to achieve people and business objectives through Company appraisal processes at the beginning of each calendar year. The employees concerned prepare the performance document (half-year and year end). The respective line authority then evaluates the performance of the employee(s) according to the measurement criteria.

In addition, the NRC formulates guidelines for evaluation and assessment of all employees in the organization. These guidelines are then passed on to Human Resources Division. These guidelines are followed when assessing the performance of all employees.

d) Mid-level Employees:

The respective line management or line authority of mid-level employees and other employees set the performance measurement criteria based on respective roles and responsibilities to achieve people and business objectives through Company appraisal processes at the beginning of each calendar year.

e) Junior-level Employees:

The respective line management or line authority of junior-level employees and other employees set the performance measurement criteria based on respective roles and responsibilities to achieve people and business objectives through Company appraisal processes at the beginning of each calendar year.

Roles and Responsibilities of the Committee

- i) NRC shall oversee, among others, the following matters and make report with recommendation to the Board;
- ii) formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following:

- iii) the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully;
- iv) the relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and
- v) remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals;
- vi) reviewing the appropriateness and relevance of the present policy;
- vii) reviewing the policy for authorizing claims for expenses from the Directors;
- viii) maintaining liaison as necessary with all other Board Committees;
- ix) identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; and
- x) developing, recommending and reviewing annually the company's human resources and training policies;

Review of the Terms of Reference

- i) The Committee shall review annually its Terms of Reference and may recommend to the Board any amendments to its Terms of Reference.
- ii) The Board shall have the authority to make amendment to this Terms of Reference at any time.

Performance Evaluation Criteria for Board, Board Committees and Directors

The Company has adopted the Board Evaluation Framework and Policy based on recommendation of the Nomination and Remuneration Committee, which sets a mechanism and criteria for evaluation of the Board, Board Committees and Directors, including Independent Directors. The Board has carried out the annual performance evaluation of the Directors individually as well as evaluation of the working of the Board and of the Committees of the Board, by way of individual and collective feedback from Directors.

Board and Board Committees evaluation is done by the Board through self-assessment and group discussions. Criteria for evaluation of the Board include:

- i) Structure and composition of the Board,
- ii) Meeting attendance,
- iii) Devotion of time for important business matters-financials,
- iv) Monitoring Internal Controls/Code of Conduct/Insider Trading Policy/ Emerging Risks/Governance and compliance issues,
- v) Adequate access to information for effective decision-making,
- vi) Strategic guidance to management through regular interactions and cohesiveness in the overall working that facilitates open discussion.

Criteria for evaluation of the Committee include:

- i) Structure and composition of the committees,
- ii) Adequacy of charter and working procedure,
- iii) Frequency of meetings,
- iv) Whether the Committee is functioning as per the charter and
- v) Whether the Committee recommendations contribute effectively to the Board decision making.

Evaluation of the Directors is done by the Board (excluding the Director whose evaluation is being done). Criteria for evaluation of the Directors include:

- i) Skill set,
- ii) Knowledge,
- iii) Attendance,
- iv) Effective participation at Board/Committee Meetings,
- v) Their contribution at the Meetings,
- vi) Leveraging on his/her experience to provide the necessary insights/guidance on Board discussions and

vii) Display of sincerity in expressing views even when they are in divergence with the rest of the Board, etc.

Independent Directors at their separate meeting evaluated the performance of the Board, Non-Independent Directors and the Chairman basis of the feedback from Executive and Non-Executive Board Members.

Activity Summary of Nomination and Remuneration Committee during the year

a) Formation of NRC and its Meetings

The Board restructured the Nomination & Remuneration Committee (NRC) on June 13, 2020 as per the requirement of BSEC Corporate Governance Code with the following composition:

- Mr. Nehal Ahmed
Director & Chairperson of the NRC
- Mrs. Zahida Fizza Kabir
Director & Member, NRC
- Mrs. Tanya Tazeen Karim
Director & Member, NRC

In 2021-22 the Committee met once, dated December 23, 2021. The Managing Director, Head of Finance and Head of HR attended the meeting by invitation of the committee.

b) The Key activities of the NRC during the year:

1. Considering the terms of reference of NRC, as approved by the Board
2. Formulated and recommend to the Board a set of corporate governance guidelines applicable to the Company
3. Formulated the Board Performance Evaluation criteria and the committee shall conduct this evaluation in such manner as it deems appropriate
4. Formulated the criteria for evaluation of independent directors and the Board and carry out evaluation of every director's performance
5. Formulated the policy relating to the remuneration of the Directors, top level executives and all employees of the Company
6. Formulated the criteria for evaluation of performance of Independent Directors and the Board Members
7. Identify the criteria for selection, transfer or placement and promotion at different levels of the company
8. Formulated and recommend to the Board for approval a CEO succession plan (the "Succession Plan"), to review the Succession Plan periodically with the CEO, to develop and evaluate potential candidates for executive positions and recommend to the Board any changes to, and any candidates for succession under, the Succession Plan.
9. Reviewed the Board's committee structure and composition and made recommendations to the Board regarding the appointment of directors to serve as members of each committee and committee chairpersons.



Nehal Ahmed
Chairman
Nomination and Remuneration Committee

ANNEXURE-E

RENATA LIMITED FINANCIAL HIGHLIGHTS


Particulars	Figures in Taka (Thousands)				
	2021-2022	2020-2021	2019-2020	2018-2019	2017-2018
Balance Sheet					
Shareholders' Equity					
Share capital	1,071,930	974,482	885,892	805,357	700,310
Proposed stock dividend	75,035	97,448	88,589	80,536	105,047
Proposed cash dividend	1,500,702	1,412,998	1,151,660	805,357	665,295
Revaluation surplus	152,869	153,361	153,854	154,331	154,808
Unappropriated profit	26,611,767	22,811,519	19,259,433	16,439,183	13,501,704
Shareholders' fund	29,412,303	25,449,808	21,539,430	18,284,763	15,127,164
Long term & deferred liabilities	1,405,429	1,368,214	1,442,915	1,303,840	1,209,209
Total	30,817,732	26,818,022	22,982,345	19,588,603	16,336,373
Application of Funds					
Property, plant & equipment-WDV	26,510,156	17,021,086	13,668,110	11,720,776	10,746,707
Investment & non-current assets	10	63,080	63,080	143,079	143,069
Current assets	15,505,410	17,298,501	15,313,364	12,337,381	9,921,903
Current liabilities	(11,197,844)	(7,564,645)	(6,062,210)	(4,612,634)	(4,475,306)
Total	30,817,732	26,818,022	22,982,345	19,588,603	16,336,373
Financial Results					
Turnover (Gross)	35,540,185	33,201,022	27,675,678	25,431,634	21,339,459
Turnover (Net)	31,070,555	29,250,907	24,164,022	22,220,887	18,603,709
Gross profit	14,725,972	13,949,496	11,531,115	11,154,921	9,346,470
Operating profit	6,526,889	6,815,171	5,970,683	5,350,427	4,623,902
EBITDA	7,721,160	7,887,079	7,130,372	6,165,632	5,239,795
Profit before taxation	6,122,668	6,733,532	5,992,008	5,213,777	4,333,061
Profit after taxation	5,110,957	5,034,821	4,129,596	3,823,362	3,196,951
Total comprehensive income	5,112,948	5,061,895	4,102,930	3,822,735	3,200,539
Dividend	1,575,737	1,510,447	1,240,249	885,892	770,342
Financial Performance					
Number of shares	107,192,982	97,448,166	88,589,242	80,535,675	70,031,022
Earnings per share (Taka)	47.68	46.97	38.52	35.67	29.82
Dividend per share (Taka)	14.70	15.50	14.00	11.00	11.00
Dividend payout %	30.83%	30.00%	30.03%	23.17%	24.10%
Effective dividend rate %	1.09%	1.17%	1.36%	0.92%	0.85%
Price earnings ratio (Times)	28.22	28.10	26.64	33.60	43.47
Market price per share (Taka)	1,345.60	1,319.70	1,026.20	1,198.40	1,296.50
Price/Equity ratio (Times)	134.56	131.97	102.62	119.84	129.65
Gross profit margin %	47.40%	47.69%	47.72%	50.20%	50.24%
Return on shareholders' fund %	17.38%	19.78%	19.17%	20.91%	21.13%
Return on capital employed %	21.28%	25.72%	27.04%	27.39%	27.79%
Debt equity ratio (Times)	0.30	0.19	0.14	0.14	0.16
Current ratio (Times)	1.38	2.29	2.53	2.67	2.22
Net operating cash flow per share (Taka)	28.07	39.45	41.55	38.76	24.36
Net asset value per share (Taka)	274.39	237.42	200.94	170.58	141.12
Number of employees	10,380	8,957	7,710	6,886	6,798

Financial Trend

TAKA (MILLIONS)




SHAREHOLDERS' FUND



TURNOVER (NET)




GROSS PROFIT



OPERATING PROFIT

Financial Trend


TAKA (MILLIONS)




EBITDA



PROFIT AFTER TAXATION




DIVIDEND




EARNINGS PER SHARE (TAKA)


Financial Trend




DIVIDEND PAYOUT %



PRICE EARNINGS RATIO (TIMES)




MARKET PRICE PER SHARE (TAKA)




RETURN ON SHAREHOLDERS' FUND %

Financial Trend



NET OPERATING CASH FLOW PER SHARE (TAKA)



NET ASSET VALUE PER SHARE (TAKA)

Statement of Value Addition

	2021-22 Taka	%	2020-21 Taka	%
Turnover and other income	31,407,011,573		29,670,396,351	
Less: Material cost and expenses	14,069,231,494		13,618,174,432	
Value added	17,337,780,079	100.0%	16,052,221,919	100.0%


Application:

Salaries and benefits to employees	5,118,424,922	29.5%	4,127,576,844	25.7%
Duties and taxes to government exchequer	7,108,397,947	41.0%	6,889,824,165	42.9%
Dividend to shareholders	1,575,736,835	9.1%	1,510,446,573	9.4%
Retained by the company	3,535,220,375	20.4%	3,524,374,337	22.0%
Total	17,337,780,079	100.0%	16,052,221,919	100.0%


■ Salaries and benefits to Employees
■ Duties and Taxes to Government Exchequer

■ Dividend to Shareholders
■ Retained by the Company

2021-2022



2020-2021



Corporate Social Responsibility

Corporate Social Responsibility (CSR) is the continuing commitment by business to behave ethically and contribute to economic development while improving the quality of life of the workforce and their families as well as of the local community and society at large. At Renata, we strongly believe that in order to be successful it is necessary to create value, not just for the company but also for the society that we live in. In our company, corporate social responsibility means caring for our employees, assisting disadvantaged members of our society, and building a sustainable environment.

Led by this believe, Renata donates substantially on various CSR activities. This includes:

A) FINANCIAL ASSISTANCE TO THE HEALTHCARE ORGANIZATIONS

Renata Limited always extended its financial support to a number of organizations involved in the treatment and healthcare. This year, Renata Limited provided financial assistance to several such organizations by donating sizeable portions out of CSR funds.

The healthcare organizations which received financial assistance from Renata Limited are given below:

Bangabandhu Sheikh Mujib Medical University (BSMMU)	Renata is proud to have gifted equipment and instruments of substantial monetary value for facilitating endocrinology, gyne-oncology and virology in the reputed Bangabandhu Sheikh Mujib Medical University (BSMMU).
SANDHANI	SANDHANI is voluntary institution run by medical and dental college students of Bangladesh. It is one of the most renowned organizations serving for humanity in the field of voluntary blood donation, motivation, vaccination & posthumous eye donations and many other voluntary activities to lessen the sufferings of distressed people since 1977.
American Chamber of Commerce in Bangladesh (AmCham)	AmCham Bangladesh initiated a project in 2020 to help the COVID-19 affected marginal farmers and their families to provide a grant to address the immediate economic needs and facilitate linkage between farmers and Government agricultural institutions for advice and support. Renata Limited is proud to associate itself with their charitable work and is one of the benefactors.
Society of Surgeons of Bangladesh	The Society of Surgeons of Bangladesh (SOSB) is a platform for all the surgeons of Bangladesh. It is an ever expanding and evolving one, pursuing the highest level of surgical care.
Society of Plastic Surgeons of Bangladesh (SPSB)	The Society of Plastic Surgeons of Bangladesh (SPSB) is a platform for all the Plastic Surgeons of Bangladesh.

Bangladesh Society of Medicine	Bangladesh Society of Medicine is an organization of Medicine specialists of Bangladesh. The Society established for ensuring the rights and benefits of Medicine Specialists and teaching the graduate and post graduate students. Renata Limited is their long-time scientific partner in different academic activities and an active participant in various activities.
Bangladesh Gastroenterology Society	Bangladesh Gastroenterology Society is the National Organization of specialists of gastrointestinal, hepatobiliary and pancreatic diseases involve in delivering specialist health care, teaching and research in this discipline.

B) HEALTHCARE FOR EMPLOYEES AND THEIR FAMILIES

The Renata health program covers all permanent employees, their spouses, and children. This comprehensive program includes surgery, hospitalization, as well as routine doctor visits. At Renata, all employees are reimbursed for their personal medical expenses.

The following areas are covered :

General, Gynecology, Cardiovascular, Diabetes, Accident, Diagnostic, Gastroenterology, Oncology, Pediatrics, Dentistry, Skin & Dermatology, Nephrology, Gastroenterology, ENT.

C) SCHOLARSHIP TO MERITORIOUS STUDENTS

HOPES (Helping Organization for Promising and Energetic Students) run a scholarship program for meritorious students. Renata Limited sponsored students for studying Medicine under the aegis of this program. Through HOPES, Renata Limited sponsors students who would otherwise not be able to pursue a degree in Medicine.

D) WOMEN'S EMPOWERMENT

Renata Ltd. is a firm believer of women empowerment. It has been supporting this cause with great enthusiasm for a long time.



Renata Ltd. feels proud to have supported Bangladesh's great woman mountaineer Wasfia Nazreen.

On March 26, 2012, Wasfia Nazreen reached the summit of Mount Everest – the youngest person from Bangladesh and the first one-woman team from our country to ever do so. Renata continued to support her in her quest to be the first Bangladeshi to climb the Seven Summits.

In 2015, Wasfia Nazreen became the first Bangladeshi to scale all the seven summits. Earlier, Renata supported her expeditions to Mount Elbrus and Everest. Carstenz Pyramid, the final climb of her seven summits expedition was also sponsored by us.

In 2022, Wasfia Nazreen was also the first Bangladeshi to scale Pakistan's notorious K2 summit. At 8,611 meters (28,251 ft), K2 Summit is the second highest mountain peak of the world. As in the previous expeditions, Renata Ltd. has been a proud sponsor of her journey once again.

E) FINANCIAL ASSISTANCE TO EX-EMPLOYEES AND THEIR CHILDREN.

Renata Limited has been providing financial assistance to its ex-employees and their children since its inception. Every year, a substantial portion of Renata Limited's total CSR expenditure is set aside for the financial assistance of ex-employees and their children.

F) TREATMENT FOR DOCTORS WITH LIFE-THREATENING ILLNESS

Renata Limited continues to fund treatment for patients diagnosed with cancer and other life-threatening illnesses.

G) NATIONAL EMERGENCY

Renata Limited has extended financial support in times of any national emergency time and again.

In 2013, the ready-made garment industry of the nation faced one of its severest tragedies. On April 24, 2013, an eight-story building in Savar collapsed, killing over 1,100 garment factory workers inside, and injuring hundreds of others. Renata provided support to the victims of this tragedy and their families.

In 2009, Cyclone Ali attacked offshore 15 districts of south-western part of Bangladesh, killing about 150 persons and destroying 2 lac houses and 3 lac acres of cultivated land and crops.

In 2019, Cyclone Bulbul caused severe flooding and storm surge in the country, with approximately 72,000 metric tons of crops being lost, with a total value of Tk 2.6 billion (US\$31 million).

In 2022, floodwater has stranded over two lakh people in Kurigram district. Due to the swelling of major rivers caused by onrush of water from upstream and incessant rainfall, rendering over 200,000 people marooned.

In all these instances, Renata Ltd stood beside the Bangladesh government in its relief program and provided generous aid to the victims of the disaster.

In 2020, Bangladesh was thrown into a crisis brought by the global pandemic COVID-19. It brought a crisis to the national economy and the impact was severe on people who survive on daily wages. Due to the country wide lock down, many lost their sources of income and had to live without wages for days.

Renata reached out to these disadvantaged groups in various ways. The 19 Depot offices of Renata, and production factory sites of Renata, located in different parts of Bangladesh, arranged for day meals for these unfortunate victims of the lock down, saving them from starvation.

In addition to the above, Renata has provided financial assistance to victims of national crisis natural calamities in many instances and resolves to do so in the future.



Product Portfolio



PHARMACEUTICAL PRODUCTS:

ANTIMICROBIALS:

Trade Name	Generic Name	Formulation	Strength	Pack Size
Bactamox	Amoxicillin Trihydrate	Tablet	250mg	10x10's
Bactamox	Amoxicillin Trihydrate	Tablet	500mg	5x10's
Bactamox	Amoxicillin Trihydrate	Paed. Drops	125mg/1.25mL	Bottle 15ml
Bactamox	Amoxicillin Trihydrate	DPS	125mg/5ml	Bottle 100ml
Bactamox IM/IV	Amoxicillin Trihydrate	Injection	500mg	1's
Cebuten	Ceftibuten Dihydrate	Capsule	400mg	2x7's
Ceftizone IM	Ceftriaxone	Injection	250mg	Vial 250mg
Ceftizone IM	Ceftriaxone	Injection	500mg	Vial 500mg
Ceftizone IM	Ceftriaxone	Injection	1gm	Vial 1gm
Ceftizone IV	Ceftriaxone	Injection	250mg	Vial 250mg
Ceftizone IV	Ceftriaxone	Injection	500mg	Vial 500mg
Ceftizone IV	Ceftriaxone	Injection	1gm	Vial 1gm
Ceftizone IV	Ceftriaxone	Injection	2gm	Vial 2gm
Ceftipime	Cefepime HCL	Injection	500mg	Vial 500mg
Ceftipime	Cefepime HCL	Injection	1gm	Vial 1gm
Ceftipime	Cefepime HCL	Injection	2gm	Vial 2gm
Cefotax IM/IV	Cefotaxime Sodium	Injection	250mg	Vial 250mg
Cefotax IM/IV	Cefotaxime Sodium	Injection	500mg	Vial 500mg
Cefotax IM/IV	Cefotaxime Sodium	Injection	1gm	Vial 1gm
Cefazid IM/IV	Ceftazidime	Injection	250mg	Vial 250mg
Cefazid IM/IV	Ceftazidime	Injection	500mg	Vial 500mg
Cefazid IM/IV	Ceftazidime	Injection	1gm	Vial 1gm
Covan	Vancomycin	Injection	500mg	Vial 500mg
Covan	Vancomycin	Injection	1gm	Vial 1gm
Doxicap	Doxycycline Hydrochloride	Capsule	50mg	5x10's
Doxicap	Doxycycline Hydrochloride	Capsule	100mg	10x10's
Diamine Penicillin	Benzathine Pen. G	Injection	12,00,000 units	Vial 12 lac units
Erythrox	Erythromycin	Tablet	250, 500mg	5x10's
Erythrox	Erythromycin	DPS	125mg/5ml	Bottle 100ml
Erpen IM/IV	Ertapenem	Injection	1gm	Vial 1gm
Furocef IM/IV	Cefuroxime Sodium	Injection	250, 750mg	Vial 250, 750mg
Furocef IM/IV	Cefuroxime Sodium	Injection	1gm	Vial 1gm
Furocef IV	Cefuroxime Sodium	Injection	1.5gm	Vial 1.5gm
Furocef	Cefuroxime Axetil	Tablet	125mg	2x5's
Furocef	Cefuroxime Axetil	Tablet	250mg	2x8's
Furocef	Cefuroxime Axetil	Tablet	500mg	2x6's
Furocef	Cefuroxime Axetil	DPS	125mg/5ml	Bottle 70ml
Furocef DS	Cefuroxime Axetil	DPS	250mg/5ml	Bottle 50ml
Flontin	Ciprofloxacin Hydrochloride	Tablet	250mg	2x10's
Flontin	Ciprofloxacin Hydrochloride	Tablet	500mg	3x10's
Flontin	Ciprofloxacin Hydrochloride	Tablet	750mg	2x10's
Flontin	Ciprofloxacin Hydrochloride	DPS	250mg/5ml	Bottle 60ml
Flontin IV	Ciprofloxacin Lactate	IV Infusion	2mg/ml	Vial 100ml
Flustar	Flucloxacillin Sodium	Capsule	250mg	12x4's
Flustar	Flucloxacillin Sodium	Capsule	500mg	7x4's
Fluster	Flucloxacillin sodium	Suspension	125mg/5ml	Bottle 100ml
Furoclav	Cefuroxime 500mg + Clavulanic Acid 125 mg	Tablet	500mg	2x7's
Furoclav	Cefuroxime 250mg + Clavulanic Acid 62.5 mg	Tablet	250mg	2x7's
Iropen IV	Imipenem/Cilastatin	Injection	500mg	Vial 500mg
Levoking	Levofloxacin Hemihydrate	Tablet	500mg	5x6's
Levoking	Levofloxacin Hemihydrate	Tablet	750mg	3x6's
Levoking	Levofloxacin Hemihydrate	Oral Solution	125mg/5ml	Bottle 100ml
Linez	Linezolid	Tablet	400mg	2x6's

*DPS= Dry Powder for Suspension

Trade Name	Generic Name	Formulation	Strength	Pack Size
ANTIMICROBIALS:				
Linez	Linezolid	Tablet	600mg	2x6's
Meropen IV	Meropenem	Injection	250mg	Vial 250mg
Meropen IV	Meropenem	Injection	500mg	Vial 500mg
Meropen IV	Meropenem	Injection	1gm	Vial 1gm
Nexolid	Tedizolid Phosphate	Tablet	200mg	1x6's
Orcef	Cefixime	Tablet	200mg	2x6's
Orcef	Cefixime	Tablet	400mg	2x6's
Orcef	Cefixime	DPS	100mg/5ml	Bottle 70ml/50ml/40ml/30ml
Orcef DS	Cefixime	DPS	200mg/5ml	Bottle 50ml
Orcef	Cefixime	Capsule	200mg	2x8's
Orcef	Cefixime	Capsule	400mg	2x6's
Polycef	Cephadrine	Capsule	250mg	5x4's
Polycef	Cephadrine	Capsule	500mg	7x4's
Polycef	Cephadrine	DPS	125mg/5ml	Bottle 100ml
Polycef DS	Cephadrine	DPS	250mg/5ml	Bottle 100ml
Polycef	Cephadrine	Injection	250mg	Vial 250mg
Polycef	Cephadrine	Injection	500mg	Vial 500mg
Polycef	Cephadrine	Injection	1gm	Vial 1gm
Polycef PD	Cephadrine	Paed. Drops	125mg/1.25ml	Bottle 15ml
Pronapen	Procaine Penicillin + Penicillin G	Injection	4,00,000 units	Vial 4 lac &
			8,00,000 units	Vial 8 lac units
Qcin	Clindamycin	Capsule	150mg	5x6's
Qcin	Clindamycin	Injection	300mg/2ml	1x5's
Qcin	Clindamycin	Capsule	300mg	5x6's
Qcin	Clindamycin	Injection	600mg/4ml	1x5's
Renamycin	Oxytetracycline	Capsule	250mg	60's
Renamycin	Oxytetracycline	Injection	50mg/ml	Vial 10ml
Trucef	Cefpodoxime Proxetil	DPS	40mg/5ml	Bottle 50ml
Trucef DS	Cefpodoxime Proxetil	DPS	80mg/5ml	Bottle 50ml
Trucef PD	Cefpodoxime Proxetil	Ped. Drops	20mg/ml	Bottle 15ml
Tazopen	Piperacillin + Tazobactam	IV Infusion	2gm/.25gm	Vial 50ml
Tazopen	Piperacillin + Tazobactam	IV Infusion	2gm/.5gm	Vial 100ml
Toplon	Gemifloxacin	Tablet	320mg	1x6's
Vcap	Neomycin Sulphate+ Polymyxin B	Soft Gelatin	35000 I.U.+ 35000 I.U.	1x6's
	Sulphate+ Nystatin+Metronidazole	Capsule	100000 I.U.+ 200mg	
Zithrin	Azithromycin	Capsule	250mg	3x5's
Zithrin	Azithromycin	Tablet	250mg, 500mg	3x5's
Zithrin	Azithromycin	DPS	200mg/5ml	Bottle 15ml/20ml/30ml/35ml/50ml
Zithrin	Azithromycin	IV Infusion	500mg	Vial 500mg
ANTI-HYPERTENSIVE				
Cardipin	Amlodipine	Tablet	5mg	6x10's
Cardipin Plus	Amlodipine+Atenolol	Tablet	5mg+50mg	6x10's
Alphapress	Prazosin Hydrochloride	Tablet	1mg & 2mg	10x10's
Alphapress XR	Prazosin Hydrochloride	Tablet	2.5mg & 5mg	3x10's
Ostan	Losartan Potassium	Tablet	25mg, 50mg	3x10's, 5x10's
Ostan Plus	Losartan Potassium+ Hydrochlorothiazide	Tablet	50mg+12.5mg	3x10's
Plagrin	Clopidogrel	Tablet	75mg	3x10's
Plagrin Plus	Clopidogrel+ Aspirin	Tablet	75mg+75mg	3x10's
Pendoril-2	Perindopril	Tablet	2mg	2x10's
Pendoril-4	Perindopril	Tablet	4mg	2x10's
Pendoril Plus-2	Perindopril + Indapamide	Tablet	2mg + 0.625mg	2x10's
Pendoril Plus-4	Perindopril + Indapamide	Tablet	4mg + 1.25mg	2x10's
Bisoren-2.5	Bisoprolol Fumarate	Tablet	2.5mg	3x10's
Bisoren-5	Bisoprolol Fumarate	Tablet	5mg	3x10's

*DPS= Dry Powder for Suspension

Trade Name	Generic Name	Formulation	Strength	Pack Size
------------	--------------	-------------	----------	-----------

ANTI-HYPERTENSIVE

Bisoren Plus 2.5	Bisoprolol+Hydrochlorothiazide	Tablet	2.5mg+6.25mg	3x10's
Bisoren Plus 5	Bisoprolol+Hydrochlorothiazide	Tablet	5mg+6.25mg	3x10's
Uritone-20	Furosemide+ Spironolactone	Tablet	20mg + 50mg	3x10's
Uritone-40	Furosemide+ Spironolactone	Tablet	40mg + 50mg	3x10's
Azisan	Azilsartan Medoxomil Potassium	Tablet	40mg	3x10's
Azisan	Azilsartan Medoxomil Potassium	Tablet	80mg	2x10's
Azisan Plus	Azilsartan + Chlorthalidone	Tablet	Azilsartan 40mg + Chlorthalidone 12.5mg	2x10's
Bisoren-M	Bisoprolol+Amlodipine	Tablet	2.5mg+5mg	3x10's
Rezor	Olmesartan	Tablet	20mg	3x10's
Rezor	Olmesartan	Tablet	40mg	3x10's
Rezor Max	Olmesartan + Amlodipine	Tablet	20mg+5mg	3x10's
Rezor Max	Olmesartan + Amlodipine	Tablet	40mg+5mg	3x10's
Nebiren	Nebivolol	Tablet	2.5mg	3x10's
Nebiren	Nebivolol	Tablet	5mg	3x10's
Cilma	Cilnidipine	Tablet	5mg	3x10's
Cilma	Cilnidipine	Tablet	10mg	3x10's

CARDIOVASCULAR

Roxolyte	Rivaroxaban	Tablet	10mg	1x10's
Maxipass	Tamsulosin Hydrochloride	Capsule	0.4mg	5x6's

ANTI-ANGINA

Antogin ER	Ranolazine	Tablet	500mg	4X5's
Trizedon MR	Trimetazidine Dihydrochloride	Tablet	35mg	3x10's

LIPID LOWERING AGENT

Taven	Atorvastatin	Tablet	10mg/20mg/40mg	3x10's
Fenobate	Fenofibrate	Capsule	200mg	5x6's
Rolip	Rosuvastatin Calcium	Tablet	5mg, 10mg, 20mg	3x10's, 2x10's

ANTI-DIABETIC

Bigmet-500	Metformin HCL	Tablet	500mg	10x10's
Bigmet-850	Metformin HCL	Tablet	850mg	10x10's
Bigmet 500 XR	Metformin HCL	Tablet	500mg	5x6's
Glicron CR	Gliclazide CR pellets	Capsule	30mg	3x10's
Glicron	Gliclazide	Tablet	80mg	3x10's
Glinta	Linagliptin	Tablet	5mg	2X10's
Sitamet	Metformin+Sitagliptin	Tablet	500mg+50mg	1x10's
Diampa	Empagliflozin	Tablet	10mg	2x10's
Diampa	Empagliflozin	Tablet	25mg	1x10's
Glinta-M	Linagliptin+Metformin	Tablet	2.5mg+500mg	3x10's
Glinta-M	Linagliptin+Metformin	Tablet	2.5mg+850mg	5x6's
Gleron	Ticagrelor INN	Tablet	90mg	1x10's

EYE-EAR AND TOPICAL PREPARATIONS

Renamycin Eye/ Ear ointment	Oxytetracycline HCL + Polymyxin-B-Sulfate	Ointment	5mg/gm	3.5gm
Renamycin otic Solution	Oxytetracycline HCL + Benzocaine	Solution	5mg/ml	Vial/Bottle 5ml
Renamycin topical Oint.	Oxytetracycline HCL + Polymyxin-B-Sulfate	Topical ointment	30mg/gm	Tube 5gm
Deltasone-N Eye/ Ear drops	Prednisolone + Neomycin	Drops	0.5%	Bottle 5ml

Trade Name	Generic Name	Formulation	Strength	Pack Size
ANTIGOUT				
Feburen	Febuxostat	Tablet	40mg	3x10's
Feburen	Febuxostat	Tablet	80mg	1x10's
NSAIDS				
Cartilage Max	Glucosamine Sulfate+Diacerein	Tablet	750mg+50mg	3x10's
Ceclofen	Aceclofenac	Tablet	100mg	5x10's
Dysmen	Mefenamic Acid	Tablet	250mg	10x10's
Dysmen	Mefenamic Acid	Tablet	500mg	5x10's
Rolac	Ketorolac	Tablet	10mg	4x14's
Rolac	Ketorolac	Injection	10mg/1ml	1x 5's
Rolac	Ketorolac	Injection	30mg/1ml	1's
Rolac	Ketorolac	Injection	60mg/2ml	1's
Recox	Etoricoxib	Tablet	120mg	2x10's
Recox	Etoricoxib	Tablet	60mg	3x10's
Recox	Etoricoxib	Tablet	90mg	2x10's
Cartilage Plus	Glucosamine Sulfate+ Chondroitin Sulfate	Tablet	250mg+200mg	5x6's
Xenapro 250	Naproxen	Tablet	250mg	5x10's
Xenapro 500	Naproxen	Tablet	500mg	5x6's
Xenapro Plus 375	Naproxen + Esomeprazole	Tablet	375mg+20mg	5x6's
Xenapro Plus 500	Naproxen + Esomeprazole	Tablet	500mg+20mg	5x6's
Rapidol	Tramadol Hydrochloride	Injection	100mg/2ml	1x5's
Maxolax	Baclofen	Tablet	10mg	3x10's
Maxolax	Baclofen	Tablet	5mg	3x10's
Migesic	Tolfenamic Acid BP	Tablet	200mg	3x10's
ANTIULCER AGENTS				
Prazole	Omeprazole	Capsule	20mg	5x14's
Maxpro	Esomeprazole	Tablet	20mg	10x14's
Maxpro	Esomeprazole	Tablet	40mg	6x10's
Maxpro	Esomeprazole	Capsule	20mg	10x14's
Maxpro	Esomeprazole	Capsule	40mg	10x10's
Maxpro	Esomeprazole	Injection	40mg	1x1's
Maxpro HP	Esomeprazole+Amoxicillin+	Capsule+Tablet+	20mg+500mg+	14x4's
	Clarithromycin	Tablet	500mg	
Protonil	Pantoprazole	Tablet	20mg	5x10's
Protonil	Pantoprazole	Tablet	40mg	3x10's
Profast	Rabeprazole	Tablet	20mg	6x10's
ANTI-PARASITIC & ANTI-PROTOZOAL AGENTS				
Xanita	Nitazoxanide	Tablet	500mg	3x6's
Xanita	Nitazoxanide	DPS	100mg/5ml	Bottle 30ml
Xanita	Nitazoxanide	DPS	100mg/5ml	Bottle 60ml
Delentin	Pyrantel Pamoate	Tablet	125mg	10x10's
Delentin	Pyrantel Pamoate	Suspension	50mg/ml	Bottle 10ml
Alentin	Albendazole	Tablet	200mg	2x40's
Alentin DS	Albendazole	Tablet	400mg	1x 25's
Protogyn	Tinidazole	Tablet	500mg	10x10's
Protogyn	Tinidazole	Tablet	1gm	5x4's
Mectin	Ivermectin	Tablet	6mg	3x10's
Mectin	Ivermectin	Tablet	12mg	2x10's
ANTI-FUNGAL AGENT				
Lucan-R	Fluconazole	Capsule	50mg	4x10's
Lucan-R	Fluconazole	Capsule	150mg	2x6's

*DPS= Dry Powder for Suspension

Trade Name	Generic Name	Formulation	Strength	Pack Size
ANTI-FUNGAL AGENT				
Lucan-R	Fluconazole	Capsule	200mg	2x6's
Lucan-R	Fluconazole	DPS	50mg/5ml	Bottle 35ml
Conasyd	Tioconazole	Cream	1% dermal	Tube 10gm
ANTI-TUBERCULOSIS AGENT				
Streptomycin	Streptomycin Sulfate	Injection	1gm	Vial 1gm
ANTI-SPASMODIC				
Algin	Tiemonium	Tablet	50mg	10x10's
Algin	Tiemonium	Injection	5mg/2ml	1x5's
Algin	Tiemonium	Syrup	10mg/5ml	Bottle 50ml, 100ml
STEROID				
Deltasone	Prednisolone	Tablet	5mg	25x10's, 50x10's
Deltasone	Prednisolone	Tablet	10mg	10x10's
Deltasone	Prednisolone	Tablet	20mg	5x10's
Deltasone	Prednisolone	Oral Solution	5mg/5ml	Bottle 100ml
Deltasone	Prednisolone	Oral Solution	5mg/5ml	Bottle 50ml
Dexa	Dexamethasone	Tablet	0.5mg	25x10's
Dexa IM/IV	Dexamethasone	Injection	5mg/ml	10's
Zodef	Deflazacort	Tablet	6mg	3x10's
Zodef	Deflazacort	Tablet	24mg	2x10's
ANTI-OSTEOPOROTIC				
Ivana	Ibandronic Acid	Tablet	150mg	1's
VITAMINS & MINERALS				
Beconex	Vitamin B-Complex	Syrup	-	Bottle 100ml
Beconex	Vitamin B-Complex	Syrup	-	Bottle 200ml
Beconex ZI	Iron+Vitamin B-Complex & Zinc	Syrup	-	Bottle 100ml
Becosules	Vitamin B-Complex	Capsule	-	16x6's
Becosules Gold	Vitamin B-Complex + Vit-C	Capsule	-	15x6's
Calcin	Calcium Carbonate	Tablet	500mg	5x10's
Calcin-D	Calcium+Vit-D	Tablet	500mg+200IU	6x10's, Pot 15's, Pot 30's
Calcin-O	Calcium Orotate	Tablet	400mg	3x10's
Calcin-O DS	Calcium Orotate	Tablet	740mg	3x10's
Calcin-O KIT	Ibandronic Acid + Calcium Orotate	Tablet	150mg+400mg	1 Kit
Calcin-M	Calcium Carbonate+Vit-D+Mineral	Tablet	-	4x10's, Pot 30's
Calciferol	Cholecalciferol	IM Injection	200000 IU/ml	1's
Calcifer	Calcium Lactate+Calcium Carbonate+Ascorbic Acid	Effervescent	1000mg+327mg+500mg	10's
Coralcin-D	Calcium (Coral source) & Vitamin D ₃	Tablet	500mg+200IU	6x10's
E-Gel	Vitamin E	Soft Gelatin Capsule	200mg	10x10's
E-Gel DS	Vitamin E	Soft Gelatin Capsule	400mg	5x10's
Ferix	Carbonyl Iron, Folic Acid and Zinc	Capsule	50mg+500mcg+22.5mg	6x10's
Kiddi	Multivitamin+Codliver oil	Syrup	-	Bottle 100ml
Kiddi	Multivitamin+Codliver oil	Syrup	-	Bottle 200ml
Lucent	Calcitriol	Soft Gelatin Capsule	0.25mcg	3x10's
Pushtikona	Micronutrient Powder	Powder in Sachet	-	1x30's
Sprinkles	Micronutrient Powder	Powder in Sachet	-	1x30's
Mazic 20	Zinc Sulfate Monohydrate	Tablet	20mg	3x10's
Mazic Jr	Zinc Sulfate Monohydrate	Syrup	4.05mg/5ml	Bottle 100ml
Mazic	Zinc Sulfate Monohydrate	Syrup	10mg/5ml	Bottle 100ml
Mazic DS	Zinc Sulfate Monohydrate	Syrup	20mg/5ml	Bottle 100ml
Magsum	Magnesium Sulfate	Injection	2.5gm /5ml	1x5 Ampoules
Neurobest	Vit B ₁ +B ₆ +B ₁₂	Tablet	100mg+200mg	6x10's

Trade Name	Generic Name	Formulation	Strength	Pack Size
VITAMINS & MINERALS				
Neurobest	Vit B ₁ +B ₆ +B ₁₂	Injection	100mg+100mg +1mg	2x5's
Vita D3	Cholecalciferol	Capsule	40000 IU	2X5's
Vita D3	Cholecalciferol	Capsule	20000 IU	2X5's
Coralcin-DX	Calcium <Coral Source> 600mg & Vitamin D3 400IU	Tablet	600mg/400IU	1x15's
Coralcin-DX	Calcium <Coral Source> 600mg & Vitamin D3 400IU	Tablet	600mg/400IU	1x30's
CEE	Vitamin-C 1000mg	Effervescent Tablet	1000mg	1x10's
ANTI-ALLERGIC				
Fenadin	Fexofenadine HCL	Tablet	60mg	3x10's
Fenadin	Fexofenadine HCL	Tablet	120mg	5x10's
Fenadin	Fexofenadine HCL	Tablet	180mg	2x10's
Fenadin	Fexofenadine HCL	Suspension	30mg/5ml	Bottle 30ml
Fenadin	Fexofenadine HCL	Suspension	30mg/5ml	Bottle 50ml
Stark	Rupatadine	Tablet	10mg	3x10's
CNS-PRODUCT				
Gaba	Gabapentin	Tablet	300mg	3x10's
Gaba-P	Pregabalin	Capsule	25mg	5x6's
Gaba-P	Pregabalin	Capsule	50mg	3x10's
Gaba-P	Pregabalin	Capsule	75mg	3x10's
Renxit	Flupentixol+Melitracen	Tablet	0.5mg+10mg	10x10's
Norry	Bromazepam	Tablet	3mg	5x10's
Cabretol	Carbamazepine	Tablet	200mg	5x10's
Cabretol	Carbamazepine	CR Capsule	200mg	5x10's
Cabretol	Carbamazepine	Syrup	100mg/5ml	Bottle 100ml
Denixil	Clonazepam	Tablet	0.5mg, 2mg, 1g	5x10's, 3x10's, 5x10's
Midzo	Midazolam	Tablet	7.5mg	3x10's
Midzo	Midazolam	Injection	15mg/3ml	1's
Mantadin	Amantadine Hydrochloride	Capsule	100mg	2x14's
Sperid	Risperidone	Tablet	1mg	5x10's
Sperid	Risperidone	Tablet	2mg	3x10's
Sperid	Risperidone	Tablet	4mg	3x10's
Cilma	Cilnidipine	Tablet	5mg	3x10's
Cilma	Cilnidipine	Tablet	10mg	3x10's
Seronex	Sertraline Hydrochloride	Tablet	25mg	5x10's
Seronex	Sertraline Hydrochloride	Tablet	50mg	5x10's
Seronex	Sertraline Hydrochloride	Tablet	100mg	3x10's
Epicet	Levetiracetam	Tablet	250mg	2x10's
Epicet	Levetiracetam	Tablet	500mg	1x10's
EPICET	Levetiracetam	Suspension	100ml	1's
Denixil	Clonazepam	Tablet	0.25mg	5x10's
Escilex	Escitalopram Oxalate	Tablet	5mg	3x10's
Escilex	Escitalopram Oxalate	Tablet	10mg	3x10's
HORMONE				
Normens	Norethisterone Acetate	Tablet	5mg	10x10's
Bredicon	Desogestrel	Tablet	75mcg	1x28's
Criptine	Bromocriptine Mesylate	Tablet	2.5mg	1x30's
Emcon 1	Levonorgestrel	Tablet	1.5mg	1x1's
Letrol	Letrozole	Tablet	2.5mg	2x5's
Ovulet 50	Clomiphene Citrate	Tablet	50mg	1x10's
Ovulet 100	Clomiphene Citrate	Tablet	100mg	1x5's

Trade Name	Generic Name	Formulation	Strength	Pack Size
HORMONE				
Medrogest	Medroxyprogesterone Acetate	Tablet	5mg, 10mg	3x10's
Thyrox 50	Levothyroxine Sodium	Tablet	50mcg	3x30's
Menorest	Tibolone	Tablet	2.5mg	1x28's
Desolon	Desogestrel+Ethinylestradiol	Tablet	0.15mg+0.03mg	1x21's
Giane 35	Cyproterone Acetate + Ethinylestradiol	Tablet	2.0mg+0.035mg	1x21's
Nandron	Nandrolone Phenylpropionate	Injection	25mg/ml	1x5's
Nandron	Nandrolone Decanoate	Injection	50mg/ml	1x1's
Gestrenol	Allylestrenol	Tablet	5mg	5x10's
Regumen	Lynestrenol+Ethinylestradiol	Tablet	2.5mg+0.05mg	1x21's
Estracon	Conjugated Estrogens	Tablet	0.625mg	30's
Microgest	Natural Micronized Progesterone	Capsule	100mg	3x10's
Microgest	Natural Micronized Progesterone	Capsule	200mg	3x10's
Microgest	Natural Micronized Progesterone	Vaginal Pessary	400mg	2x5's
Novelon	Drospirenone and Ethinylestradiol	Tablet	3mg & 0.03mg	1x28's
Novelon lite	Drospirenone and Ethinylestradiol	Tablet	3mg & 0.02mg	1x28's
Danzol	Danazol	Capsule	100mg & 200mg	3x10's, 2x10's
Cabolin	Cabergoline	Tablet	0.5mg, 1mg	1x4's
Indula	Misoprostol	Tablet	200mcg	3x10's
MIF	Mifepristone	Tablet	200mg	1x3's
Androcap	Testosterone undecanoate	Capsule	40mg	3x10's
Gynova	Micronized estradiol	Tablet	2mg	3x10's
5X	Ulipristal Acetate	Tablet	30mg	1's
Mercazole	Carbimazole	Tablet	5mg	6x10's
AB Kit	Mifepristone+Misoprostol	Tablet	200mg+200mcg	1x5's
Rephaston	Dydrogesterone	Tablet	10mg	2x10'S
Estracon	Conjugated Estrogen	Cream	0.625mg	1's
Thyrox	Levothyroxine sodium	Tablet	100mcg	60's
PTU	Propylthiouracil	Tablet	50mg	4x14's
ANTI-CANCER				
Proscan	Flutamide	Tablet	250mg	3x10's
Sofenib	Sorafenib	Tablet	200mg	3x4's
Erloren	Erlotinib	Tablet	100mg	1x7's
Erloren	Erlotinib	Tablet	150mg	1x7's
Tyrokin	Imatinib	Tablet	400mg	1x10's
Tyrokin	Imatinib	Tablet	100mg	1x10's
Laparen	Lapatinib	Tablet	250mg	1x10's
Niloren	Nilotinib	Capsule	200mg	2x6's
OXYTOCIC				
Arbecin	Carbetocin	IV Injection	1ml	1x1's
Oxyton	Oxytocin	Injection	5 I.U./ml	1x10's
ANTI-FIBRINOLYTICS				
Xamic	Tranexamic Acid	Capsule	500mg	2x10's
Xamic	Tranexamic Acid	Injection	500mg/5ml	1x5's
ANTI-ASTHMA				
Odmon	Montelukast	Chewable Tablet	4mg	3x10's
Odmon	Montelukast	Tablet	5mg	3x10's
Odmon	Montelukast	Tablet	10mg	3x10's
Pulmino	Doxofylline	Tablet	400mg	5X6's
Pulmino	Doxofylline	Tablet	200mg	5X6's
Trulax	Levosulbutamol	Syrup	1mg/5ml	Bottle 100ml

Trade Name	Generic Name	Formulation	Strength	Pack Size
ANTI-ASTHMA				
Totifen	Ketotifen	Tablet	1mg	10x10's
Totifen	Ketotifen	Syrup	1mg/5ml	Bottle 100ml
EXPECTORANT				
Topex	Guaiphenesin Pseudoephedrine	Syrup	131.25mg/5ml	Bottle 100ml
Recof	Ambroxol Hydrochloride	Syrup	15mg/5ml	Bottle 100ml
Recof PD	Ambroxol Hydrochloride	Paed. Drops	6mg/ml	Bottle 15ml
Reducof	Dextromethorphan HBr, Phenylephrine HCL & Triprolidine HCL	Syrup	20mg+10mg+2.5mg	Bottle 100ml
GASTROPROKINETIC AGENTS				
Domiren	Domperidone	Tablet	10mg	15x10's
Domiren PD	Domperidone	Paed. Drops	5mg/ml	Bottle 15ml
Domiren	Domperidone	Suspension	5mg/5ml	Bottle 60ml, 100ml
ORAL REHYDRATION SALINE				
Saline-R	ORS Salt	Powder		Sachet 20's
NARCOTIC ANALGESIC				
Fentanyl	Fentanyl Citrate	IV Injection	100mcg/2ml	1x5's
ANTIPYRETIC/ ANALGESIC				
Pyralgin	Paracetamol	Tablet	500mg	50x10's
Pyralgin	Paracetamol	Suspension	120mg/5ml	Bottle 60ml
Pangesic	Paracetamol + Tramadol Hydrochloride	Tablet	325mg/37.5mg	5x6's
AMINO ACID SUPPLEMENT				
Protemin	5% Composite Amino Acid Solution with D-sorbitol	IV Infusion	- Bottle	500ml
ANTIEMETIC				
Emeren	Ondansetron	Tablet	4mg	3x10's
Emeren	Ondansetron	Tablet	8mg	3x10's
Emeren	Ondansetron	Injection	8mg/4ml	1x5's
Emeren	Ondansetron	Syrup	4mg/5ml	Bottle 50ml
Vomiren	Palonosetron	Tablet	0.5mg	2x10's
Vomiren	Palonosetron	Capsule	0.5mg	2x10's
ANESTHETIC				
Neos-R	Neostigmine	Injection	5ml, 1ml	1x5's
Kain	Ketamine	Injection	50mg/ml	1's
Sivacaine Heavy	Bupivacaine+Dextrose	Injection	5mg+80mg	1x5's
Epidron	Ephedrine	Injection	5mg/ml	1x5's
ANTIVIRAL				
Enteca	Entecavir Tablet	0.5mg	1x10's	
Buviren	Sofosbuvir	Tablet	400mg	1x6's
Fapravir	Favipiravir	Tablet	200mg	1x10's
OTHERS				
Performax	Sildenafil Tablet	50mg	1x4's	
Performax	Sildenafil Tablet	100mg	1x4's	
EAZY JELLY	Hydroxyethyl Cellulose & Glycerine	Lubricant	50gmTube	1's

Trade Name	Generic Name	Formulation	Strength	Pack Size
OTHERS				
Feristar	Iron Sucrose	Injection	100mg Iron/5ml	1's
Honycol	Liquid Sugar & Glycerol	Linctus	(0.75 ml+1.93 ml)/5ml	Bottle 100ml, 200ml
Mez IV	Metronidazole	IV Infusion	0.5% W/V	Bottle 100ml
Normanal	Diosmin + Hesperidin	Tablet	450mg + 50mg	3x10's
Phenocept	Mycophenolate Mofetil	Tablet	500mg	3x10's
Tegarid	Tegaserod	Tablet	6mg	3x10's
Tolter	Tolterodine Tartrate	Tablet	1mg & 2mg	3x10's
Tritin	Trimebutine Maleate	Tablet	100mg	3x10's
Ledomide	Lenalidomide	Capsule	10mg	2x6's
Ledomide	Lenalidomide	Capsule	25mg	2x6's
Laxana	Lubiprostone	Capsule	8mg	3x10's
Laxana	Lubiprostone	Capsule	24mg	2x10's

ANIMAL HEALTH PRODUCTS

ANTIBIOTIC

Renamycin AF Tablet	Oxytetracycline USP	Tablet	500mg	5 x 4's
Renamycin Injectable Solution	Oxytetracycline USP	Injection	50mg/ml	10ml
Renamycin-100 with PVP	Oxytetracycline USP	Injection	100mg/ml	10ml, 100ml
Renamycin LA	Oxytetracycline USP	Long Acting Injection	200mg/ml	10ml
Pronapen 40 lac	Procaine Penicillin BP	Injection	3MIU+1MIU	Vial 40 lac
Streptopen	Benzyl Penicillin Sodium	Injection	1.5MIU+ 0.5MIU+2.5gm	Vial 0.5g, 2.5g
	Procaine Penicillin BP			
	Benzyl Penicillin Sodium			
	Streptomycin USP			
Gentaren	Gentamicin Sulphate	Injection	100mg/ml	10ml & 100ml
Gentaren	Gentamicin	Powder	200mg/gm	100gm & 500gm
Renamox	Amoxycillin	Tablet	500mg	2x10's
Renaflox	Ciprofloxacin	Injection	50mg/ml	10ml, 30ml & 100ml
Neoren 50	Neomycin	Powder	500mg/gm	100gm

CEPHALOSPORIN

Renacef	Ceftriaxone	Injection	1gm, 2gm	Vial 1gm & 2gm
Ceftiren	Ceftiofur Sodium	Injection	0.5gm, 1gm	Vial 0.5gm & 1gm

SULPHONAMIDES

Diadin	Sulphadimidine Sodium BP	Injection	333mg/ml	30ml, 100ml
Diadin	Sulphadimidine BP	Bolus	5gm	10 x 2's
Sulpha -3	Sulphadiazine USP	Bolus	1.666gm+	10 x 2's
	Sulphadimidine BP		1.666gm+	
	Sulphapyridine USP		1.666gm	
	Sulphadiazine + Trimethoprim		1000mg+200mg	
Renatrim				

Trade Name	Generic Name	Formulation	Strength	Pack
ANTHELMINTIC				
Helmex	Albendazole USP	Tablet	600mg	5 x 4's
Nitronex 34%	Nitroxynil BP	Injection	340mg/ml	10ml, 30ml
Tremacid	Oxyclozanide BP	Tablet	1000mg	5 x 4's
Renadex	Triclabendazole + Levamisole	Tablet	900mg+600mg	10 x 2's
ANTIPROTOZOAL				
Ectorid	Imidocarb Dipropionate	Injection	133.26mg/ml	10ml
Renamet Bolus	Metronidazole	Bolus	2gm//Bolus	4 x 6's
ANTI-HISTAMINIC				
Dellergen	Promethazine HCL USP	Injection	50mg/ml	10ml
Dellergen	Promethazine HCL USP	Bolus	150mg/Bolus	7 x 6's
Renacin	Chlorpheniramine Maleate	Injection	10mg/ml	10ml, 100ml
NSAID				
Pyralglin	Paracetamol	Tablet	2gm	5 x 4's
Fevenil	Tolfenamic Acid	Injection	4gm/100ml	30ml, 10ml
Renaspirin	Carbasalate Calcium & Ascorbic Acid	Powder	7.632g & 0.748 g/10gm	10g, 100g
Melocam	Meloxicam	Injection	0.5g/100ml	10ml
Melocam	Meloxicam	Bolus	100mg/Bolus	10 x 4's
GLUCOCORTICOID				
Predexanol Plus	Prednisolone Sodium Dexamethasone Sodium	Injection	20mg/ml+4mg/ml	10ml
APPETIZER & RUMENOTORIC				
Anorexon	Cobalt Sulphate BP Dried Ferrous Sulfate USP Thiamine Mononitrate USP Vitamin B12 USP Choline Bitartrate BP	Tablet	50mg+ 100mg+ 25mg+ 20mcg+ 9.1mg	10 x 6's
Anorexon DS	Cobalt Sulphate BP Dried Ferrous Sulfate USP Thiamine Mononitrate USP Vitamin B12 USP Choline Bitartrate BP	Bolus	100mg+ 200mg+ 50mg+ 40mcg+ 18.2mg	10 x 4's, 7 x 6's
Rumenton	Antimony Potassium Tartrate USP Ferrous Sulphate USP	Bolus	2gm+2gm	10 x 2's
Stomavet	Ammonium Bi-carbonate BP Nuxvomica Powder BP Sodium Bi-carbonate BP Gentian Powder BP Ginger Powder BP	Powder	5gm+ 1.4gm+ 13gm+ 0.3gm+ 0.3gm/20gm	20g x 20's
METABOLIC				
Cal-D-Mag	Calcium Gluconate USP Dextrose USP Magnesium Hypophosphate BP Chlorocresol (as preservative) BP	Injection	20.8+20.0+5.0+0.1mg/ml	200ml, 500ml
Vitaphos	Toldimphos Cyanocobalamine (Vit B12) BP	Injection	200mg+0.05mg/ml	30ml
Catophos	Butaphosphan Cyanocobalamine (Vit B12) BP	Injection	100mg+0.05mg/ml	100ml, 30ml
Levabon Rumen E	Saccharomyces Cerevisiae	Powder	100cfu/gm	20kg

Trade Name	Generic Name	Formulation	Strength	Pack
METABOLIC				
Rumen E	Saccharomyces Cerevisiae	Powder	100cfu/gm	100g
Rena-DCAD	Magnesium sulphate Aluminium sulphate	Powder	50% & 32.5%	1 Kg
Cal-Boost gel	Ionic calcium & magnesium supplement	Gel	43.5gm & 2.5gm/300ml	300 ml
VITAMIN-MINERAL INJECTION				
Hemovit	Iron+Copper+ cobalt+Vitamin B-complex	Injection	15mg+0.2mg+ 0.7mg+202.86mg/ml	10ml
Renasol AD ₃ E	Vitamin A, D ₃ & E	Injection	0.5MIU+0.075MIU+ 50mg/ml	10ml, 30ml & 100ml
POULTRY PRODUCTS				
Enrocin	Enrofloxacin	Oral Solution	100mg/ml	100ml, 1L
Micronid	Erythromycin Thiocyanate Sulphadiazine USP Trimethoprim USP	Powder	180mg+150mg+30mg/gm	10g, 100g
Sultrik	Sulfachloropyridazine+ Trimethoprim	Powder	100mg+20mg/gm	100g
Mycostop	Tylosin BP	Powder	200mg/gm	100g, 1kg
Doxivet	Doxycycline USP	Powder	100mg/gm	100g
Renatrim	Sulphadiazine BP Trimethoprim BP	Suspension	400mg+80mg/ml	100ml
Renamox 30%	Amoxycillin	Powder	300mg/gm	100g, 500g, 1kg
Renaquine 20%	Flumequine INN	Liquid	200mg/ml	100ml
Renagard 45%	Tiamulin Hydrogen Fumarate	Powder	450mg/gm	100g
Renaflox	Ciprofloxacin	Powder	200mg/gm	100g
Renaflox	Ciprofloxacin USP	Oral solution	100mg/ml	100ml
Myco-Out	Erythromycin Estolate USP Neomycin Sulphate USP Sulphadimidine Sodium BP Trimethoprim USP Bromhexine Hydrochloride BP	Water soluble powder	36mg/gm 51.50mg/gm 107.90mg/gm 18mg/gm 1.66mg/gm	100g
Tilmisin	Tilmicosin	Solution	25mg	100ml
ANTHELMINTIC				
Avinex	Levamisole HCL USP	Powder	300mg/gm	10g, 100g
ANTI-COCCIDIAL				
Coxicure	Sulphaclozine Sodium Monohydrate INN	Powder	300mg/gm	100g
Renazuril	Toltrazuril	Suspension	25mg/ml	100ml
ELECTROLYTE				
Renalyte	Vitamin A Sodium Bi-carbonate BP Sodium Chloride BP Dextrose BP Potassium Chloride BP	Powder	2MIU+ 500gm+ 266gm+ 179.6gm+ 50gm/kg	1kg
ORT-Ren	Sodium chloride, Citric acid, potassium citrate, potassium monophosphate	Oral saline	40.13%, 2.43%, 0.6% & 20.7%	Paired sachet A 9.72g & B 22.31g

Trade Name	Generic Name	Formulation	Strength	Pack
NUTRITION PRODUCTS				
Rena WS	Vit B Complex+A+D+E+C	Powder	111.52+0.1MIU+0.025MIU+20mg+300mg/gm	10g, 50g, 100g, 1kg
Rena C	Ascorbic Acid	Powder	999.00mg/gm	100g, 1kg
Rena K	Menadione Sodium bisulphite	Powder	100mg/gm	10g
Renasol AD ₃ E	Vitamin A, D ₃ + E +20mg/ml	Oral Solution	0.1MIU+0.02MIU	100ml, 1L
Renavit DB	Vitamin & Mineral Premix	Powder		100g, 500g, 1kg
Renavit DB Plus	Vitamin, Mineral & Amino Acid Premix	Powder		1kg
Rena Sel-E	Vitamin E + Selenium	Oral Solution	80mg+0.6mg/ml	100ml, 1L
Renagest	Amino Acid + Vitamins + Minerals	Liquid	Amino Acid, Vitamins & Minerals	100ml & 500ml
NUTRITIONAL PREMIX				
Rena Breeder	Vitamin+Mineral	Powder	44.99gm+68.42gm/kg	2.5kg
Rena Broiler	Vitamin+Mineral	Powder	41.73gm+72.38gm/kg	2.5kg
Rena Grower	Vitamin+Mineral	Powder	31.06gm+52.36gm/kg	2.5kg
Rena Layer	Vitamin+Mineral	Powder	35.38gm+47.59gm/kg	2.5kg
Rena Fish	Vitamin+Mineral	Powder	43.75gm+53.55gm/kg	1kg
IMPORTED				
Availa 4	Zinc+Manganese +Copper +Cobalt+AminoAcid	Powder	51.5mg+28.6mg +18.0mg+1.8mg +204.8mg/gm	10gm, 100gm, 500gm & 25kg
Availa Z/M	Zinc+Manganese Chealeted with AA	Powder	40mg+ 40mg/gm	500gm & 25kg
Biotronic SE	Formic Acid+Propionic Acid	Powder	23mg+5mg/ml	25kg
Rena pH	Formic Acid+Propionic Acid+ Lactic Acid	Oral Solution	23mg+5mg+ 1mg/ml	100ml, 1L
Mycofix Plus 3.0	SBM+Epoxidase+Esterase+ Phytogenic+Phycophytic	Powder	NA	25kg
Mycofix Select 3.0	SBM+Epoxidase+ Phytogenic+Phycophytic	Powder	NA	25kg
Mycofix Secure	Bentonite	Powder	100%	25kg
Biomim Phytase 5000	Phytase Enzyme	Powder	5000FTU/gm	25kg
Rena Phytase 400	Phytase Enzyme	Powder	400FTU/gm	1kg
Lisovit	Muramidase+Peroxidase+ FOS+Vitamin E+C	Powder	NA	10gm, 100gm & 1kg
Renagest	Vitamin+Mineral +Amino Acid	Oral Solution	3.58mg+0.078mg +67.33mg/ml	100ml, 500ml
Poultry TMC Plus	Zinc+Manganese+ Copper+ Iron+Iodine+ Selenium+MHA	Powder	32mg+ 32mg+8mg+ 5mg+1.2mg+ 0.15mg+400mg/gm	25kg
Mintrex PSe	Zinc+Manganese+ Copper+ Selenium+MHA	Powder	40mg+40mg+ 20mg+ 3mg+540mg/gm	25kg
Poultry Star Sol	Pro & Prebiotic	Powder	NA	10gm
Poultry Star me	Pro & Prebiotic	Powder	NA	25kg
NephCare Plus	Nephrotonic	Oral solution	NA	100ml, 500ml
Digesterom PEP MGE	Phytogenic Growth Promoter	Powder	NA	25kg
Ren A Tox	Liquid Toxin binder	Solution	NA	100ml, 1L
Rena Cal-P	Calcium+Phosphorous	Solution	24.02mg+8.39mg/ml	1L, 5L
Renaliv	Herbal Liver Tonic	Solution	NA	1L
RespoCare Plus	Herbal Expectorant	Solution	NA	100ml, 250ml

Trade Name	Generic Name	Formulation	Strength	Pack
IMPORTED				
FAM 30	Iodophore	Liquid	27.5mg/ml	100ml, 1L,
GPC8	Gluataraldehyde+QAC	Liquid	120mg+40mg/ml	100ml, 1L
Shift	Trisodium based Detergent	Solution	113mg/ml	1L, 25L
Rena Cal-P	Calcium Phosphate	Water soluble powder	42mg/gm	500g & 1Kg
	Monosodium Phosphate		15mg/gm	
	Vitamin C		6mg/gm	
	Vitamin B12		10mg/gm	
	Vitamin D3		400IU	
	Disodium Citrate		0.27mg/gm	
Renazyme CS	Xylanase, Cellulase, Beta-glucanase, Amylase, Protease, Mannanase, Pectinase	Solution	10000 IU, 200000 IU, 1400 IU, 7000 IU, 10 IU, 100 IU, 5 IU	100ml
Availa Zn 120	Zinc amino acid complex	Powder	120mg/gm	100gmX10's, 25kg
GasFree	Saponin+Glycocompound	Powder		100gmX10's
Heparen	Choline chloride & Vitamin BT/ Levocarnitine	Oral solution	3.5gm & 1gm /100 ml	500 ml
Rena-Kol	Activated Charcoal	Oral solution	16.40%	500ml
Profeed	Polyphenol	Powder	>75%	10gm & 100gm
Dige Max EE	Phytogenic Essential oil	Liquid	Phytogenic essential oils	500ml
Rena-CR	Chromium	Powder	1 ppm/gm	10gm & 100gm
Renagest	Amino Acid + Vitamins + Minerals	Liquid	Amino Acid, Vitamins & Minerals	100ml & 500ml
Ozinc Plus-18	Zinc and Methionine	Powder	180mg/gm	10gm & 100gm

VACCINES

LIVE VACCINES

IZOVAC Clone	Attenuated NDV	Lyophilized	Clone 10 ⁶ EID ₅₀	1000 Doses
IZOVAC Lasota	Attenuated NDV	Lyophilized	Lasota 10 ⁶ EID ₅₀	1000 Doses
IZOVAC H120 Clone	Attenuated NDV & Attenuated IBV	Lyophilized	Clone 10 ⁶ EID ₅₀ & H120 10 ³ EID ₅₀	1000 Doses
IZOVAC H120 Lasota	Attenuated NDV & Attenuated IBV	Lyophilized	Lasota 10 ⁶ EID ₅₀ & H120 10 ³ EID ₅₀	1000 Doses
IZOVAC Gumboro2	Attenuated intermediate IBDV	Lyophilized	Winterfield 2512 10 ³ EID ₅₀	1000 Doses
IZOVAC Gumboro2	Attenuated intermediate Plus IBDV	Lyophilized	Winterfield 2512 10 ^{2.7} EID ₅₀	1000 Doses
IZOVAC Marek HVT +Diluent	Attenuated MDV serotype 3	Lyophilized	Strain FC 126	1000 Doses

KILLED VACCINES

IZOVAC ND	Inactivated NDV	Injection	Lasota 50PD ₅₀	1000 Doses
IZOVAC ND-EDS	Inactivated NDV & Inactivated EDS virus	Injection	Lasota 50PD ₅₀	1000 Doses
IZOVAC ND-EDS-IB	Inactivated ND virus, Inactivated EDS virus & Inactivated IB virus	Injection	NDV 50PD ₅₀ EDS'76 strain 127 & IBV strain M41, D274 & D1466 as per PhEu	EDS'76 10 ⁸ EID ₅₀ 1000 Doses
IZOVAC Coryza3	Inactivated Infectious Coryza (IC)	Injection	<i>Haemophilus Paragallinarum</i> , Serotype A 5x10 ⁸ CFU, <i>Haemophilus Paragallinarum</i> , Serotype B 5x10 ⁸ CFU, <i>Haemophilus Paragallinarum</i> , Serotype C 5x10 ⁸ CFU,	1000 Doses

Trade Name	Generic Name	Formulation	Strength	Pack
KILLED VACCINES				
IZOVAC ND-IBD	Inactivated ND virus & Inactivated IBD virus	Injection	NDV 50PD ₅₀ & IBDV Winterfield 2512 RP≥ 1	1000 Doses
Vaxxon Aviflu	H9N2 AI Virus	Liquid	≥5 Log2	1000 Doses
AQUA PRODUCTS				
Aquastar Pond	Water Probiotic	Powder	NA	500gm, 1kg
BioMin Aquaboost	Amino Acid Complex	Powder	NA	1000gm, 25kg
Hepa Protect Aqua	Flavanoids	Powder	NA	100gm, 25kg
Oxy-Ren	Sodium Carbonate Peroxhydrate	Powder	130mg/gm	1kg
Aquastar grow out	Gut Probiotic	Powder	NA	100gm
Levabon Aqua	Saccharomyces cerevisiae	Powder	10 ¹² cfu/gm	100gmX5's
Oxy-Ren	Sodium carbonate peroxyhydrate	Tablet	130mg/gm tablet	1kg
Zeoren	Alluminium sodium silicate	Granular	750mg/gm	10kg
Gas Free	Yucca	Powder	NA	100g
Ammo-Ren	Nitrifying & Denitrifying bacteria (Probiotics)	Powder	NA	1kg
Rena-Bind	Binding Agent	Liquid	NA	1 L
Rena-Pro	Soil Probiotics	Powder	NA	1kg
Rena-C Aqua	Ascorbic Acid	Powder	99gm/100gm	1kg

Renata Limited Separate and Consolidated Financial Statements

For the year ended 30 June 2022

Independent Auditor's Report to the shareholders of Renata Limited

Report on the Audit of the Separate and Consolidated Financial Statements

Opinion

We have audited the separate financial statements of Renata Limited (the "Company") as well as the consolidated financial statements of Renata Limited and its subsidiaries (the Group), which comprise the Separate and Consolidated statement of financial position as at 30 June 2022 and the Separate and Consolidated statement of profit or loss and other comprehensive income, Separate and Consolidated statement of changes in equity and Separate and Consolidated statement of cash flows for the year then ended, and notes to the Separate and Consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying Separate and Consolidated financial statements give a true and fair view of the Separate and Consolidated financial position of the Group as at 30 June 2022 and of its Separate and Consolidated financial performance and its Separate and Consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs).

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Separate and Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to note # 1.3 to the Separate and Consolidated financial statements which describe the amalgamation of the subsidiaries Renata Agro Industries Limited and Purnava Limited with the Company. The Board of Directors of Renata Agro Industries Limited, Purnava Limited and Renata Limited in their joint meeting held on 01 March 2022 approved the amalgamation of Renata Agro Industries Limited and Purnava Limited with the Company, whereby the Subsidiaries will merge with the Company and the Company shall be the surviving entity. Our opinion is not modified in respect of this matter. The financial statements reflect financial result of the amalgamated entity.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Separate and Consolidated Financial Statements of the current period. These matters were addressed in the context of our audit of the Separate and Consolidated financial statements as a whole and in forming our opinion thereon and we do not provide a separate opinion on these matters.

Key audit matters for the audit of financial statements are as under:

1. Revenue (Turnover)	
See note # 26 and 26(a) to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
<p>ISAs require that, as part of our overall response to the risk of fraud, when identifying and assessing the risks of material misstatement due to fraud, we evaluate which types of revenue or revenue transactions might give rise to potential fraud risks.</p> <p>The principal activities of the Group are manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products and consumer products across a number of geographical areas in home and abroad. We have specifically focused this key audit matter to cut-off and occurrence for revenue recorded within 30 June 2022. Pressures to meet stakeholders' expectations could provide incentives to record revenues where controls of the goods have not passed.</p>	<p>We performed walkthroughs of the revenue cycle at significant components to gain an understanding of when the revenue should be recognized, to map out the relevant controls end to end and the processes in place.</p> <p>We assessed the design and implementation of these controls. We tested the sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents. We have tested the design and operating effectiveness of key controls focusing on the following:</p> <ul style="list-style-type: none"> • Calculation of discounts, incentives and rebates; • Segregation of duties in invoice creation and modification; • Timing of revenue recognition; • Cross match sales order, sales invoices and dispatch carefully. <p>We performed analytical reviews to identify any unusual or one-off material revenue transactions. We identified and considered the impact of any credit notes or inventory returns occurring after year-end, including evaluating the impact of any material overdue debts from customers.</p> <p>With regard to the implementation of IFRS 15 "Revenue from Contract with Customers", we verified management's conclusion from assessing different types of contracts and the accuracy of the revised accounting policies in light of the industry specific circumstances and our understanding of the business. We tested the appropriateness of the accounting treatment on a sample basis. In addition, we verified the accuracy of IFRS 15 related disclosures.</p> <p>We were satisfied that the revenue recognition policies have been applied appropriately. Based on the work performed, we concluded that revenue has been recorded appropriately.</p>
2. Carrying value of investment in subsidiaries	
See note # 1.4 and 7 to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
Renata Limited has invested in equity shares of its subsidiaries namely Renata (UK) Limited and Renata Pharmaceuticals (Ireland) Limited. As at 30 June 2022	We have reviewed management's analysis of impairment assessment and recoverable value of subsidiaries in accordance with IAS-36 "Impairment of Assets".

Key audit matters	How the matters were addressed in our audit
<p>the carrying value of the investments that have been eliminated upon consolidation are accordingly, BDT 110 in Renata (UK) Limited and BDT 9,610 in Renata Pharmaceuticals (Ireland) Limited.</p> <p>At the time of audit of our separate financial statements of the Company, we have considered the recoverable value of the Company's investment in subsidiaries.</p>	<p>In particular, our discussions with management was focused on the continued appropriateness of the value in use model, the key assumptions used in the model, the reasonably possible alternative assumptions, particularly where they had the most impact on the value in use calculation. The balance of the investment in subsidiaries is eliminated in the consolidation.</p> <p>We also checked the mathematical accuracy of the valuation model, challenged the discount rate used within the model, inputs used in the determination of assumptions within the model were challenged and corroborating information was obtained in reference to third party sources. We carefully checked the elimination of the investment in subsidiaries and found correct.</p>
3. Inventory	
See note # 8 and 8(a) to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
<p>At the reporting date, the carrying value of inventory amounted to Taka 8,485,601,428 which is 20.20% total assets of the Group and the Company. Inventories were considered as a key audit matter due to the size of the balance and because inventory valuation involves management judgement.</p> <p>Inventory valuation and existence was an audit focus area because of the number of locations/stores that inventory was held at, and the judgement applied in the valuation of inventory to incorporate inventory shrinkage.</p> <p>According to the Group's accounting policy, inventories are measured at the lower of cost or net realizable value.</p> <p>The Group has specific procedures for identifying risk for obsolete items and measuring inventories at the lower of cost and net realizable value.</p>	<ul style="list-style-type: none"> Assessing the compliance of Group's accounting policies over inventory with applicable accounting standards. Assessing the inventory valuation process and practices. On major locations, we tested the effectiveness of the key controls. Assessing the analyses made by management with respect to slow moving and obsolete stock. Attending inventory count on 30 June 2022 and reconciling the count results to the inventory listings to test the completeness of data. Comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories. Reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year. Evaluating the correctness of the valuation of raw materials and packing material as per FIFO method. Reviewing the calculation of standard labor hours and their regular comparison with actual labor hours of production; and reviewing the process of valuing work-in-progress. <p>We were satisfied that the inventory recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that inventories have been recorded appropriately.</p>

4. Property, plant and equipment and capital work-in-progress

See note # 5, 6 and 6(a) to the Separate and Consolidated financial statements

Key audit matters	How the matters were addressed in our audit
<p>At the reporting date, the carrying value of the Group's property, plant and equipment and capital work-in-progress amounted to Taka 14,725,402,176 and 11,784,753,989 respectively and of the Company. The valuation of property, plant, and equipment was identified as a key audit matter due to the significance of this balance to the financial statements, as well as the significance of management's judgments in determining its valuation.</p> <p>In considering the valuation of property, plant, and equipment, we focused on the assessment of the followings:</p> <ul style="list-style-type: none"> • Inherent risks associated with property, plant and equipment. • Potential misstatements in property, plant, and equipment on account of frauds and errors. • Assessment of useful lives of assets. • Assessment of impairment of assets. <p>Inherent risks associated with property, plant and equipment</p> <ul style="list-style-type: none"> • Property, plant and equipment may include assets that should have been derecognized following sale, other transfer of rights or abandonment or impairment. • Expenditure that should have been recognized as property, plant and equipment but has not been so recognized, including capitalized finance costs. • Depreciation may have been incorrectly calculated. • Potential misstatements in property, plant, and equipment on account of frauds and errors. • Purchase of an asset at an inflated price especially from a related party. • Wrong write-off of the asset as scrap, obsolescence, missing, donated, or destroyed. • Expenditures for repairs and maintenance recorded as property, plant and equipment or vice versa. 	<ul style="list-style-type: none"> • We obtained an understanding of the client and its environment to consider inherent risk related to property, plant, and equipment. Our understanding includes: <ul style="list-style-type: none"> > Obtaining an understanding of the internal control over property, plant, and equipment. > Assessing the risks of material misstatement and designing tests of controls and substantive procedures that cover the following aspects: • Substantiate the existence of property, plant, and equipment. • Establish the completeness of recorded property, plant, and equipment. • Verify the cut-off of transactions affecting property, plant, and equipment. • Establish the proper valuation or allocation of property, plant, and equipment and the accuracy of transactions affecting property, plant, and equipment. • Determine the correctness and appropriateness of classification of property, plant and equipment. • We obtained an understanding of the potential misstatements in property, plant, and equipment on account of frauds and errors. • We evaluated the assumptions made by management in the determination of useful lives to ensure that these are consistent with the principles of IAS 16 "Property, Plant and Equipment". • We compared the useful lives of each class of asset in the current year to the prior year to determine whether there were any significant changes in the useful lives of assets, and considered the reasonableness of changes based on our knowledge of the business and the industry. • We verified records e.g. contractor bills, work orders and certification of work performed by the specialized personnel to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work-in-progress.

Key audit matters	How the matters were addressed in our audit
<ul style="list-style-type: none"> Capitalization of expenditure which are not normally attributable to the cost of the property, plant and equipment. Recording of an asset purchased, which in effect has not actually been received by the entity at all. <p><u>Valuation of capital work-in-progress to PPE</u></p> <p>Management needs to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work-in-progress. An appropriate system needs to put in place to capture all directly identifiable costs, which can be capitalized, to be so accumulated to capital work-in-progress whilst expenses which are not eligible for being capitalized are identified and charged to revenue in the normal course.</p> <p><u>Assessment of useful lives of assets</u></p> <p>Management applies estimates and judgments in its determination of useful lives of assets and reviews the useful lives of assets at each financial year end and adjusts for changes, where appropriate.</p> <p><u>Impairment of assessment</u></p> <p>At the end of each reporting period, management assesses whether there is any indication that an asset may be impaired. If any such indication exists, management estimates the recoverable amount of the asset. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount.</p>	<ul style="list-style-type: none"> We also verified the date on which the assets are moved from the capital work-in-progress account to the property, plant and equipment (the date on which the asset is ready for intended use), so that the depreciation on property, plant and equipment has been computed correctly. We reconciled the movement of capital work-in-progress from opening to closing, specifically verifying additions during the year, capital assets completed during the year and impairment of any opening capital work-in-progress items. We assessed whether there are circumstances that indicate a possible impairment of property, plant and equipment and if such circumstances exist, how the same have been dealt with by the entity. <p>We were satisfied that the property, plant and equipment recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that property, plant and equipment have been recorded appropriately.</p>
5. Contingent liabilities with regard to tax	
See note # 38 to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
<p>The range of possible outcomes for contingencies can be wide and management is required to make certain judgments in respect of estimates of contingencies in order to assess the adequacy of tax provisions.</p> <p>The Group and the Company disclosed contingent liabilities amounted to Taka 117,992,958 in respect of unresolved disputed tax claimed by the tax authority over the years.</p>	<p>We evaluated the design and tested the operating effectiveness of controls in respect of the recognition and measurement of uncertain tax provisions. We determined that we could rely on these controls for the purposes of our audit.</p> <p>With the assistance of our tax specialists, we evaluated management's judgments and estimates of tax exposures and contingencies in order to assess the adequacy of the Group's tax provisions. In understanding and evaluating</p>

Key audit matters	How the matters were addressed in our audit
Contingent liabilities were considered as a key audit matter because unexpected adverse outcomes could significantly impact the Group's reported profit and balance sheet position.	<p>management's judgments, we considered the status of recent and current tax authority audits and enquiries, judgmental positions taken in tax returns and current year estimates and developments in the tax environment.</p> <p>Based on the work performed, we concluded that contingent liabilities in respect of tax have been disclosed appropriately.</p>
6. Related party transactions	
Key audit matters	How the matters were addressed in our audit
The Group has related party transactions and we focused on identification of related parties and disclosure of related party transactions in accordance with relevant accounting standards.	<p>Our audit procedures amongst others included the following:</p> <ul style="list-style-type: none"> • Evaluated the design and tested the operating effectiveness of controls over identification and disclosure of related party transactions. • Evaluated the transactions among the related parties and tested material accounts balances. • Evaluated the Board of Director's approval for the related parties' transactions. • Evaluated the disclosures in the Separate and Consolidated financial statements in compliance with IAS 24 "Related Party Disclosures". <p>The related party transactions were separately disclosed in the separate financial statements in note # 44.</p>
7. Employee benefits	
See note # 23, 23.2, 23(a) and 23.1(a) to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
<p><u>Worker's participation and welfare fund (note # 23.2 and 23.1(a))</u></p> <p>As per section 234 (1)(b) of Bangladesh Labour Act 2006 (as amended in 2013) 5% of the net profit of each year, not later than nine (9) months from the close of that period, is required to be transferred to the Fund, the proportion of the payment to the Participation Fund and the Welfare Fund being 80:10. The remaining 10% of the amount of net profit shall be paid by the Group to the Workers' Welfare Foundation Fund, as formed under the provision of the Bangladesh Worker's Welfare Foundation Act, 2006. Of the 80% being transferred to the participation fund, two-third has to be distributed in equal proportions to all the members (beneficiary) of the fund in cash and one-third has to be invested in accordance with the manner as stated in section 242 of that Act.</p>	<p><u>Worker's participation and welfare fund</u></p> <p>We have checked the adequacy of WPPF fund provision and distribution thereof and observed that, the requirement of the Labour Act 2006 (as amended in 2013) followed properly.</p> <p>After distribution of some amount, balance of the fund has been transferred to a separate account meant for WPPF for future distribution without any interest payable on the undistributed amount.</p> <p><u>Defined contribution plan</u></p> <p>We have checked the contribution of the employees and the contribution of the employer to the provident fund and confirmed the distribution as per Labour Act 2006 (as amended in 2013) and found correct. We confirmed that</p>

Key audit matters	How the matters were addressed in our audit
<p><u>Defined contribution plan (note # 23 and 23(a))</u></p> <p>The Group operates a recognised provident fund scheme where employees contribute 8.33% up to 5 years and over 5 years 10% of their basic salary with equal contribution by the Group. The provident fund is being considered as defined contribution plan being managed by a Board of Trustees. Renata Limited recognises contributions payable as an expense in the period in which the employee provides services. A liability is recognised where contributions arise in relation to an employee's service, but remain unpaid at the period end.</p> <p><u>Defined benefit plan</u></p> <p>The Group operates a defined benefit schemes which in total are significant in the context of the overall financial position. Liability for gratuity is provisioned and transferred within due time to the fund on the basis of actuarial valuation. At year end the Group and the Company reported a net defined benefits scheme expense of Taka 45,493,732. The Group had transferred the total contribution to the fund except for Taka 8,798,751 which is a current liability payable to the fund. Therefore, valuation of the benefit and expenses thereon is considered as a key audit matter. There is separate trustee of this benefit plan.</p>	<p>fund forfeited during current and earlier financial year from existing employees have been returned to the mother account and from past employees are currently under the process of being retrieved.</p> <p><u>Defined benefit plan</u></p> <p>Our audit procedures included updating our understanding of the business processes followed by the Group for accounting and valuing their defined benefit plan.</p> <p>We obtained sufficient audit evidence to conclude that the inputs and methodologies used to determine the liability and determination of the expenses and its basis for defined benefit plan.</p> <p>We assessed the design and operating effectiveness of the Group's key controls supporting the identification, measurement and oversight of valuation of the defined benefits payable provision and expenses thereon.</p> <p>We examined the basis on which gratuity is payable to the employee and worked out the liability for gratuity taking into consideration the actuarial valuation.</p> <p>We ensured that the basis of computing gratuity is valid; verify the computation of liability on aggregate basis and transferred to the fund within the financial year.</p> <p>Employee data used in calculating obligation is also tested and appropriateness and presentation of the disclosures against IAS 19: Employee Benefits were assessed.</p>
8. Measurement of Deferred Tax Liability	
See note # 20 and 20(a) to the Separate and Consolidated financial statements	
Key audit matters	How the matters were addressed in our audit
<p>Group and the Company reported net deferred tax liability totaling Taka 1,405,428,896 as at 30 June 2022.</p> <p>Significant judgment is required in relation to deferred tax liability as it is dependent on forecasts of future profitability over a number of years.</p>	<p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the Group's key controls over the recognition and measurement of deferred tax assets and liabilities and the assumptions used in estimating the future taxable expense of the Group.</p> <p>We also assessed the completeness and accuracy of the data used for the estimations of future taxable expense.</p> <p>We evaluated the reasonableness of key assumptions, timing of reversal of temporary differences and expiration of tax loss carry forwards, recognition and measurement of deferred tax liability.</p>

Key audit matters	How the matters were addressed in our audit
	<p>We assessed the adequacy of the Group's disclosures setting out the basis of deferred tax liability balances and the level of estimation involved.</p> <p>We also assisted in evaluating the tax implications, the reasonableness of estimates and calculations determined by management.</p> <p>Finally assessed the appropriateness and presentation of disclosures as per IAS 12 "Income Taxes".</p>

9. IT systems and controls

Key audit matters	How the matters were addressed in our audit
Our audit procedures have been focused on IT systems (Desa & Oracle) and controls due to the pervasive nature and complexity of the IT environment, the large volume of transactions processed in numerous locations (Head office, Factories and Depots) daily and the reliance on automated and IT is dependent on manual controls	<p>We tested the design and operating effectiveness of the Group's IT access controls over the information systems that are critical to financial reporting.</p> <p>We tested IT general controls (logical access, changes in data management and aspects of IT operational controls). This included testing that requests for access to systems were appropriately reviewed and authorized.</p> <p>We tested the Group's periodic review of access rights. We also inspected requests of changes to systems for appropriate approval and authorization. We considered the control environment relating to various interfaces, configuration and other application layer controls identified as key to our audit. Where deficiencies were identified, we tested compensating controls or performed alternate procedures with CISA expert.</p> <p>In addition, we understood where relevant, changes were made to the IT landscape during the audit period and tested those changes that had a significant impact on financial reporting.</p>

Other Information

Management is responsible for the other information. The other information comprises the directors' reports, financial highlights, financial trend, statement of value addition and certification on corporate governance but doesn't include the financial statements and our auditor's report. The directors' reports, financial highlights, financial trend, statement of value addition and certification on corporate governance are expected to be made available to us after the date of this auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified

above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read the directors' reports, financial highlights, financial trend, statement of value addition and certification on corporate governance that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Separate and Consolidated Financial Statements and Internal Controls

Management is responsible for the preparation of the Separate and Consolidated financial statements that give a true and fair view in accordance with IFRSs, the

Companies Act 1994, the Securities and Exchange Rules 1987, relevant notifications issued by Bangladesh Securities and Exchange Commission (BSEC) and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of Separate and Consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the Separate and Consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Separate and Consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Separate and Consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Separate and Consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Separate and Consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Separate and Consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Separate and Consolidated financial information of the entities or business activities within the Group to express an opinion on the Separate and Consolidated financial statements. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Separate and Consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, the Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission (BSEC), we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of account as required by law have been kept by the Group so far as it appeared from our examination of these books;
- c) the Separate and Consolidated statement of financial position and Separate and Consolidated statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account and returns; and
- d) the expenditure incurred was for the purposes of the Group's business.

Signed for & on behalf of
ACNABIN
Chartered Accountants



Md Moniruzzaman FCA
Partner

ICAB Enrollment No. 787
DVC: 2210230787AS273187

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2022

	Notes	Amount in Taka	
		30 June 2022	30 June 2021
ASSETS			
Non-current assets			
Property, plant and equipment	5	14,725,402,176	13,217,220,343
Capital work-in-progress	6	11,784,753,989	3,803,865,530
Investment in subsidiaries	7	9,720	63,080,096
		26,510,165,885	17,084,165,969
Current assets			
Inventories	8	8,485,601,428	5,929,259,939
Trade receivables	9	3,254,334,666	2,827,278,511
Other receivables	10	610,976,453	1,131,368,235
Advances, deposits and prepayments	11	841,243,294	590,572,952
Investment in shares and FDR	12	1,534,717,004	5,463,936,588
Cash and cash equivalents	13	778,537,319	1,356,084,645
		15,505,410,164	17,298,500,870
TOTAL ASSETS		42,015,576,049	34,382,666,839
EQUITY AND LIABILITIES			
Shareholders' equity			
Share capital	14	1,071,929,820	974,481,660
Revaluation surplus	15	152,868,676	153,361,486
Other reserves	16	219,337,788	(43,065,180)
Fair value reserve	17	26,568,540	24,775,182
Retained earnings	18	27,941,598,635	24,340,254,640
		29,412,303,459	25,449,807,788
Non-current liabilities			
Deferred tax liabilities	20	1,405,428,896	1,368,214,166
		1,405,428,896	1,368,214,166
Current liabilities			
Short term bank loan and overdrafts	21	8,896,466,406	4,801,509,900
Trade payables	22	494,644,501	398,897,541
Other payables	23	778,997,804	987,848,868
Unclaimed dividend account	24	23,895,674	41,339,582
Provision for taxation	25	1,003,839,309	1,335,048,994
		11,197,843,694	7,564,644,885
TOTAL EQUITY AND LIABILITIES		42,015,576,049	34,382,666,839
Net Asset Value (NAV) per share	33	274.39	237.42

The annexed notes from 1 to 46 form an integral part of these Financial Statements.


CEO & Managing Director


Director


Chief Financial Officer

This is the Statement of Financial Position referred to in our separate report of even date.

Signed for & on behalf of
ACNABIN
Chartered Accountants



Md Moniruzzaman FCA
Partner
ICAB Enrollment No. 787
DVC: 2210230787AS273187

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2022

		Amount in Taka	
	Notes	2021-2022	2020-2021
Turnover	26	31,070,554,548	29,250,906,541
Cost of sales	27	(16,344,582,496)	(15,301,410,933)
Gross profit		14,725,972,052	13,949,495,608
Administrative expenses	28	(729,496,527)	(658,662,410)
Selling, marketing and distribution expenses	29	(7,469,586,870)	(6,475,662,160)
Operating profit		6,526,888,655	6,815,171,038
Other income	30	336,457,026	419,489,810
Finance costs	31	(434,543,968)	(164,452,215)
Profit before contribution to workers' participation fund		6,428,801,713	7,070,208,633
Contribution to workers' participation and welfare fund		(306,133,415)	(336,676,598)
Profit before tax		6,122,668,298	6,733,532,035
Tax expenses	32		
Current tax	25	(975,613,222)	(1,776,239,454)
Deferred tax	20	(36,097,866)	77,528,329
		(1,011,711,088)	(1,698,711,125)
Net profit after tax for the year		5,110,957,210	5,034,820,910
Other comprehensive income			
Net profit after tax for the year		5,110,957,210	5,034,820,910
Items that will not be reclassified to profit or loss			
Fair value adjustment on investment in shares, net of tax		1,793,358	26,732,969
Realised gain on disposal of shares		197,467	341,432
Total comprehensive income for the year		5,112,948,035	5,061,895,311
Basic Earnings Per Share (EPS)	34	47.68	46.97

The annexed notes from 1 to 46 form an integral part of these Financial Statements.



CEO & Managing Director


Director


Chief Financial Officer

This is the Statement of Profit or Loss and Other Comprehensive
Income referred to in our separate report of even date.

Signed for & on behalf of
ACNABIN
Chartered Accountants


Md Moniruzzaman FCA
Partner
ICAB Enrollment No. 787
DVC: 2210230787AS273187

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2022

						Amount in Taka
Particulars	Attributable to equity holders of Renata Limited					Total equity
	Share capital	Revaluation surplus	Other reserve	Fair value reserve	Retained earnings	
Balance at 01 July 2020	885,892,420	153,854,296	(43,065,180)	(1,957,787)	20,544,705,799	21,539,429,548
Stock dividend issued	88,589,240	-	-	-	(88,589,240)	-
Final dividend (cash dividend)	-	-	-	-	(1,151,660,146)	(1,151,660,146)
Adjustment of deferred tax liability due to extra depreciation charged to revaluation reserve	-	143,075	-	-	-	143,075
Depreciation adjustment on revalued assets	-	(635,885)	-	-	635,885	-
Net profit after tax for the year	-	-	-	-	5,034,820,910	5,034,820,910
Fair value adjustment on investment in shares, net of tax	-	-	-	26,732,969	-	26,732,969
Realised gain on disposal of shares	-	-	-	341,432	-	341,432
Transfer between reserves- realised gain on disposal of shares	-	-	-	(341,432)	341,432	-
Balance at 30 June 2021	974,481,660	153,361,486	(43,065,180)	24,775,182	24,340,254,640	25,449,807,788
Balance at 01 July 2021	974,481,660	153,361,486	(43,065,180)	24,775,182	24,340,254,640	25,449,807,788
Stock dividend issued	97,448,160	-	-	-	(97,448,160)	-
Final dividend (cash dividend)	-	-	-	-	(1,412,998,407)	(1,412,998,407)
Other reserves due to merger of Renata Agro Industries Limited	-	-	426,898,535	-	-	426,898,535
Other reserves due to merger of Purnava Limited	-	-	(164,495,567)	-	-	(164,495,567)
Adjustment of deferred tax liability due to extra depreciation charged to revaluation reserve	-	143,075	-	-	-	143,075
Depreciation adjustment on revalued assets	-	(635,885)	-	-	635,885	-
Net profit after tax for the year	-	-	-	-	5,110,957,210	5,110,957,210
Fair value adjustment on investment in shares, net of tax	-	-	-	1,793,358	-	1,793,358
Realised gain on disposal of shares	-	-	-	197,467	-	197,467
Transfer between reserves- realised gain on disposal of shares	-	-	-	(197,467)	197,467	-
Balance at 30 June 2022	1,071,929,820	152,868,676	219,337,788	26,568,540	27,941,598,635	29,412,303,459

The annexed notes from 1 to 46 form an integral part of these Financial Statements.


CEO & Managing Director


Director


Chief Financial Officer

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2022

		Amount in Taka	
	Notes	2021-2022	2020-2021
A. Cash flows from operating activities			
Collection from customers and other income		36,458,908,456	33,974,880,854
Payment of VAT	26	(4,469,630,437)	(3,950,115,578)
Payment to suppliers, employees and others		(27,378,997,096)	(23,842,513,181)
Cash generated by operations		4,610,280,923	6,182,252,095
Finance costs		(271,099,653)	(151,499,311)
Payment of tax	25	(1,329,841,519)	(1,801,542,908)
Net cash flow from operating activities	35	3,009,339,751	4,229,209,876
B. Cash flows from investing activities			
Purchase of property, plant and equipment		(10,099,449,998)	(4,356,158,213)
Investment in shares and FDR		3,990,179,499	(712,322,038)
Advance payment to subsidiaries		-	124,474,197
Sale proceeds of property, plant and equipment	5.5	29,049,244	31,690,465
Net cash used in investing activities		(6,080,221,255)	(4,912,315,589)
C. Cash flows from financing activities			
Bank loan received/ (repaid) (net)		3,849,152,644	1,808,039,452
Dividend paid		(1,430,442,313)	(1,141,492,848)
Net cash flow from financing activities		2,418,710,331	666,546,604
D. Effect of exchange rate changes on cash and cash equivalents		24,828,736	(352,076)
E. Net cash outflow for the year (A+B+C+D)		(627,342,437)	(16,911,185)
F. Cash and cash equivalents at the beginning of the year		1,356,084,645	1,372,995,830
G. Cash and cash equivalents of Renata Agro Industries Limited and Purnava Limited due to merger at the beginning of the year		49,795,111	-
H. Cash and cash equivalents at the end of the year (E+F+G)	13	778,537,319	1,356,084,645
Net Operating Cash Flow Per Share (NOCEPS)	36	28.07	39.45

The annexed notes from 1 to 46 form an integral part of these Financial Statements.


CEO & Managing Director


Director


Chief Financial Officer

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2022

	Notes	Amount in Taka	
		30 June 2022	30 June 2021
ASSETS			
Non-current assets			
Property, plant and equipment	5	14,725,402,176	13,690,410,915
Capital work-in-progress	6(a)	11,784,753,989	3,889,099,941
		26,510,156,165	17,579,510,856
Current assets			
Inventories	8(a)	8,485,601,428	6,020,650,235
Trade receivables	9(a)	3,254,334,666	2,932,197,182
Other receivables	10(a)	610,807,116	751,203,875
Advances, deposits and prepayments	11(a)	841,243,294	619,853,101
Investment in shares and FDR	12	1,534,717,004	5,463,936,588
Cash and cash equivalents	13(a)	778,573,780	1,405,952,680
		15,505,277,288	17,193,793,661
TOTAL ASSETS		42,015,433,453	34,773,304,517
EQUITY AND LIABILITIES			
Share capital	14	1,071,929,820	974,481,660
Revaluation surplus	15	152,868,676	153,361,486
Other reserves	16	219,337,788	(43,065,180)
Fair value reserve	17(a)	26,568,540	24,775,183
Retained earnings	18(a)	27,941,462,335	24,601,846,926
Equity attributable to equity holders of Renata Limited		29,412,167,159	25,711,400,075
Non-controlling interests	19	-	52,711
Total equity		29,412,167,159	25,711,452,786
Non-current liabilities			
Deferred tax liabilities	20(a)	1,405,428,896	1,369,274,868
		1,405,428,896	1,369,274,868
Current liabilities			
Short term bank loan and overdrafts	21	8,896,466,406	4,801,509,900
Trade payables	22(a)	494,644,501	399,760,719
Other payables	23(a)	778,991,508	1,091,899,066
Unclaimed dividend account	24	23,895,674	41,339,582
Provision for taxation	25(a)	1,003,839,309	1,358,067,596
		11,197,837,398	7,692,576,863
TOTAL EQUITY AND LIABILITIES		42,015,433,453	34,773,304,517
Net Asset Value (NAV) Per Share	33(a)	274.39	239.86

The annexed notes from 1 to 46 form an integral part of these Consolidated Financial Statements.


CEO & Managing Director


Director


Chief Financial Officer

This is the Consolidated Statement of Financial Position referred to
in our separate report of even date.

Signed for & on behalf of
ACNABIN
Chartered Accountants



Md Moniruzzaman FCA
Partner
ICAB Enrollment No. 787
DVC: 2210230787AS273187

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENT OF
PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2022

		Amount in Taka	
	Notes	2021-2022	2020-2021
Turnover	26(a)	31,070,554,548	29,970,701,575
Cost of sales	27(a)	(16,344,582,496)	(15,787,075,979)
Gross profit		14,725,972,052	14,183,625,596
Administrative expenses	28(a)	(729,496,527)	(656,914,651)
Selling, marketing and distribution expenses	29(a)	(7,469,586,870)	(6,663,797,531)
Operating profit		6,526,888,655	6,862,913,414
Other income	30(a)	336,457,026	420,897,243
Finance costs	31(a)	(434,583,746)	(168,334,900)
Profit before contribution to workers' participation fund		6,428,761,935	7,115,475,757
Contribution to workers' participation and welfare fund		(306,133,415)	(338,022,024)
Profit before tax		6,122,628,520	6,777,453,733
Tax expenses	32(a)		
Current tax	25(a)	(975,613,222)	(1,794,552,362)
Deferred tax	20(a)	(36,097,866)	78,656,532
		(1,011,711,088)	(1,715,895,830)
Net profit after tax for the year		5,110,917,432	5,061,557,903
Attributable to:			
Equity holders of Renata Limited		5,110,917,432	5,061,555,446
Non-controlling interests		-	2,457
Total profit after tax for the year		5,110,917,432	5,061,557,903
Other comprehensive income			
Items that will not be reclassified to profit or loss			
Fair value adjustment on investment in shares, net of tax		1,793,358	26,732,969
Realised gain on disposal of shares		197,467	28,015,898
Total comprehensive income for the year		5,112,908,257	5,116,306,770
Attributable to:			
Equity holders of Renata Limited		5,112,908,257	5,116,302,862
Non-controlling interests		-	3,908
Total comprehensive income for the year		5,112,908,257	5,116,306,770
Basic Earnings Per Share (EPS)	34(a)	47.68	47.22

The annexed notes from 1 to 46 form an integral part of these Consolidated Financial Statements.



CEO & Managing Director


Director


Chief Financial Officer

This is the Consolidated Statement of Profit or Loss and Other Comprehensive Income referred to in our separate report of even date.

Signed for & on behalf of
ACNABIN
Chartered Accountants


Md Moniruzzaman FCA
Partner
ICAB Enrollment No. 787
DVC: 2210230787AS273187

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 JUNE 2022

Amount in Taka

Particulars	Attributable to equity holders of Renata Limited							Non-controlling interests	Total equity
	Share capital	Revaluation surplus	Tax holiday reserve	Other reserves	Fair value reserve	Retained earnings	Equity for Renata Limited		
Balance at 01 July 2020	885,892,420	153,854,296	46,637,673	(43,065,180)	13,709,475	20,705,254,771	21,762,283,455	48,803	21,762,332,258
Stock dividend issued	88,589,240	-	-	-	-	(88,589,240)	-	-	-
Final dividend (cash dividend)	-	-	-	-	-	(1,151,660,146)	(1,151,660,146)	-	(1,151,660,146)
Adjustment of deferred tax liability due to extra depreciation charged to revaluation reserve	-	143,075	-	-	-	-	143,075	-	143,075
Depreciation adjustment on revalued assets	-	(635,885)	-	-	-	635,885	-	-	-
Net profit after tax for the year	-	-	-	-	-	5,061,555,446	5,061,555,446	2,457	5,061,557,903
Transfer of tax holiday reserve	-	-	(46,637,673)	-	-	46,637,673	-	-	-
Fair value adjustment on investment in shares of Renata Limited, net of tax	-	-	-	-	26,732,969	-	26,732,969	-	26,732,969
Recognition of remaining gain upon disposal of shares of Renata Agro Industries Limited	-	-	-	-	12,003,844	-	12,003,844	1,451	12,005,295
Realised gain on disposal of shares of Renata Limited	-	-	-	-	341,432	-	341,432	-	341,432
Transfer between reserves- realised gain on disposal of shares of Renata Agro Industries Limited and Renata Limited	-	-	-	-	(28,012,537)	28,012,537	-	-	-
Balance at 30 June 2021	974,481,660	153,361,486	-	(43,065,180)	24,775,183	24,601,846,926	25,711,400,075	52,711	25,711,452,786
Balance at 01 July 2021	974,481,660	153,361,486	-	(43,065,180)	24,775,183	24,601,846,926	25,711,400,075	52,711	25,711,452,786
Stock dividend issued	97,448,160	-	-	-	-	(97,448,160)	-	-	-
Final dividend (cash dividend)	-	-	-	-	-	(1,412,998,407)	(1,412,998,407)	-	(1,412,998,407)
Transfer to Other reserves due to merger of Renata Agro Industries Limited and Purnava Limited	-	-	-	-	-	(262,402,968)	(262,402,968)	-	(262,402,968)
Adjustment of provision for unrealised profit due to merger of Renata Agro Industries Limited and Purnava Limited	-	-	-	-	-	661,449	661,449	-	661,449
Adjustment of non-controlling interests due to merger of Renata Agro Industries Limited and Purnava Limited	-	-	-	-	-	52,711	52,711	(52,711)	-
Other reserves due to merger of Renata Agro Industries Limited	-	-	-	426,898,535	-	-	426,898,535	-	426,898,535
Other reserves due to merger of Purnava Limited	-	-	-	(164,495,567)	-	-	(164,495,567)	-	(164,495,567)
Adjustment of deferred tax liability due to extra depreciation charged to revaluation reserve	-	143,075	-	-	-	-	143,075	-	143,075
Depreciation adjustment on revalued assets	-	(635,885)	-	-	-	635,885	-	-	-
Net profit after tax for the year	-	-	-	-	-	5,110,917,432	5,110,917,432	-	5,110,917,432
Fair value adjustment on investment in shares, net of tax	-	-	-	-	1,793,358	-	1,793,358	-	1,793,358
Realised gain on disposal of shares	-	-	-	-	197,467	-	197,467	-	197,467
Transfer between reserves- realised gain on disposal of shares	-	-	-	-	(197,467)	197,467	-	-	-
Balance at 30 June 2022	1,071,929,820	152,868,676	-	219,337,788	26,568,540	27,941,462,335	29,412,167,159	-	29,412,167,159



CEO & Managing Director



Director



Chief Financial Officer

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED AND ITS SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2022

		Amount in Taka	
	Notes	2021-2022	2020-2021
A. Cash flows from operating activities			
Collection from customers and other income		36,458,908,456	35,051,209,035
Payment of VAT	26	(4,469,630,437)	(3,979,429,961)
Payment to suppliers and employees		(27,378,997,096)	(24,784,539,496)
Cash generated by operations		4,610,280,923	6,287,239,578
Finance costs		(271,136,116)	(155,381,996)
Payment of tax	25(a)	(1,329,841,519)	(1,811,462,006)
Net cash flow from operating activities	35(a)	3,009,303,288	4,320,395,576
B. Cash flows from investing activities			
Purchase of property, plant and equipment		(10,099,449,998)	(4,423,351,881)
Investment in shares, FDR and others		3,990,179,499	(633,915,427)
Income from investment		-	27,674,466
Sale proceeds of property, plant and equipment	5.5	29,049,244	31,690,465
Net cash used in investing activities		(6,080,221,255)	(4,997,902,377)
C. Cash flows from financing activities			
Loan (repaid) / received (net)		3,849,152,644	1,808,039,452
Dividend paid		(1,430,442,313)	(1,141,492,848)
Net cash flow from financing activities		2,418,710,331	666,546,604
D. Effect of exchange rate changes on cash and cash equivalents		24,828,736	(352,076)
E. Net cash outflow for the year (A+B+C+D)		(627,378,900)	(11,312,273)
F. Cash and cash equivalents at the beginning of the year		1,405,952,680	1,417,264,953
G. Cash and cash equivalents at the end of the year (E+F)	13(a)	778,573,780	1,405,952,680
Net Operating Cash Flow Per Share (NOCFPS)	36(a)	28.07	40.30

The annexed notes from 1 to 46 form an integral part of these Consolidated Financial Statements.



CEO & Managing Director



Director



Chief Financial Officer

Place: Dhaka
Date: 22 October 2022

RENATA LIMITED

NOTES TO THE SEPARATE AND CONSOLIDATED FINANCIAL STATEMENTS AS AT AND FOR THE YEAR ENDED 30 JUNE 2022

1. Reporting entity

1.1 Company profile

Renata Limited (the "Company") is a public limited company incorporated in Bangladesh in 1972 as Pfizer Laboratories (Bangladesh) Limited under the Companies Act 1913. The Company was listed with Dhaka Stock Exchange Limited on 12 May 1979. Subsequently, the Company was renamed as Renata Limited in 1993. The registered office of the Company is situated at Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216.

1.2 Principal activities

The principal activities of the Group are manufacturing, marketing and distribution of pharmaceutical, animal health products, oncology-based products, agro-based products, poultry products, consumer products and so on.

1.3 Amalgamation of Renata Agro Industries Limited and Purnava Limited (Transferor Companies) with Renata Limited (Transferee Company)

Renata Limited acquired 99.99% of equity interest in Renata Agro Industries Limited on 7 April 2001 and 99.99% of equity interest in Purnava Limited on 16 September 2004. The Transferor Companies have many similar objectives with the Transferee Company and therefore the business of the Transferor Companies can be conveniently and advantageously combined together with the Transferee Company. Since the top management of these three Companies are same, the amalgamation will result in a horizontal integration and consequent saving of considerable costs. The amalgamation shall reduce the warehousing costs of materials and other costs and create greater value as the ultimate company, the Transferee Company, shall achieve higher long- term financial returns than could be achieved by both the Transferor and Transferee Companies individually. For the purpose of conducting their business more efficiently and profitably, the Board of Directors of the Companies decided to undertake a Scheme of Amalgamation of Renata Agro Industries Limited and Purnava Limited with Renata Limited under provision of section 228 & 229 of the Companies Act, 1994.

After approval of the Board of Directors and consent of minority shareholders of both the Transferor Companies, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned the Scheme of Amalgamation of Renata Agro Industries Limited and Purnava Limited with Renata Limited on 05 September 2022 with effect from the appointed date 01 July 2021. The audited financial statements of the Transferor Companies on 30 June 2021 have been used to account for the assets and liabilities of these Transferor Companies in the books of Renata Limited.

Renata Agro Industries Limited and Purnava Limited will no longer continue as a separate entity as a result of amalgamation, rather all the undertakings have entirely been transferred to Renata Limited at its continuing value. In accordance with the Scheme of Amalgamation, ordinary shares of the Transferor Companies held by the Transferee Company on the Record Date shall be cancelled and deemed to have been cancelled without any further act or deed and no shares of the Transferee Company are required to be issued in lieu thereof. The Transferee Company shall pay in consideration at cash for value of share (s) to the minority shareholder of the Transferor Companies on the basis of Face Value of the share of the Transferor Companies. Investment of the Transferee Company in equity shares of Transferor Companies shall be treated as intercompany transaction and shall be eliminated/negated. Finally, excess/deficit of the net assets of the Transferor Companies pursuant to the Scheme of Amalgamation, shall be transferred and credited/debited to the "Other Reserves" in the books of the Transferee Company.

1.4 Subsidiaries

Subsidiaries are entities controlled by Renata Limited. An investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. The followings are the subsidiaries of Renata Limited:

Renata (UK) Limited

Renata (UK) Limited, a subsidiary Company of Renata Limited, was incorporated on 26 September 2013 as a private limited company under the UK Companies Act 2006. The registered office of the Company is situated at Greenway Business Centre, Harlow Business Park, Harlow, England, CM19 5QE. Renata Limited holds 100% of equity interest in Renata (UK) Limited acquired as on 9 April 2018.

Renata Pharmaceuticals (Ireland) Limited

Renata Pharmaceuticals (Ireland) Limited, a subsidiary Company of Renata Limited, was incorporated on 24 April 2019 as a private limited company under the Irish Companies Act 2014. The registered office of the Company is situated at 13/18 City Quay, Dublin 2, Ireland. Renata Limited holds 100% of equity interest in Renata Pharmaceuticals (Ireland) Limited.

2. Basis of preparation of financial statements

2.1 Reporting framework and compliance thereof

The separate and the consolidated financial statements have been prepared in compliance with the requirements of the Companies Act 1994, the Securities and Exchange Rules 1987, the Listing Regulations of Dhaka Stock Exchange (DSE) and other relevant local laws as applicable, and in accordance with the International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board (IASB) and adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

2.2 Application of International Financial Reporting Standards (IFRSs)

The following IFRSs are applicable for the financial statements for the year under review:

IAS 1	Presentation of financial statements
IAS 2	Inventories
IAS 7	Statement of cash flows
IAS 8	Accounting policies, changes in accounting estimates and errors
IAS 10	Events after the reporting period
IAS 12	Income taxes
IAS 16	Property, plant and equipment
IAS 19	Employee benefits
IAS 21	The effects of changes in foreign exchange rates
IAS 23	Borrowing costs
IAS 24	Related party disclosures
IAS 27	Separate financial statements
IAS 33	Earnings per share
IAS 34	Interim financial reporting
IAS 36	Impairment of assets
IAS 37	Provisions, contingent liabilities and contingent assets
IFRS 3	Business combinations
IFRS 7	Financial instruments: disclosures
IFRS 9	Financial instruments
IFRS 10	Consolidated financial statements
IFRS 12	Disclosure of interests in other entities
IFRS 13	Fair value measurement
IFRS 15	Revenue from contracts with customers

2.3 Measurement of elements in the financial statements

Measurement is the process of determining the monetary amounts at which the elements of the financial statements are to be recognized and carried in the statement of financial position and profit or loss and other comprehensive income. The measurement basis adopted by the Group is historical cost except for few of the property, plant and equipment, financial assets and inventories which are stated in the accounting policies mentioned in the respective notes.

2.4 Basis of consolidation

The group financial statements include the financial statements of Renata Limited and subsidiaries that it controls. The Group prepares consolidated financial statements using uniform accounting policies for like transactions and other events in similar circumstances. Consolidation of an investee shall begin from the date the investor obtains control of the investee and cease when the investor loses control of the investee. Intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the Group are eliminated in full. Profits or losses resulting from intra-group transactions that are recognized in assets are eliminated in full. The Group presents non-controlling interests, if present, in the consolidated statement of financial position within equity, separately from the equity of the owners of Renata Limited.

2.5 Functional and presentational currency and level of precision

The financial statements are prepared in Bangladesh Taka (BDT), which is Group's functional currency. All financial information is presented in BDT and has been rounded off to the nearest BDT.

2.6 Use of estimates and judgment

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRS) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and disclosures requirements for contingent assets and liabilities during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: Accounting Policies, Changes in Accounting Estimates and Errors. In particular, significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, amortization, impairment, net realizable value of inventories, accruals, taxation and provision.

2.7 Comparative information and rearrangement thereof

Comparative figures have been re-arranged wherever considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

2.8 Going concern

When preparing financial statements, management makes an assessment of the Group's ability to continue as a going concern. The Group prepares financial statements on a going concern basis. The Group has assessed the impact of COVID-19 on its going concern and found no threat in upcoming years.

2.9 Accrual basis of accounting

The Group prepares its financial statements, except for cash flow information, using the accrual basis of accounting. Since the accrual basis of accounting is used, the Group recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the Framework.

2.10 Materiality and aggregation

The Group presents separately each material class of similar items. The Group presents separately items of a dissimilar nature or function unless they are immaterial. Financial statements result from processing large numbers of transactions or other events that are aggregated into classes according to their nature or function.

2.11 Offsetting

The Group does not offset assets and liabilities or income and expenses, unless required or permitted by an IFRS.

2.12 Date of authorization for issue of the financial statements

On 22 October 2022 the Board of Directors reviewed the separate and consolidated financial statements and authorized them for issue.

3. Summary of significant accounting policies

The Group selects and applies its accounting policies consistently for similar transactions, other events and conditions, unless an IFRS specifically requires or permits categorization of items for which different policies may be appropriate. The accounting policies set out below have been applied consistently in all material respects to all period presented in these financial statements:

Changes in accounting policies

The Group changes its accounting policy only if the change is required by an IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the Group's financial position, financial performance or cash flows. Changes in accounting policies is to be made through retrospective application by adjusting opening balance of each affected components of equity i.e., as if new policy has always been applied.

Changes in accounting estimates

Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss account.

Correction of error in prior period financial statements

The Group corrects material prior period errors retrospectively by restating the comparative amounts for the prior period(s) presented in which the error occurred; or if the error occurred before the earliest prior period presented, restating the opening balances of assets, liabilities and equity for the earliest prior period presented.

3.1 Property, plant and equipment (PPE)

Recognition and measurement

The cost of an item of property, plant and equipment is recognized as an asset if, and only if it is probable that future economic benefits will flow to the Group and the cost of the item can be measured reliably. An item of property, plant and equipment that qualifies for recognition as an asset is measured at its cost.

Elements of Costs

- Purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates.
- Costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by the management.
- The initial estimate of the cost of dismantling and removing the item and restoring the site on which it is located.

Subsequent Costs

- Costs of day-to-day servicing [repairs and maintenance] are recognized as expenditure as incurred.
- Replacement parts are capitalized, provided the original cost of the items they replace is derecognized.

Measurement of property, plant and equipment after recognition

Cost model

After recognition as an asset, an item of property, plant and equipment is carried at its cost less any accumulated depreciation and any accumulated impairment losses.

Revaluation model

After recognition as an asset, an item of property, plant and equipment is to be measured at a revalued amount, which is its fair value less subsequent accumulated depreciation and impairment accumulated losses.

Where an asset's carrying amount is increased as a result of a revaluation, the increase is recognized in other comprehensive income and accumulated in equity under the heading of revaluation surplus. However,

the increase is recognized in profit or loss to the extent that it reverses a revaluation decrease of the same asset previously recognized in profit or loss. Where an asset's carrying amount is decreased as a result of a revaluation, the decrease is recognized in profit or loss. However, the decrease is recognized in other comprehensive income to the extent of any credit balance existing in the revaluation surplus in respect of that asset. The revaluation surplus included in equity in respect of an item of property, plant and equipment is transferred directly to retained earnings as the asset is used by the Group.

Depreciation

The depreciation charge for each period is recognized in profit or loss unless it is included in the carrying amount of another asset. Depreciation of an asset begins when it is available for use, i.e., when it is in the location and condition necessary for it to be capable of operating in the manner intended by management. The residual value and the useful life of an asset is reviewed at least at each financial year-end and, if expectations differ from previous estimates, the change(s) shall be accounted for as a change in an accounting estimate. Depreciation has been charged on straight-line method on all property, plant and equipment that have already been put on operation except land. Full month's depreciation is charged from the month the asset is put into use and no depreciation is charged for the month of disposal. Rates of depreciation considering the useful lives of respective assets are as follows:

Asset Type	Depreciation rate (%)	
	30 June 2022	30 June 2021
Buildings	1.54-5	1.54-5
Plant and machinery	5-20	5-20
Automobiles	25	25
Office equipment	10-12.5	10-12.5
Furniture and fixtures	10	10

Derecognition of property, plant and equipment

The carrying amount of an item of property, plant and equipment is derecognized on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from derecognition of an item of property, plant and equipment is included as other income in profit or loss when the item is derecognized. When the revalued assets are disposed of, the respective revaluation surplus is transferred to retained earnings.

3.2 Leases

IFRS 16 introduces a single, on-balance sheet lease accounting model for lessees. A lessee recognizes a right-to-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. There are recognition exemptions for short-term leases and leases of low-value items. Lessor accounting remains similar to the current standard- i.e., lessors continue to classify leases as finance or operating leases. The standard is effective for annual periods beginning on or after 1 January 2019, but also with permission for early adoption.

The Group has applied the exemption for short-term leases and booked its rental payments as expenses in profit or loss given that the enforceable period of all its current contracts are cancellable in the short-term and has no purchase option.

3.3 Capital work-in-progress

Capital work- in- progress represents the cost incurred for acquisition and construction of items of property, plant and equipment that were not ready for use at the end of 30 June 2022 and these were stated at cost. In case of imported components, capital work- in- progress is recognized when risks and rewards associated with such assets are transferred to the Group, i.e., at the time shipment is confirmed by the supplier.

3.4 Impairment of assets

If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. That reduction is an impairment loss. An impairment loss on a non-revalued asset is recognized in profit or loss. However, an impairment loss on a revalued asset is recognized in other comprehensive income to the extent that the impairment loss does not exceed the amount in the revaluation surplus for that same asset. Such an impairment loss on a revalued asset reduces the revaluation surplus for that asset.

The Group assesses at the end of each reporting period whether there is any indication that an asset may be impaired. If any such indication exists, the Group estimates the recoverable amount of the asset.

3.5 Financial instruments

3.5.1 Financial assets

All financial assets that are within the scope of IFRS 9 are required to be measured at amortized cost or fair value, with movements through other comprehensive income or the income statement on the basis of Group's business model for managing the financial assets and the contractual cash flow characteristics of the financial assets.

Investment in subsidiaries

Separate financial statements are to enhance the relevance, reliability and comparability of the information that a parent entity provides in its separate financial statements for a group of entities under its control. The Group has disclosed the information to enable users of the financial statements to evaluate the nature of the relationship between Renata and its subsidiaries. Investment in subsidiaries is accounted for in the Company's separate financial statements at cost.

Investment in shares

The Group has elected to designate equity investments as measured at Fair Value through Other Comprehensive Income (FVTOCI). They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealized gains and losses are recognized in other comprehensive income. On disposal of the equity investment, gains and losses that have been deferred in other comprehensive income are transferred directly to retained earnings.

Dividends on equity investments and distributions from funds are recognized in the income statement when the Group's right to receive payment is established.

Investment in fixed deposit receipt

Fixed deposit, comprising funds held with banks and other financial institutions, are initially measured at fair value, plus direct transaction costs, and are subsequently measured at amortized cost using the effective interest method at each reporting date. Changes in carrying value are recognized in profit.

Trade receivables

Trade receivables are measured in accordance with the business model under which each portfolio of trade receivable is held. The Group has a portfolio of trade receivables that is being managed within a business model whose objective is to collect contractual cash flows, and are measured at amortized cost. Trade receivables measured at amortized cost are carried at the original invoice amount less allowance for expected credit losses.

Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether and the extent to which settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer.

When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. Subsequent recoveries of amounts previously provided for or written off are credited to the income statement.

Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, balances with banks and financial institutions, and highly liquid investments with maturities of three months or less when acquired. They are readily convertible into known amounts of cash and are held at amortized cost under the hold to collect classification, where they meet the hold to collect "solely payments of principals and interests" test criteria under IFRS 9. Those not meeting these criteria are held at fair value through profit and loss.

3.5.2 Financial liabilities

Borrowings

All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the income statement over the period of the relevant borrowing.

Trade payables

Trade payables are recognized initially at fair value. Subsequent to initial recognition they are measured at amortized cost using the effective interest method.

3.5.3 Impairment of financial assets

IFRS 9 requires an expected credit loss (ECL) model to be applied to financial assets. The expected credit loss model requires the Group to account for expected losses as a result of credit risk on initial recognition of financial assets and to recognize changes in those expected credit losses at each reporting date. The Group recognizes a loss allowance on trade receivables based on lifetime expected credit losses.

3.6 Inventories

Measurement

Inventories are measured at the lower of cost and net realizable value except for goods in transit which are valued at cost.

Cost of inventories

The costs of inventories are comprised of all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Cost of active materials, raw materials and packing materials is assigned by using the first-in, first-out (FIFO) cost formula. Cost of work-in-progress and finished stocks are determined by using FIFO cost formula including allocation of manufacturing overheads related to bringing the inventories to their present condition. The Group uses standard cost method for measurement of cost of finished goods.

Recognition as an expense

When inventories are sold, the carrying amount of those inventories is recognized as an expense in the period in which the related revenue is recognized. The amount of any write-down of inventories to net realizable value and all losses of inventories is recognized as an expense in the period the write-down or loss occurs. The amount of any reversal of any write-down of inventories, arising from an increase in net realizable value, is recognized as a reduction in the amount of inventories recognized as an expense in the period in which the reversal occurs.

3.7 Other liabilities

Recognition

A provision is recognized when the Group has a present obligation (legal or constructive) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the obligation. If these conditions are not met, no provision is recognized. Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amount due to employees.

The Group does not recognize a contingent liability. A contingent liability is disclosed; unless the possibility of an outflow of resources embodying economic benefits is remote. The Group does not recognize a contingent asset. Contingent assets usually arise from unplanned or other unexpected events that give rise to the possibility of an inflow of economic benefits to the Group.

Measurement of provisions

The amount recognized as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period.

Changes and use of provisions

Provisions is reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed.

3.8 Post-employment benefits

Defined contribution plan

The Group operates a recognized provident fund scheme. The provident fund is being considered as defined contribution plan and managed by a Board of Trustees. The employees contribute 8.33% up to 5 years and over 5 years 10% of basic salary with equal contribution by the Group.

Defined benefit plan

The Group had operated an unfunded gratuity plan till 29 December 2015 and thereafter, effective from 30 December 2015, the scheme has been converted to a funded one. The fund is managed by a Board of Trustees. Actuarial valuation of the fund is carried out at 30 June 2022 by a professional actuary.

Group insurance scheme

The Group operates a group insurance scheme for its permanent employees.

Worker's participation and welfare fund

The Group has created a workers' participation and welfare fund in compliance with "The Bangladesh Labour Act, 2006" (as amended in 2013) and 5% of profit before charging such expenses is transferred to this fund.

3.9 Borrowing cost

The Group capitalizes borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset as part of the cost of that asset. The Group recognizes other borrowing costs as an expense in the period in which it incurs them.

3.10 Reporting foreign currency transactions

Initial recognition

A foreign currency transaction is recorded, on initial recognition in the functional currency, by applying to the foreign currency amount the spot exchange rate between the functional currency and the foreign currency at the date of the transaction.

Subsequent measurement

A foreign currency transaction may give rise to assets or liabilities that are denominated in a foreign currency. These assets and liabilities are translated into the Group's functional currency at each reporting date. Foreign currency monetary items outstanding at the end of the reporting date are translated using the closing rate. The difference between this amount and the previous carrying amount in functional currency is an exchange gain or loss. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements is recognized in profit or loss in the period in which they arise.

3.11 Revenue recognition

The Group receives revenue for supply of goods to external customers against orders received. The majority of contracts that the Group enters into relate to sales orders containing single performance obligations for the delivery of pharmaceutical, animal health, agro-based and consumer healthcare products.

Product revenue is recognized when control of the goods is passed to the customer. The point at which control passes is determined by each customer arrangement, but generally occurs on delivery to the customer. Value added tax and other sales taxes are excluded from revenue.

Product revenue represents net invoice value including fixed and variable consideration. Variable consideration arises on the sale of goods as a result of discounts and allowances given and accruals for estimated future returns and rebates. Revenue is not recognized in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur.

The methodology and assumptions used to estimate rebates and returns are monitored and adjusted regularly in the light of contractual and legal obligations, historical trends, past experience and projected market conditions. Once the uncertainty associated with the returns and rebates is resolved, revenue is adjusted accordingly. The scheme has been recognized as per 5 step model of IFRS-15 "Revenue from contract with customers".

3.12 Taxation

The tax expense for the period comprises current tax and deferred tax. Tax is recognized in the income statement, except in the case it relates to items recognized in other comprehensive income or directly in equity. In this case, the tax is also recognized in other comprehensive income or directly in equity.

Current tax

The current income tax charge is calculated based on tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax

Principle of recognition

Deferred tax is recognized as income or an expense amount within the tax charge, and included in the net profit or loss for the period. Deferred tax relating to items dealt with as other comprehensive income is recognized as tax relating to other comprehensive income within the statement of profit or loss and other comprehensive income.

Deferred tax relating to items dealt with directly in equity (such as the correction of an error or retrospective application of a change in accounting policy) is recognized directly in equity.

Taxable temporary difference

A deferred tax liability is recognized for all taxable differences, except to the extent that the deferred tax liability arises from the initial recognition of goodwill; or the initial recognition of an asset or liability in a transaction which is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Deductible temporary difference

A deferred tax asset is recognized for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilized, unless the deferred tax asset arises from the initial recognition of an asset or liability in a transaction that is not a business combination; and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

Measurement

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

3.13 Earnings per share [EPS]

Basic EPS

The Group calculates basic earnings per share amounts for profit or loss attributable to ordinary equity holders of the parent entity. Basic earnings per share is calculated by dividing profit or loss attributable to ordinary equity holders of the parent entity (the numerator) by the weighted average number of ordinary shares outstanding (the denominator) during the period.

The Group presents basic earnings per share in the statement of profit or loss and other comprehensive income. The Group presents basic earnings per share with equal prominence for all periods presented. The Group presents basic earnings per share, even if the amounts are negative (i.e., a loss per share).

3.14 Statement of cash flows

Statement of cash flows has been prepared in accordance with the International Accounting Standard IAS-7, 'Statement of Cash Flows' under direct method. Cash comprises cash on hand and demand deposits. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. The Group has presented the effect of exchange rate changes on cash and cash equivalents due to currency translation in the Statement of cash flow in accordance with IAS-7.

3.15 Operating segments

As there is a single business and geographic segment within which the Group operates, no segment reporting is felt necessary.

3.16 Related party disclosures

Relationship between a parent and its subsidiaries is disclosed irrespective of whether there have been transactions between them. The Group discloses key management personnel compensation. The Group discloses the nature of the related party relationship as well as information about those transactions and outstanding balances, including commitments, necessary for users to understand the potential effect of the relationship on the financial statements. The Group complies with IAS-24 "Related party disclosures" regarding these disclosures. The Group takes approval from its Board of Directors and post facto approval from the general body of its shareholders for related party transactions in compliance with BSEC Notification No. BSEC/CMRRCD/2009-193/2/Admin/103 dated February 05, 2020 and BSEC Order No. SEC/CMMRRCD/2006-159/Admin/02-10 dated September 10, 2006 as applicable.

3.17 Events after the reporting period

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorized for issue. Two types of events can be identified: adjusting events: those that provide evidence of conditions that existed at the end of the reporting period and non-adjusting events: those that are indicative of conditions that arose after the reporting period.

3.18 Financial risk management

The Group's activities expose it to a variety of financial risks and those activities involve the analysis, evaluation, acceptance and management of some degree of risk or combination of risks. Taking risk is core to the financial business, and operational risks are an inevitable consequence of being in business. The Group's aim is therefore to achieve an appropriate balance between risk and return and minimize potential adverse effects on the Group's financial performance. The Group's risk management policies are designed to identify and analyze these risks, to set appropriate risk limits and controls, and to monitor the risks and adherence to limits by means of reliable and up-to-date information systems. The Group regularly reviews its risk management policies and systems to reflect changes in markets, products and emerging best practices.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The senior management of the Group carefully manages its exposure to credit risk. Credit exposures arise principally in receivables from customers into the Group's asset portfolio. The credit risk management and control are controlled through the credit policies of the Group which are updated regularly. The Group is also exposed to other credit risks arising from balances with banks which are controlled through board approved counterparty limits.

Liquidity risk

Liquidity risk is defined as the risk that the Group will not be able to settle or meet its obligations on time or at a reasonable price.

The Group's approach toward managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation. Typically, management ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including the servicing of financial obligations through preparation of the cash forecast prepared based on time line of payment of the financial obligations and accordingly arrange for sufficient liquidity/fund to make the expected payments within due date.

Market risk

The Group takes on exposure to market risks, which is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risks arise from open positions in interest rate and currency, all of which are exposed to general and specific market movements and changes in the level of volatility of market rates or prices such as interest rates, credit spreads and foreign exchange rates.

a) Currency risk

The Group is exposed to currency risk on certain receivables and payables such as receivables from foreign customers and payables for import of raw materials, machinery and equipment. The majority of the Group's foreign currency transactions is denominated in US Dollar and relates to procurement of raw materials, machinery and equipment from abroad.

b) Interest rate risk

Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group takes on exposure to the effects of fluctuations in the prevailing levels of market interest rates on both its fair value and cash flow risks. Interest margins may increase as a result of such changes but may reduce losses in the event that unexpected movements arise.

3.19 Impact of COVID-19

On 11 March 2020, World Health Organization (WHO) declared a global pandemic due to Corona Virus related respiratory disease commonly called as COVID-19. To contain the spread of this disease, along with many other countries of the world, Government of Bangladesh has also taken a number of measures such as declaration of general holiday, enforcement of lock down, social distancing etc. As a result of these measures, businesses and economic activities of the country are affected.

However, considering the facts and circumstances, Management believes that there is no material uncertainty or possibility of impairment of assets which may cast doubt on the Group's ability to continue as a going concern in the foreseeable future.

Name of the Company	Relationship	Name of the Auditors
Renata (UK) Limited	Subsidiary	Exempted from Audit (As per section 477 of Companies Act 2006 of UK)
Renata Pharmaceuticals (Ireland) Limited	Subsidiary	Exempted from Audit (As per section 360 of Companies Act 2014 of Ireland)

4. Director's responsibilities statement

The Board of Directors is responsible for the preparation and presentation of the separate and the consolidated financial statements.

5. Property, plant and equipment

Property, plant and equipment of Renata Limited and the Group as at 30 June 2022

Amount in Taka

Particulars	Cost / Revaluation					Depreciation						Written down value as at 30 June 2022
	Balance as at 1 July 2021	Amount of Renata Agro Industries Limited & Purnava Limited as at 01 July 2021 due to merger	Addition during the year	Disposal / adjustment during the year	Balance as at 30 June 2022	Rate %	Balance as at 1 July 2021	Amount of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	Charge for the year	Disposal / adjustment during the year	Balance as at 30 June 2022	
Freehold land												
At cost	1,666,155,673	121,655,045	582,420,185	-	2,370,230,903		-	-	-	-	-	2,370,230,903
On revaluation	179,132,078	-	-	-	179,132,078		-	-	-	-	-	179,132,078
	1,845,287,751	121,655,045	582,420,185	-	2,549,362,981		-	-	-	-	-	2,549,362,981
Buildings												
At cost	4,659,929,641	412,555,175	309,672,087	36,977,709	5,345,179,194	1.54-5	929,375,053	171,838,667	167,123,988	36,977,709	1,231,359,999	4,113,819,195
On revaluation	41,291,251	-	-	-	41,291,251	1.54-5	15,920,156	-	635,885	-	16,556,041	24,735,210
	4,701,220,892	412,555,175	309,672,087	36,977,709	5,386,470,445		945,295,209	171,838,667	167,759,873	36,977,709	1,247,916,040	4,138,554,405
Plant and machinery	11,315,712,113	262,786,978	937,729,268	47,038,744	12,469,189,615	5 - 20	4,591,368,259	164,555,002	758,760,688	43,700,776	5,470,983,173	6,998,206,442
Automobiles	580,233,927	62,431,476	236,839,744	128,375,150	751,129,996	25	390,701,077	51,623,057	100,222,506	126,855,710	415,690,930	335,439,066
Office equipment	976,048,600	13,646,355	93,251,121	6,769,994	1,076,176,083	10 - 12.5	488,106,358	12,226,580	104,413,061	6,769,994	597,976,005	478,200,078
Furnitures and fixtures	355,308,546	4,556,455	43,883,545	786,040	402,962,506	10	141,120,583	4,197,606	32,791,154	786,041	177,323,302	225,639,204
Total 30 June 2022	19,773,811,829	877,631,484	2,203,795,950	219,947,637	22,635,291,626		6,556,591,486	404,440,912	1,163,947,282	215,090,230	7,909,889,450	14,725,402,176

Property, plant and equipment of Renata Limited as at 30 June 2021

Amount in Taka

Particulars	Cost / Revaluation					Depreciation						Written down value as at 30 June 2021
	Balance as at 1 July 2020	Amount of Renata Oncology Limited due to merger	Addition during the year	Disposal / adjustment during the year	Balance as at 30 June 2021	Rate %	Balance as at 1 July 2020	Amount of Renata Oncology Limited due to merger	Charge for the year	Disposal / adjustment during the year	Balance as at 30 June 2021	
Freehold land												
At cost	1,528,380,964	-	142,219,206	4,444,497	1,666,155,673		-	-	-	-	-	1,666,155,673
On revaluation	179,132,078	-	-	-	179,132,078		-	-	-	-	-	179,132,078
	1,707,513,042	-	142,219,206	4,444,497	1,845,287,751		-	-	-	-	-	1,845,287,751
Buildings												
At cost	3,993,033,166	-	674,365,902	7,469,427	4,659,929,641	1.54-5	798,642,999	-	131,516,037	783,983	929,375,053	3,730,554,588
On revaluation	41,291,251	-	-	-	41,291,251	1.54-5	15,284,271	-	635,885	-	15,920,156	25,371,095
	4,034,324,417	-	674,365,902	7,469,427	4,701,220,892		813,927,270	-	132,151,922	783,983	945,295,209	3,755,925,683
Plant and machinery	9,894,103,475	-	1,422,879,038	1,270,400	11,315,712,113	5 - 20	3,937,069,134	-	655,569,525	1,270,400	4,591,368,259	6,724,343,854
Automobiles	528,699,641	-	85,005,379	33,471,093	580,233,927	25	345,396,909	-	76,411,113	31,106,945	390,701,077	189,532,850
Office equipment	893,011,533	-	83,862,067	825,000	976,048,600	10 - 12.5	392,535,943	-	95,801,510	231,095	488,106,358	487,942,242
Furnitures and fixtures	296,892,470	-	58,432,376	16,300	355,308,546	10	111,976,282	-	29,160,601	16,300	141,120,583	214,187,963
Total 30 June 2021	17,354,544,579	-	2,466,763,968	47,496,718	19,773,811,829		5,600,905,537	-	989,094,671	33,408,722	6,556,591,486	13,217,220,343

Consolidated property, plant and equipment as at 30 June 2021
Amount in Taka

Particulars	Cost / Revaluation				Depreciation					Written down value as at 30 June 2021
	Balance as at 1 July 2020	Addition during the year	Disposal / adjustment during the year	Balance as at 30 June 2021	Rate %	Balance as at 1 July 2020	Charge for the year	Disposal / adjustment during the year	Balance as at 30 June 2021	
Freehold land										
At cost	1,650,015,610	142,239,606	4,444,497	1,787,810,719		-	-	-	-	1,787,810,719
On revaluation	179,132,078	-	-	179,132,078		-	-	-	-	179,132,078
	1,829,147,688	142,239,606	4,444,497	1,966,942,797		-	-	-	-	1,966,942,797
Buildings										
At cost	4,322,621,317	757,332,926	7,469,427	5,072,484,816	1.54-5	951,291,958	150,705,744	783,983	1,101,213,719	3,971,271,097
On revaluation	41,291,251	-	-	41,291,251	1.54-5	15,284,271	635,885	-	15,920,156	25,371,095
	4,363,912,568	757,332,926	7,469,427	5,113,776,067		966,576,229	151,341,629	783,983	1,117,133,875	3,996,642,192
Plant and machinery	10,156,890,453	1,422,879,038	1,270,400	11,578,499,091	5-20	4,089,539,109	667,654,557	1,270,400	4,755,923,266	6,822,575,825
Automobiles	586,069,957	90,066,539	33,471,093	642,665,403	25	389,711,742	83,719,336	31,106,945	442,324,132	200,341,271
Office equipment	907,736,760	84,034,267	825,000	990,946,027	10 -12.5	404,643,727	97,104,326	231,095	501,516,958	489,429,069
Furnitures and fixtures	300,197,854	58,432,376	16,300	358,613,930	10	114,745,238	29,405,231	16,300	144,134,169	214,479,761
Total 30 June 2021	18,143,955,280	2,554,984,753	47,496,718	20,651,443,315		5,965,216,045	1,029,225,077	33,408,722	6,961,032,400	13,690,410,915

5.1 Initially recognised value of fully depreciated assets included in property, plant and equipment is as follows:

	30 June 2022	30 June 2021
	Taka	Taka
Building	41,426,533	4,448,824
Plant and machinery	804,881,585	678,248,074
Automobiles	334,857,447	274,786,270
Office equipment	164,708,455	139,429,635
Furniture and fixtures	54,723,503	39,992,447
	1,400,597,523	1,136,905,250

5.2 The freehold lands of the Company measuring 289.560 acres are located at:

Mirpur, Dhaka	12.000 acres	12.000 acres
Pekua, Cox's Bazar	45.340 acres	45.340 acres
Barisal Sadar	0.290 acres	0.290 acres
Gondogram, Bogura	0.270 acres	0.270 acres
Lakshimpur, Rajshahi City Corporation	0.149 acres	0.149 acres
Dogri, Rajendrapur, Gazipur	23.824 acres	18.581 acres
Kashor Gore, Bhaluka, Mymensingh	38.188 acres	38.013 acres
Sagordighi, Tangail	13.805 acres	13.805 acres
Siddikhali, Tangail	1.050 acres	1.050 acres
Ghatail, Tangail	13.234 acres	13.234 acres
Dhamsur, Bhaluka, Mymensingh	26.370 acres	26.370 acres
Turag, Dhaka	0.949 acres	0.949 acres
Sreepur, Gazipur	13.830 acres	13.830 acres
Keranigonj, Dhaka	0.590 acres	0.590 acres
Faridpur Sadar, Faridpur	0.410 acres	0.410 acres
Debipur, Sarishadi, Feni Sadar	0.599 acres	0.599 acres
Chatropur, Mymensingh	0.558 acres	0.558 acres
Phulbaria, Mymensingh	8.503 acres	8.503 acres
Bypass Mor, Digharkanda, Mymensingh	0.035 acres	0.035 acres
Tetulia, Dakshin Surma, Sylhet	0.483 acres	0.483 acres
Betgari, Shajahanpur, Bogura	0.555 acres	0.555 acres
Lohaboy, Bhaluka	4.463 acres	4.463 acres
Narangi, Bhaluka	6.605 acres	6.605 acres
Batabaria and Haratoli, Sadar Dakshin, Cumilla	0.580 acres	0.580 acres
Salna, Purabari	0.307 acres	0.307 acres
Sathkhamair, Sreepur	8.229 acres	8.229 acres
Bhobainagar, Kotwali Sadar, Dinajpur	0.803 acres	0.803 acres
Uttam, Rangpur Sadar, Rangpur	0.710 acres	0.710 acres
Kandila, Gala, Tangail Sadar	1.400 acres	1.400 acres
Kalameshwar, Gazipur Sadar	0.509 acres	0.509 acres
Mouchak, Kaliakair, Gazipur	1.982 acres	1.982 acres
Norh Pelaid, Sreepur, Gazipur	4.130 acres	- acres
Kashor, Bhaluka, Mymensingh	22.670 acres	- acres
Lokhindor, Shagordighi, Gathail, Tangail	10.920 acres	- acres
Lohaboy, Bhaluka, Mymensingh	12.830 acres	- acres
Morchi, Bhaluka, Mymensingh	9.640 acres	- acres
Mohishmara, Modhupur, Tangail	2.750 acres	- acres
Total	289.560 acres	221.202 acres

5.3 Depreciation for the year has been charged to:

Cost of sales (Note-27.2)
Administrative expenses (Note-28)
Selling, marketing and distribution expenses (Note-29)

30 June 2022 Taka	30 June 2021 Taka
959,679,524	812,453,874
20,149,133	17,393,036
184,118,623	159,247,761
1,163,947,282	989,094,671

5.4 The freehold land and buildings were revalued by a firm of professional valuers in the year 1995 and the increase in net carrying amount as a result of revaluation were shown as addition/valuation in that year.

5.5 Gain/ (loss) on disposal of property, plant and equipment

Amount in Taka					
Original cost	Accumulated depreciation	Net book value	Sale proceeds	Gain/ (loss)	
				2021-2022	2020-2021
219,947,637	215,090,230	4,857,407	29,049,244	24,191,834	17,602,471

6. Capital work-in-progress

Opening balance
Add: Amount of Renata Agro Industries Limited as at 01 July 2021 due to merger
Add: Addition during the year

Less: Capitalized as property, plant and equipment (Note-6.1)

30 June 2022 Taka	30 June 2021 Taka
3,803,865,530	1,914,471,284
85,234,411	-
9,061,374,661	3,756,900,087
12,950,474,602	5,671,371,371
1,165,720,613	1,867,505,841
11,784,753,989	3,803,865,530

This represents mainly construction of buildings for Bhaluka general manufacturing facility, Bhaluka MDI facility, Bhaluka central finished goods and raw material store, Habirbari PPF-3 manufacturing facility, Rajendrapur oncology injectable facility, Rajendrapur PPF-2 warehouse, extension of Rajendrapur general manufacturing facility, extension of Rajendrapur PPF-2 manufacturing facility, extension of Mirpur nutrition facility, Tangail depot, extension of Mirpur QC lab, Rajendrapur pellet and softgel facility, extension of Turag depot, extension of Korotoa depot, extension of Kirtonkhola depot, installation of plant and machinery, their components and other fixed assets procured from foreign and local vendors.

6.1 The break down of capitalized property, plant and equipment is as follows:

Buildings
Plant and machinery
Office equipment
Furniture and fixtures
Automobiles

268,635,443	501,403,051
866,678,480	1,332,446,716
10,962,534	12,177,696
16,977,252	21,478,378
2,466,904	-
1,165,720,613	1,867,505,841

6 (a) Consolidated capital work- in-progress

Opening balance
Addition during the year

Capitalized as property, plant and equipment

3,889,099,941	2,020,732,811
9,061,374,661	3,818,839,995
12,950,474,602	5,839,572,806
1,165,720,613	1,950,472,865
11,784,753,989	3,889,099,941

7	Investment in subsidiaries	No. of shares	30 June 2022	30 June 2021
			Taka	Taka
	Renata Agro Industries Limited (Note-7.1)	-	-	60,570,476
	Purnava Limited (Note-7.2)	-	-	2,499,900
	Renata (UK) Limited (Note-7.3)	1	110	110
	Renata Pharmaceuticals (Ireland) Limited (Note-7.4)	100	9,610	9,610
		101	9,720	63,080,096

7.1 Investment in subsidiary company - Renata Agro Industries Limited

Renata Limited acquired 99.99% of equity interest in Renata Agro Industries Limited (419,949 ordinary shares of Taka 100 each) on 7 April 2001. Purchase consideration with regard to the acquisition of shares amounted to Taka 60,570,476. Renata Limited and Renata Agro Industries Limited were operating under common control. After approval of the Board of Directors and consent of minority shareholder, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned the scheme of amalgamation of Renata Agro Industries Limited with Renata Limited with effect from the appointed date 01 July 2021.

7.2 Investment in subsidiary company - Purnava Limited

Renata Limited acquired 99.99% of equity interest in Purnava Limited (24,999 ordinary shares of Taka 100 each) on 16 September 2004. Purchase consideration with regard to the acquisition of shares amounted to Taka 2,499,900 being face value of shares. Renata Limited and Purnava Limited were operating under common control. After approval of the Board of Directors and consent of minority shareholder, the Hon'ble High Court Division of the Supreme Court of Bangladesh has sanctioned the scheme of amalgamation of Purnava Limited with Renata Limited with effect from the appointed date 01 July 2021.

7.3 Investment in subsidiary company - Renata (UK) Limited

Renata Limited acquired 100% of equity interest in Renata (UK) Limited (1 ordinary share of GBP 1 each) on 9 April 2018. Purchase consideration with regard to the acquisition of the share amounted to GBP 1 being face value of the share. Renata Limited and Renata (UK) Limited have been operating under common control.

7.4 Investment in subsidiary company - Renata Pharmaceuticals (Ireland) Limited

Renata Limited acquired 100% of equity interest in Renata Pharmaceuticals (Ireland) Limited (100 ordinary share of Euro 1 each) on 24 April 2019. Purchase consideration with regard to the acquisition of the share amounted to Euro 100 being face value of the share. Renata Limited and Renata Pharmaceuticals (Ireland) Limited have been operating under common control.

8	Inventories	30 June 2022	30 June 2021
		Taka	Taka
	Finished goods		
	- Pharmaceutical	1,385,865,274	1,047,309,859
	- Animal health	777,197,665	692,657,106
	- Consumer products	98,419,533	-
	- Agro-based products	3,880,719	-
		2,265,363,191	1,739,966,965
	Work-in-process	451,379,546	232,605,418
	Raw materials	764,877,638	651,546,732
	Raw materials- agro-based products	34,059,781	-
	Bulk materials	2,731,913,856	1,794,652,896
	Packing materials	810,309,156	524,618,088
	Consumable stores, spares and reagent materials	673,578,638	257,144,288
	Stock in transit	887,676,746	958,858,980
		8,619,158,552	6,159,393,367
	Provision for obsolete inventories	(133,557,124)	(230,133,428)
		8,485,601,428	5,929,259,939

8(a) Consolidated inventories	30 June 2022 Taka	30 June 2021 Taka
Finished goods		
- Pharmaceutical	1,385,865,274	1,047,309,859
- Animal health	777,197,665	692,657,106
- Consumer products	98,419,533	-
- Agro-based products	3,880,719	-
Purnava Limited	-	52,108,805
Renata Agro Industries Limited	-	16,610,508
	2,265,363,191	1,808,686,278
Work-in-process	451,379,546	232,605,418
Raw materials	764,877,638	655,405,605
Raw materials- agro-based products	34,059,781	-
Bulk materials	2,731,913,856	1,794,652,896
Packing materials	810,309,156	540,584,033
Consumable stores, spares and reagent materials	673,578,638	257,144,288
Stock in transit	887,676,746	961,705,145
	8,619,158,552	6,250,783,663
Provision for obsolete inventories	(133,557,124)	(230,133,428)
	8,485,601,428	6,020,650,235

9 Trade receivables

Trade receivables- unsecured (Note-9.1)	3,407,104,287	2,932,533,813
Allowances for doubtful receivables	(152,769,621)	(105,255,302)
	3,254,334,666	2,827,278,511

9.1 Trade receivables disclosure as per Schedule-XI, Part-I, of the Companies Act, 1994

Receivables due below six months	2,900,940,691	2,507,254,327
Receivables due over six months	506,163,596	425,279,486
	3,407,104,287	2,932,533,813

9 (a) Consolidated trade receivables

Trade receivables- unsecured	3,407,104,287	3,041,248,988
Allowances for doubtful receivables	(152,769,621)	(109,051,806)
	3,254,334,666	2,932,197,182

10 Other receivables

Inter-company receivables (Note-10.1)		
- Renata Agro Industries Limited	-	48,499,554
- Purnava Limited	-	337,500,000
- Renata (UK) Limited	169,337	169,337
Value Added Tax (VAT) recoverable	515,102,604	530,442,621
Sundry receivables- unsecured but considered good	95,704,512	214,756,723
	610,976,453	1,131,368,235

10.1 Inter-company receivables include advances given to subsidiaries on need basis.

10 (a) Consolidated other receivables

Sundry receivables - unsecured but considered good	95,704,512	214,756,723
Value Added Tax (VAT) recoverable	515,102,604	536,447,152
	610,807,116	751,203,875

11 Advances, deposits and prepayments

Advances

	30 June 2022 Taka	30 June 2021 Taka
Advance to employees for motorcycle	128,548,336	147,082,804
Loan to employees against salary	74,440,493	57,939,387
Advance for house rent	5,122,034	9,467,962
Advance for inventory	254,508,883	198,821,831
Advance to third parties	153,884,742	-
Advance to field force (sales personnel)	21,569,942	19,232,692
Advance to staff against expenses (other than petty cash)	44,747,287	61,107,627
Advance to staff against petty expenses	1,687,500	1,484,500
Advance against tour expenses	5,568,001	2,546,513
Other advances	16,925,342	1,569,407
	707,002,560	499,252,723

Deposits

Tender deposits	69,725,784	41,504,177
Gazipur Palli Bidyut Samity	15,748,000	18,248,000
Mymensingh Palli Bidyut Samity	22,756,000	12,256,000
Titans Gas Transmission and Distribution Co. Limited	5,783,100	5,783,100
Ministry of Health & Population Department of Health Services	5,340,741	-
Dhaka Electric Supply Co. (DESCO) Limited	2,310,000	2,310,000
Linde Bangladesh Limited	1,878,592	1,248,000
Bangladesh Ansar O Gram Protirokkha Bahini (Bangladesh Ansar and VDP)	536,461	536,461
Ethiopian Pharmaceuticals Supply Agency (EPSA)	306,033	-
Radisson Water Garden Hotel	200,000	200,000
Bangladesh Customs House, Dhaka Airport	200,000	200,000
Meghna Model Service Center	110,000	110,000
Bangladesh Power Development Board, Bogura	232,534	232,534
Bangladesh Power Development Board, Sylhet	90,000	90,000
Essence Industrial Gases Limited	795,000	210,000
Sundarban Industrial Complex Limited	79,865	79,865
Spectra International Ltd.	12,000	-
Bangladesh Petroleum Exploration & Production Co. Limited	7,000	7,000
Dhaka Medical College & Hospital	1,540	1,540
	126,112,650	83,016,677

Prepayments

Insurance premium	8,128,084	8,303,552
	8,128,084	8,303,552
	841,243,294	590,572,952

(a) All advances, deposits and prepayments are considered regular and recoverable in the normal course of business.

(b) The maximum amount due from officers (manager and above) against salary during the year was Tk. 23,686,613.

(c) No amount was due from the Directors, Managing agent, Managers and other officers of the Company and any of them severally or jointly with any other person except as stated in (b) above.

11(a) Consolidated advances, deposits and prepayments

Advances

Advance to employees for motorcycle	128,548,336	147,082,804
Loan to employees against salary	74,440,493	58,306,998
Advance for house rent	5,122,034	9,467,962
Advance for inventory	254,508,883	198,868,590
Advance to third parties	153,884,742	-
Advance to staff against expenses (other than petty cash)	44,747,287	61,107,627
Advance against expenses	5,568,001	2,565,200
Other advances	40,182,784	50,108,830
	707,002,560	527,508,011

	30 June 2022 Taka	30 June 2021 Taka
Deposits		
Tender deposits	69,725,784	41,504,177
Mymensingh Palli Bidyut Samity	22,756,000	12,256,000
Gazipur Palli Bidyut Samity	15,748,000	18,248,000
Dhaka Electric Supply Co. (DESCO) Limited	2,310,000	2,310,000
Linde Bangladesh Limited	1,878,592	1,248,000
Bangladesh Ansar O Gram Protirokkha Bahini (Bangladesh Ansar and VDP)	536,461	536,461
Titas Gas Transmission and Distribution Co. Limited	5,783,100	5,783,100
Ministry of Health & Population Department of Health Services	5,340,741	-
Ethiopian Pharmaceuticals Supply Agency (EPSA)	306,033	-
Radisson Water Garden Hotel	200,000	200,000
Meghna Model Service Center	110,000	110,000
Bangladesh Customs House, Dhaka Airport	200,000	200,000
Bangladesh Power Development Board, Bogura	232,534	232,534
Bangladesh Power Development Board, Sylhet	90,000	90,000
Essence Industrial Gases Limited	795,000	210,000
Sundarban Industrial Complex Limited	79,865	79,865
Spectra International Ltd.	12,000	-
Bangladesh Petroleum Exploration & Production Co. Limited	7,000	7,000
Dhaka Medical College & Hospital	1,540	1,540
	126,112,650	83,016,677
Prepayments		
Insurance premium	8,128,084	9,328,413
	8,128,084	9,328,413
	841,243,294	619,853,101

12 Investment in shares and FDR

Investment in shares (Note-12.1)	87,063,008	93,378,750
Investment in FDR (Note-12.2)	1,447,653,996	5,370,557,838
	1,534,717,004	5,463,936,588

	Cost 30 June 2022 Taka	Market value 30 June 2022 Taka	30 June 2021 Taka
12.1 Investment in shares			
Square Pharma Limited	31,399,794	50,516,887	550,237,145
British American Tobacco Bangladesh Company Limited	9,196,406	22,314,480	17,821,029
Grameenphone Limited	14,948,644	11,764,000	13,976,000
Shahjibazar Power Co. Ltd.	-	-	6,725,093
ACI Formulations Limited	-	-	2,223,000
Central Depository Bangladesh Limited (unquoted)	1,569,450	1,569,450	1,569,450
Marico Bangladesh Limited	428,334	898,191	827,033
	57,542,628	87,063,008	93,378,750

12.2 Investment in FDR

Delta Brac Housing Finance Corporation Ltd.	-	776,865,172
IDLC Finance Limited	479,998,276	1,641,691,050
IPDC Finance Limited	324,260,000	2,375,391,316
Commercial Bank of Ceylon PLC (foreign currency (USD) FDR)	643,395,720	576,610,300
	1,447,653,996	5,370,557,838

13 Cash and cash equivalents

Cash in hand

30 June 2022
Taka

3,722,525

30 June 2021
Taka

2,925,000

Cash at bank

Standard Chartered Bank
Eastern Bank Limited
Bank Asia Limited
Commercial Bank of Ceylon PLC
Sonali Bank Limited
Citibank N. A.
Agrani Bank Limited
The City Bank Limited
BRAC Bank Limited
United Commercial Bank Limited
Bangladesh Commerce Bank Limited
Pubali Bank Limited
Islami Bank Bangladesh Limited
Dutch-Bangla Bank Limited

203,892,362
76,185,685
161,268,161
219,908,817
4,626,580
3,519,669
8,540,243
2,473,099
92,177,111
182,292
91,014
1,843
21,839
1,069

772,889,784

170,927,993
277,367,261
417,662,338
259,772,613
25,055,925
15,456,784
44,519,694
8,591,871
131,836,268
182,292
91,934
-
-
-

1,351,464,973

Balance with City Bank Capital Resources Limited

1,680,494

1,461,798

Balance with ICB Securities Trading Company Limited

244,516

232,874

1,925,010

1,694,672

778,537,319

1,356,084,645

13(a) Consolidated cash and cash equivalents

Cash in hand

3,722,635

3,922,357

Cash at bank

Standard Chartered Bank
Eastern Bank Limited
Bank Asia Limited
Commercial Bank of Ceylon PLC
Sonali Bank Limited
Citibank N. A.
Agrani Bank Limited
The City Bank Limited
BRAC Bank Limited
Islami Bank Bangladesh Limited
Dutch-Bangla Bank Limited
Pubali Bank Limited
Bangladesh Commerce Bank Limited
Janata Bank Limited
United Commercial Bank Limited

203,928,713
76,185,685
161,268,161
219,908,817
4,626,580
3,519,669
8,540,243
2,473,099
92,177,111
21,839
1,069
1,843
91,014
-
182,292

772,926,135

178,878,700
305,497,978
418,380,557
259,772,613
25,127,290
15,456,784
44,559,433
8,591,871
135,068,395
8,092,726
8,909
601,543
91,934
12,084
182,292

1,400,323,109

Balance with City Bank Capital Resources Limited

1,680,494

1,461,798

Balance with ICB Securities Trading Company Limited

244,516

245,416

1,925,010

1,707,214

778,573,780

1,405,952,680

14 Share capital

30 June 2022
Taka

30 June 2021
Taka

Authorized share capital

285,000,000 ordinary shares of Tk.10 each

2,850,000,000

2,500,000,000

As Per Clause (6) [Page# 07] of the Judgement and Order (Company Matter No. 48 of 2022) of the Honorable High Court Division of the Supreme Court of Bangladesh, the authorized share capital of the Transferor Companies (Renata Agro Industries Limited and Purnava Limited) stand added and be part of the authorized share capital of the Transferee Company (Renata Limited). Authorized share capital of Renata Agro Industries Limited and Purnava Limited have been added to the authorized share capital of Renata Limited to that extent accordingly.

Issued, subscribed and paid up capital

1,294,260 ordinary shares of Tk.10 each issued for cash

12,942,600

12,942,600

1,724,490 ordinary shares of Tk.10 each issued for consideration other than cash

17,244,900

17,244,900

104,174,232 ordinary shares (94,429,416 ordinary shares as at 30 June 2021) of Tk.10 each issued as bonus shares

1,041,742,320

944,294,160

1,071,929,820

974,481,660

These shares are listed with Dhaka Stock Exchange Limited and quoted at Tk 1,345.60 per share on 30 June 2022.

As at 30 June 2022, the shareholding position of the Company was as follows:

Name of the shareholders	Nationality/ Incorporated in	Number of shares	Face value Taka	% of total shareholdings
Sajida Foundation	Bangladesh	54,764,954	547,649,540	51.09%
Business Research International Corp. Inc.	Panama	23,307,989	233,079,890	21.74%
Shadharan Bima Corporation	Bangladesh	4,689,661	46,896,610	4.38%
ICB Unit Fund	Bangladesh	4,676,019	46,760,190	4.36%
Investment Corporation of Bangladesh	Bangladesh	3,338,984	33,389,840	3.12%
Other shareholders	Bangladesh & others	16,415,375	164,153,750	15.31%
		107,192,982	1,071,929,820	100%

As at 30 June 2022, the classification of shareholders of the Company by holdings was as follows:

Holdings	No. of shareholders as per folio	No. of shareholders as per BOID	No. of total shareholders	No. of shareholdings	% of total shareholdings
Less than 500 shares	86	5,369	5,455	463,807	0.43%
501 to 5000 shares	31	999	1,030	1,667,945	1.56%
5,001 to 10,000 shares	12	140	152	1,092,451	1.02%
10,001 to 20,000 shares	7	78	85	1,221,492	1.14%
20,001 to 30,000 shares	4	39	43	1,046,297	0.98%
30,001 to 40,000 shares	1	13	14	481,564	0.45%
40,001 to 50,000 shares	1	14	15	667,376	0.62%
50,001 to 100,000 shares	2	35	37	2,586,611	2.41%
100,001 to 1,000,000 shares	-	27	27	7,966,764	7.43%
Over 1,000,000 shares	1	5	6	89,998,675	83.96%
	145	6,719	6,864	107,192,982	100%

	30 June 2022 Taka	30 June 2021 Taka
15 Revaluation surplus		
Land	179,132,078	179,132,078
Buildings	25,371,095	26,006,980
	204,503,173	205,139,058
Less: Depreciation adjustment on revalued buildings	(635,885)	(635,885)
	203,867,288	204,503,173
Less: Adjustment of deferred tax on revaluation surplus	(50,998,612)	(51,141,687)
	152,868,676	153,361,486

16 Other reserves

The deficit amounts of Tk. 43,065,180 and Tk. 164,495,567 and the surplus amount of Tk. 426,898,535 of the net assets of Renata Oncology Limited, Purnava Limited and Renata Agro Industries Limited respectively have been transferred and debited/ credited (as applicable) to 'Other reserves' in the books of Renata Limited pursuant to their Schemes of Amalgamation.

17 Fair value reserve

Opening balance	24,775,182	(1,957,787)
Fair value adjustment on investment in shares, net of tax	1,793,358	26,732,969
Realised gain on disposal of shares	197,467	341,432
Transfer between reserves- realised gain on disposal of shares	(197,467)	(341,432)
	26,568,540	24,775,182

17(a) Consolidated fair value reserve

Opening balance	24,775,183	13,709,475
Fair value adjustment on investment in shares, net of tax	1,793,358	26,732,969
Recognition of remaining gain upon disposal of shares of Renata Agro Industries Limited	-	12,003,844
Realised gain on disposal of shares	197,467	341,432
Transfer between reserves- realised gain on disposal of shares	(197,467)	(28,012,537)
	26,568,540	24,775,183

18 Retained earnings

Opening balance	24,340,254,640	20,544,705,799
Net profit after tax for the year	5,110,957,210	5,034,820,910
Stock dividend issued	(97,448,160)	(88,589,240)
Final dividend (cash dividend)	(1,412,998,407)	(1,151,660,146)
Depreciation adjustment on revalued assets	635,885	635,885
Transfer between reserves- realised gain on disposal of shares	197,467	341,432
	27,941,598,636	24,340,254,640

18(a) Consolidated retained earnings

Opening balance	24,601,846,926	20,705,254,771
Net profit after tax for the year	5,110,917,432	5,061,555,446
Stock dividend issued	(97,448,160)	(88,589,240)
Final dividend (cash dividend)	(1,412,998,407)	(1,151,660,146)
Depreciation adjustment on revalued assets	635,885	635,885
Transfer to Other reserves due to merger of Renata Agro Industries Limited & Purnava Limited	(262,402,968)	-
Adjustment of provision for unrealised profit due to merger of Renata Agro Industries Limited and Purnava Limited	661,449	-
Adjustment of non-controlling interests due to merger of Renata Agro Industries Limited and Purnava Limited	52,711	-
Transfer from tax holiday reserve	-	46,637,673
Transfer between reserves- realised gain on disposal of shares	197,467	28,012,537
	27,941,462,335	24,601,846,926

	30 June 2022 Taka	30 June 2021 Taka
19. Non-controlling interests		
Share capital	-	5,200
Retained earnings and reserve (including tax holiday reserve)	-	47,511
	-	52,711

20. Deferred tax liabilities

Opening balance	1,368,214,166	1,442,915,240
Amount of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	1,060,700	-
Addition during the year	36,154,030	(74,701,074)
	1,405,428,896	1,368,214,166

Computation of deferred tax for the year ended 30 June 2022

	Carrying amount	Tax base	Taxable/(deductible) temporary difference	Deferred tax liabilities/ (assets)
	Taka	Taka	Taka	Taka
Property, plant and equipment	12,355,171,273	5,791,271,386	6,563,899,887	1,438,829,742
Provision for doubtful debt	(152,769,621)	-	(152,769,621)	(34,373,165)
Provision for gratuity	(8,798,751)	-	(8,798,751)	(1,979,719)
Investment in shares	87,063,008	57,542,628	29,520,380	2,952,038
Deferred tax liabilities/(assets) as at 30 June 2022				1,405,428,896

Deferred tax liabilities/(assets) as at 30 June 2021

Amount of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	1,060,700
Increase in deferred tax liabilities/(assets) during the year	36,154,030

Allocation of deferred tax liabilities/(assets) during the year

Charged to fair value reserve (OCI)	199,239
Adjustment for reduction of revaluation surplus due to charges of extra depreciation	(143,075)
Charged to profit or loss	36,097,866
	36,154,030

Computation of deferred tax for the year ended 30 June 2021

	Carrying amount	Tax base	Taxable/(deductible) temporary difference	Deferred tax liabilities/ (assets)
	Taka	Taka	Taka	Taka
Property, plant and equipment	11,551,064,672	5,229,805,801	6,321,258,871	1,389,143,811
Provision for doubtful debt	(105,255,302)	-	(105,255,302)	(23,682,443)
Investment in shares	93,378,750	65,850,774	27,527,976	2,752,798
Deferred tax liabilities/(assets) as at 30 June 2021				1,368,214,166

Deferred tax liabilities/(assets) as at 30 June 2020

Increase in deferred tax liabilities/(assets) during the year	(74,701,074)
---	---------------------

Allocation of deferred tax liabilities/(assets) during the year

Charged to fair value reserve (OCI)	2,970,330
Adjustment for reduction of revaluation surplus due to charges of extra depreciation	(143,075)
Charged to profit or loss	(77,528,329)
	(74,701,074)

20.(a) Deferred tax liabilities

30 June 2022 Taka	30 June 2021 Taka
1,369,274,868	1,446,845,163
36,154,030	(77,570,295)
1,405,428,896	1,369,274,868

Computation of deferred tax for the year ended 30 June 2022

	Carrying amount	Tax base	Taxable/(deductible) temporary difference	Deferred tax liabilities/(assets)
	Taka	Taka	Taka	Taka
Property, plant and equipment	12,355,171,273	5,791,271,386	6,563,899,887	1,438,829,742
Provision for doubtful debt	(152,769,621)	-	(152,769,621)	(34,373,165)
Provision for gratuity	(8,798,751)	-	(8,798,751)	(1,979,719)
Investment in shares	87,063,008	57,542,628	29,520,380	2,952,038
Deferred tax liabilities/(assets) as at 30 June 2022				1,405,428,896

Deferred tax liabilities/(assets) as at 30 June 2021

1,369,274,868

Increase in deferred tax liabilities/(assets) during the year

36,154,030

Allocation of deferred tax liabilities/(assets) during the year

Charged to fair value reserve (OCI)	199,239
Adjustment for reduction of revaluation surplus due to charges of extra depreciation	(143,075)
Charged to profit or loss	36,097,866
	36,154,030

Computation of deferred tax for the year ended 30 June 2021

	Carrying amount	Tax base	Taxable/(deductible) temporary difference	Deferred tax liabilities/(assets)
	Taka	Taka	Taka	Taka
Property, plant and equipment	12,024,255,244	5,645,763,980	6,378,491,264	1,394,536,205
Provision for doubtful debt	(109,051,806)	-	(109,051,806)	(24,189,583)
Provision for gratuity	(38,245,522)	-	(38,245,522)	(3,824,552)
Investment in shares	93,378,750	65,850,774	27,527,976	2,752,798
Deferred tax liabilities/(assets) as at 30 June 2021				1,369,274,868

Deferred tax liabilities/(assets) as at 30 June 2020

1,446,845,163

Increase in deferred tax liabilities/(assets) during the year

(77,570,295)

Allocation of deferred tax liabilities/(assets) during the year

Charged to fair value reserve (OCI)	1,229,312
Adjustment for reduction of revaluation surplus due to charges of extra depreciation	(143,075)
Charged to profit or loss	(78,656,532)
	(77,570,295)

21	Short term bank loan and overdrafts	30 June 2022 Taka	30 June 2021 Taka
	Eastern Bank Limited (Note-21.1)	190,871,759	1,531,854
	The City Bank Limited (Note-21.2)	1,254,115,839	296,956,034
	Standard Chartered Bank (Note-21.3)	1,526,035,695	1,245,635,658
	Citibank N. A. (Note-21.4)	1,492,940,610	821,460,494
	Bank Asia Limited (Note-21.5)	583,683,454	504,911,141
	Commercial Bank of Ceylon PLC (Note-21.6)	2,304,060,828	1,931,014,719
	BRAC Bank Limited (Note-21.7)	1,544,758,221	-
		8,896,466,406	4,801,509,900

The terms and conditions of the facility available for Overdraft, Acceptance, LATR, Revolving, Import and Demand loan are as follows:

21.1 Eastern Bank Limited

Overdraft

Purpose : To finance overhead cost and duty payment.
Facility limit : Tk. 30 million.
Repayment : Within 365 days from the date of disbursement.

Letter of credit/ Acceptance (Sight/Usance)/ Import finance

Purpose : To import plant and machinery and raw materials.
Facility limit : Combined Tk. 758.3 million.
Repayment : Within 180 days from the date of disbursement.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.
- iii) Registered hypothecation by way of pari-passu with RJSC on entire inventory book debts and other floating assets and plant and machinery of the Company in favor of Eastern Bank Limited.

21.2 The City Bank Limited

Letter of credit/ Acceptance (Sight/Usance)/ Import finance/ Short term loan

Purpose : To import API, excipient, packing and finished materials, to retire sight letter of credit documents opened for procurement of API, excipient, packing and finished materials, and for payment of duty and other charges related to import and VAT.
Facility limit : Combined Tk. 2,200 million.
Repayment : Within 180 days from the date of disbursement.

Overdraft

Purpose : To meet the day to day operating, promotional, and marketing expenses.
Facility limit : Tk. 100 million.
Repayment : Within 365 days from the date of disbursement.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited with RJSC on pari-passu security sharing basis with the existing lenders.

21.3 Standard Chartered Bank

Letter of credit/ Loan against trust receipt (LATR)/ Acceptance

Purpose	: To open letter of credits for import of raw materials, packing materials, capital machinery, spares and other items required for regular course of business, for retirement of documents of only sight letter of credits, and to provide acceptance against letter of credits issued by the bank.
Facility limit	: Combined Tk. 4,950 million.
Repayment	: Within 180/365 days from the date of disbursement.

Overdraft

Purpose	: For working capital purposes.
Facility limit	: Tk. 150 million.
Repayment	: Overdraft to be cleaned up for 3 days in one year.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.

21.4 Citibank N. A.

Letter of credit/ Acceptance (Sight/Usance)/ Import finance

Purpose	: To open letter of credits for import of raw materials, packing materials, capital machinery, spares and other items required for regular course of business, and to refinance import letter of credits.
Facility limit	: Combined USD 28,800,000.
Repayment	: Within 180/360 days from the date of disbursement.

Short term loan

Purpose	: To finance local purchase of active and raw materials, packing materials, capital machinery, spares and other items required for regular course of business.
Facility limit	: Combined USD 6,000,000.
Repayment	: Within 180 days from the date of disbursement.

Overdraft

Purpose	: To finance regular selling, general and administrative expenses.
Facility limit	: Combined USD 2,000,000.
Repayment	: On demand.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.

21.5 Bank Asia Limited

Revolving letter of credit

Purpose	: To import raw materials, machineries and spare parts for the Company.
Facility limit	: Tk. 2,100 million.
Repayment	: Within 180 days from the date of disbursement.

Revolving LATR

Purpose	: Retirement of documents of only sight letter of credits.
Facility limit	: Tk. 150 million.
Repayment	: Within 120 days from the date of disbursement.

Overdraft

Purpose : For payment of duty VAT, taxes and operating expenses.
 Facility limit : Tk. 250 million.
 Repayment : Within 180 days from the date of disbursement.

Revolving demand loan

Purpose : For procurement of pharmaceuticals and packing materials from local sources.
 Facility limit : Tk. 50 million.
 Repayment : Within 180 days from the date of disbursement.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.

21.6 Commercial Bank of Ceylon PLC

Facility limit : Combined Tk. 3,500 million.
 Repayment : Within 180/360 days from the date of disbursement.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.

21.7 Brac Bank Limited

Purpose : To open letter of credits for import of raw materials, packing materials, capital machinery, spares and other items required for regular course of business, and to refinance import letter of credits.
 Facility limit : Combined Tk. 2,550 million
 Repayment : Within 180/360 days from the date of disbursement.

Security

- i) First charge over all present and future inventories and trade receivable of Renata Limited under pari-passu security sharing agreement.
- ii) First charge over all present and future plant and machinery of Renata Limited jointly as above.

22 Trade payables

Payable to suppliers
 Toll manufacturing charges (Sharif and NAFCO)

30 June 2022
Taka

480,090,723
14,553,778
494,644,501

30 June 2021
Taka

398,897,541
-
398,897,541

Aging of the above payables is given below:

Payables due below six months
 Payables due over six months

478,421,923
16,222,578
494,644,501

369,979,205
28,918,336
398,897,541

	30 June 2022 Taka	30 June 2021 Taka
22(a) Consolidated trade payables		
Payable to suppliers	480,090,723	399,760,719
Toll manufacturing charges (Sharif and NAFCO)	14,553,778	-
	494,644,501	399,760,719
Aging of the above payables is given below:		
Payables due below six months	478,421,923	370,817,906
Payables due over six months	16,222,578	28,942,813
	494,644,501	399,760,719

23 Other payables

VAT and other payables	641,429,835	691,541,438
Advance from customers (Note-23.1)	15,980,905	233,129,728
Workers' participation fund (Note-23.2)	10,980,525	14,946,526
Provident fund (Note-23.3)	-	37,317
Export commission payable	50,154,477	23,755,925
Accrued interest	57,342,452	24,428,324
Salary payable	3,100,000	-
Payable for investment in Renata Pharmaceuticals (Ireland) Limited	9,610	9,610
	778,997,804	987,848,868

23.1 This amount represents advances received from customers against sales and for which respective sales have accrued in the subsequent financial period.

23.2 Workers' participation fund

Opening balance	14,946,526	64,199,608
Add: Amount of Renata Agro Industries Limited as at 01 July 2021 due to merger	9,231,263	-
Addition during the year	306,133,415	336,676,598
	330,311,204	400,876,206
Transferred during the year	(319,330,679)	(385,929,680)
	10,980,525	14,946,526

23.3 Provident fund forfeited from outgoing employees have been returned to Renata Limited.

23(a) Consolidated other payables

VAT and other payables	641,433,149	759,155,332
Advance from customers	15,980,905	233,129,728
Workers' participation fund [Note-23.1(a)]	10,980,525	24,177,789
Provident fund	-	27,251,968
Export commission payable	50,154,477	23,755,925
Accrued interest	57,342,452	24,428,324
Salary payable	3,100,000	-
	778,991,508	1,091,899,066

23.1(a) Consolidated workers' participation fund

Opening Balance	24,177,789	74,973,837
Addition during the year	306,133,415	338,022,024
	330,311,204	412,995,861
Transferred during the year	(319,330,679)	(388,818,072)
	10,980,525	24,177,789

24 Unclaimed dividend account

Unclaimed dividend upto 4 years
Unclaimed dividend above 4 years

30 June 2022
Taka

23,895,674
-
23,895,674

30 June 2021
Taka

23,128,347
18,211,235
41,339,582

25 Provision for taxation

Opening balance
Amount of Renata Agro Industries Limited and
Purnava Limited as at 01 July 2021 due to merger
Provision made during the year

1,335,048,994
23,018,602
975,613,222
2,333,680,828
(1,329,841,519)
1,003,839,309

1,360,352,448
-
1,776,239,454
3,136,591,902
(1,801,542,908)
1,335,048,994

Payment made during the year

25(a) Consolidated provision for taxation

Opening balance
Provision made during the year

1,358,067,596
975,613,222
2,333,680,828
(1,329,841,519)
1,003,839,309

1,367,971,535
1,794,552,362
3,162,523,897
(1,804,456,301)
1,358,067,596

Payment made during the year

26 Turnover

Pharmaceutical products
Animal health products
Contract manufacturing
Agro-based products
Consumer products

2021-2022			2020-2021
Gross Turnover	Less: VAT	Turnover (net)	Turnover (net)
26,783,767,507	3,851,002,687	22,932,764,820	19,681,337,757
5,868,790,928	506,689,722	5,362,101,206	5,093,084,333
1,987,162,149	78,253,219	1,908,908,930	4,476,484,451
251,123,756	-	251,123,756	-
649,340,645	33,684,809	615,655,836	-
35,540,184,985	4,469,630,437	31,070,554,548	29,250,906,541

During the year, sale of pharmaceutical products includes export sales of Tk. 1,208,092,354 equivalent to US\$ 14,069,426 (Tk. 798,597,697 equivalent to US\$ 9,420,241 for the year ended 30 June 2021).

26(a) Consolidated turnover (net)

Renata Limited
Renata Agro Industries Limited
Purnava Limited

2021-2022
Taka

31,070,554,548
-
-
31,070,554,548

2020-2021
Taka

29,047,194,362
288,083,827
635,423,386
29,970,701,575

27 Cost of sales

	2021-2022 Taka	2020-2021 Taka
Raw materials consumed - (Note-27.1)	12,034,764,140	11,120,675,818
Factory overhead - (Note-27.2)	5,000,263,242	4,236,764,832
Manufacturing costs	17,035,027,382	15,357,440,650
Add: Opening work-in-process	232,605,418	357,440,076
	17,267,632,800	15,714,880,726
Less: Closing work-in-process	451,379,546	232,605,418
Cost of goods manufactured	16,816,253,254	15,482,275,308
Add: Opening finished goods	1,739,966,965	1,559,102,590
Add: Opening finished goods of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	53,725,468	-
Cost of goods available for sale	18,609,945,687	17,041,377,898
Less: Closing finished goods	2,265,363,191	1,739,966,965
	16,344,582,496	15,301,410,933

27.1 Raw materials consumed

Opening stock	2,970,817,716	2,306,524,310
Add: Opening stock of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	19,833,561	-
Add: Purchase during the year	13,385,273,294	11,784,969,224
Total materials available	16,375,924,571	14,091,493,534
Less: Closing stock	4,341,160,431	2,970,817,716
Raw materials consumed	12,034,764,140	11,120,675,818

27.2 Factory overhead

Salaries, wages and other benefits	1,783,323,542	1,416,326,623
Factory employees' free lunch, snacks and tea expenses	213,110,826	171,422,970
Uniform for workers	11,403,981	10,360,271
Travelling and conveyance	145,924,333	118,292,278
Stationeries and supplies	62,031,991	74,979,672
Postage, telex, fax and telephone	7,377,194	7,111,832
Repairs and maintenance	459,338,438	436,452,620
Consumable stores and laboratory supplies	238,994,084	212,975,463
Electricity, fuel, gas and water	752,649,437	668,900,756
Rent	5,617,996	6,334,240
Registration and renewals	2,368,755	3,129,934
Insurance premium	15,028,320	9,917,031
Depreciation (Note-5.3)	959,679,524	812,453,874
Cleaning & security services	101,474,850	85,257,766
Automobile expenses	35,090,734	29,279,815
Toll charges	181,596,719	150,781,534
Training expenses	753,148	3,060
Health and safety	6,299,337	17,972,666
Other expenses	18,200,033	4,812,427
	5,000,263,242	4,236,764,832

27.3 Purchases, issues and stocks of raw materials

Purchases, issues and stocks of raw materials used in production of various finished goods formulations are measured and expressed in different units i.e. kilogram, activity, liter, pieces. In view of different units in use, the following table has been presented in value only.

Amount of Taka					
Major material group	Opening stocks	Opening stock of Renata Agro Industries Limited and Purnava Limited as at 01 July 2021 due to merger	Purchases	Consumption	Closing stocks
Bulk materials	1,794,652,896	-	7,768,967,925	6,831,706,965	2,731,913,856
Raw materials	651,546,732	-	2,486,158,602	2,372,827,696	764,877,638
Packing materials	524,618,088	15,965,945	3,059,722,067	2,789,996,944	810,309,156
Agro-based raw materials	-	3,867,616	70,424,700	40,232,535	34,059,781
	2,970,817,716	19,833,561	13,385,273,294	12,034,764,140	4,341,160,431
Consumable stores	21,268,117	15,646,558	137,278,598	114,782,196	59,411,077
Maintenance stores and spares	235,876,171	-	829,663,034	451,371,644	614,167,561
	257,144,288	15,646,558	966,941,632	566,153,840	673,578,638
	3,227,962,004	35,480,119	14,352,214,926	12,600,917,980	5,014,739,069

As per Part II of Schedule XI of the Companies Act, 1994 the quantities of raw materials, purchases and stocks should be expressed in quantitative denomination. However, this could not be provided as the Company deals with large number of products both locally made and imported.

Materials available in local market are procured from the local manufacturers. Materials are imported from the following countries either directly from the manufacturers or suppliers approved by the Drug Administration:

India	Japan	Italy	New Zealand
China	Thailand	Denmark	Indonesia
Hong Kong	South Korea	Spain	Argentina
Singapore	United States of America (USA)	Germany	Brazil
Malaysia	United Kingdom (UK)	Austria	Czech Republic

27(a) Consolidated cost of sales

	2021-2022 Taka	2020-2021 Taka
Renata Limited	16,344,582,496	15,302,055,678
Renata Agro Industries Limited	-	348,232,424
Purnava Limited	-	136,787,877
	16,344,582,496	15,787,075,979

28 Administrative expenses

Salaries, wages and allowances	347,442,116	292,900,534
Travelling and conveyance	41,062,109	32,738,830
Training expenses	3,793,548	2,444,153
Stationeries and supplies	14,087,437	17,068,289
Postage, telex, fax and telephone	8,041,071	12,803,755
Electricity, fuel, gas and water	16,018,488	25,777,407
Employees' free lunch, snacks and tea expenses	49,323,075	41,335,243
Staff uniform	230,299	121,820
Rent	11,737,122	37,675,024
Repairs and maintenance	20,215,922	30,006,790
Govt. taxes and license fees	4,301,819	3,340,997
Cleaning & security services	12,485,780	13,734,532
Depreciation (Note-5.3)	20,149,133	17,393,036
Software and hardware support services	41,434,049	30,335,505
Insurance premium	13,363,726	9,332,556
Automobile expenses	29,094,952	28,049,648
Legal and professional expenses	2,808,322	2,522,257

	2021-2022 Taka	2020-2021 Taka
Audit fees	1,092,500	1,035,000
Board meeting attendance fee	570,000	500,000
Subscription and membership fees	1,683,886	2,689,461
Meeting and corporate expenses	34,284,183	25,328,188
Health and safety	80,527	4,002,806
Other expenses	56,196,463	27,526,579
	729,496,527	658,662,410

28(a) Consolidated administrative expenses

Salaries, wages and allowances	347,442,116	304,162,242
Travelling and conveyance	41,062,109	32,836,415
Training expenses	3,793,548	2,444,153
Stationeries and supplies	14,087,437	17,188,677
Postage, telex, fax and telephone	8,041,071	12,922,288
Electricity, fuel, gas and water	16,018,488	25,777,407
Employees' free lunch, snacks and tea expenses	49,323,075	41,502,806
Staff uniform	230,299	121,820
Rent	11,737,122	13,675,024
Repairs and maintenance	20,215,922	36,532,460
Govt. taxes and license fees	4,301,819	3,885,855
Cleaning & security services	12,485,780	13,735,407
Depreciation	20,149,133	19,098,374
Software and hardware support services	41,434,049	30,335,505
Insurance premium	13,363,726	10,203,886
Automobile expenses	29,094,952	28,452,651
Legal and professional expenses	2,808,322	2,597,007
Audit fees	1,092,500	1,216,510
Board meeting attendance fee	570,000	500,000
Subscription and membership fees	1,683,886	2,744,461
Meeting and corporate expenses	34,284,183	25,328,188
Health and safety	80,527	4,002,806
Other expenses	56,196,463	27,650,709
	729,496,527	656,914,651

29 Selling, marketing and distribution expenses

Salaries, wages and allowances	2,987,659,264	2,418,349,687
Travelling and conveyance	718,995,404	651,524,885
Training expenses	7,810,562	4,219,236
Stationeries and supplies	94,458,326	91,012,001
Postage, telex, fax and telephone	83,922,135	84,432,479
Electricity, fuel, gas and water	37,086,052	35,315,035
Employees' free lunch, snacks and tea expenses	256,516,089	226,916,618
Staff uniform	3,131,912	852,466
Rent	34,193,841	30,524,135
Repairs and maintenance	20,084,208	25,304,894
Govt. taxes and license fees	39,525,546	40,140,024
Cleaning & security services	90,271,855	86,788,592
Depreciation (Note-5.3)	184,118,623	159,247,761
Insurance premium	24,755,127	35,555,262
Automobile expenses	53,091,310	49,654,561
Journal and advertisement	29,635,640	28,113,308
Free sample	159,833,820	148,961,858
Marketing and sales promotional expenses	169,149,313	164,456,546
Product literature	470,639,870	370,277,928
Distribution expenses	743,132,285	689,281,797
Export expenses	132,546,108	64,872,566

	2021-2022 Taka	2020-2021 Taka
Special discount	555,101,328	537,851,505
Business and brand development expenses	296,227,107	265,971,401
Subscription and membership fees	1,110,218	9,717,296
Meeting and corporate expenses	125,497,795	146,022,095
Health and safety	30,474,375	37,565,369
Market research and new products	69,279,700	10,175,812
Other expenses	51,339,057	62,557,043
	7,469,586,870	6,475,662,160

29(a) Consolidated selling, marketing and distribution expenses

Salaries, wages and allowances	2,987,659,264	2,510,179,973
Travelling and conveyance	718,995,404	678,781,004
Training expenses	7,810,562	4,219,236
Stationeries and supplies	94,458,326	92,592,379
Postage, telex, fax and telephone	83,922,135	86,071,629
Electricity, fuel, gas and water	37,086,052	37,748,022
Employees' free lunch, snacks and tea expenses	256,516,089	231,708,057
Staff uniform	3,131,912	852,466
Rent	34,193,841	30,524,135
Repairs and maintenance	20,084,208	27,568,105
Govt. taxes and license fees	39,525,546	40,319,781
Cleaning & security services	90,271,855	86,909,727
Depreciation	184,118,623	163,475,858
Insurance premium	24,755,127	35,681,788
Automobile expenses	53,091,310	50,630,627
Journal and advertisement	29,635,640	31,885,851
Free sample	159,833,820	152,228,741
Marketing and sales promotional expenses	169,149,313	168,863,337
Product literature	470,639,870	403,168,870
Distribution expenses	743,132,285	689,798,098
Export expenses	132,546,108	64,872,566
Special discount	555,101,328	537,851,505
Business and brand development expenses	296,227,107	265,971,401
Subscription and membership fees	1,110,218	9,734,796
Meeting and corporate expenses	125,497,795	147,735,503
Health and safety	30,474,375	37,565,369
Market research and new products	69,279,700	10,175,812
Other expenses	51,339,057	66,682,895
	7,469,586,870	6,663,797,531

30 Other income

Scrap sales and others	3,030,755	20,598,726
Dividend income	5,045,314	4,021,585
Cash incentive received against export	91,404,600	5,804,000
Interest income	212,784,523	371,463,028
Gain/ (loss) on disposal of property, plant and equipment (Note-5.5)	24,191,834	17,602,471
	336,457,026	419,489,810

30(a) Consolidated other income

Scrap sales and others	3,030,755	20,598,726
Dividend income	5,045,314	5,020,518
Cash incentive received against export	91,404,600	5,804,000
Interest income	212,784,523	371,871,528
Gain/ (loss) on disposal of property, plant and equipment	24,191,834	17,602,471
	336,457,026	420,897,243

31 Finance costs

Interest expenses
Exchange loss
Bank charges

2021-2022 Taka

127,933,182
279,125,386
27,485,400
434,543,968

2020-2021 Taka

101,431,374
38,814,833
24,206,008
164,452,215

31(a) Consolidated finance costs

Interest expenses
Exchange loss
Bank charges

127,933,182
279,125,386
27,525,178
434,583,746

104,678,485
38,814,833
24,841,582
168,334,900

32 Tax expenses

Current tax
Deferred tax

975,613,222
36,097,866
1,011,711,088

1,776,239,454
(77,528,329)
1,698,711,125

32.1 Reconciliation of effective tax rate

Profit before tax

Expected income tax using applicable tax rate
Effect of prior year adjustment
Effect of foreseeable non deductible expenses
Effect of lower tax rate

Effective current tax

Effective deferred tax

%

2021-2022 Taka

%

2020-2021 Taka

6,122,668,298
22.50% 1,377,600,367
-6.41% (392,314,436)
0.45% 27,283,735
-0.60% (36,956,444)
15.93% **975,613,222**
0.59% **36,097,866**
16.52% **1,011,711,088**

6,733,532,035
22.50% 1,515,044,708
1.07% 71,734,818
3.12% 210,370,507
-0.31% (20,910,579)
26.38% **1,776,239,454**
-1.15% **(77,528,329)**
25.23% **1,698,711,125**

32(a) Consolidated tax expenses

Current tax
Deferred tax

2021-2022 Taka

975,613,222
36,097,866
1,011,711,088

2020-2021 Taka

1,794,552,362
(78,656,532)
1,715,895,830

32.1(a) Reconciliation of effective tax rate

Profit before tax

Expected income tax using applicable tax rate
Effect of prior year adjustment
Effect of foreseeable non deductible expenses
Effect of lower tax rate
Effect of higher/ minimum tax rate of subsidiaries

Effective current tax

Effective deferred tax

%

2021-2022 Taka

%

2020-2021 Taka

6,122,628,520
22.50% 1,377,591,417
-6.41% (392,314,436)
0.45% 27,292,685
-0.60% (36,956,444)
0.00% -
15.93% **975,613,222**
0.59% **36,097,866**
16.52% **1,011,711,088**

6,777,453,733
22.50% 1,524,927,090
1.06% 71,734,818
3.10% 210,370,507
-0.31% (20,910,579)
0.12% 8,430,526
26.48% **1,794,552,362**
-1.16% **(78,656,532)**
25.32% **1,715,895,830**

33 Net asset value (NAV) per share

The computation of NAV is given below:

	30 June 2022 Taka	30 June 2021 Taka
Equity attributable to the ordinary shareholders	29,412,303,459	25,449,807,788
Weighted average number of ordinary shares outstanding during the year	107,192,982	107,192,982
Net asset value (NAV) per share	274.39	237.42

Last year's NAV has been adjusted due to issuance of bonus shares.

33.1 Weighted average number of ordinary shares outstanding during the year

Opening number of shares	97,448,166
Bonus shares issued in December 2021	9,744,816
	107,192,982

33(a) Consolidated net asset value (NAV) per share

The computation of EPS is given below:

Earnings attributable to the ordinary shareholders (net profit after tax for the year)	29,412,167,159	25,711,400,075
Weighted average number of ordinary shares outstanding during the year (Note-31.1)	107,192,982	107,192,982
Basic earnings per share (EPS)	274.39	239.86

Last year's EPS has been adjusted as per the requirement of IAS 33 "Earnings Per Share".

34 Basic earnings per share (EPS)

The computation of EPS is given below:

	2021-2022 Taka	2020-2021 Taka
Earnings attributable to the ordinary shareholders (net profit after tax for the year)	5,11,09,57,210	5,03,48,20,910
Weighted average number of ordinary shares outstanding during the year	10,71,92,982	10,71,92,982
Basic earnings per share (EPS)	47.68	46.97

Last year's EPS has been adjusted as per the requirement of IAS 33 "Earnings Per Share".

34(a) Consolidated basic earnings per share (EPS)

The computation of EPS is given below:

Earnings attributable to the ordinary shareholders (net profit after tax for the year)	5,110,917,432	5,061,555,446
Weighted average number of ordinary shares outstanding during the year	107,192,982	107,192,982
Basic earnings per share (EPS)	47.68	47.22

Last year's EPS has been adjusted as per the requirement of IAS 33 "Earnings Per Share".

35 Net cash flow from operating activities

Profit before tax	6,122,668,298	6,733,532,035
Adjustments for:		
Depreciation and amortization expenses	1,169,034,360	989,094,671
Provision for bad debts & others	46,876,869	13,137,681
Finance costs	434,543,968	164,452,215
(Gain)/ loss on disposal of property, plant and equipment	(24,191,834)	(17,602,471)
Loss on sale of birds	6,404,969	-
Cash generated from operations before changes in working capital	7,755,336,630	7,882,614,131

	2021-2022 Taka	2020-2021 Taka
<i>Adjustments for:</i>		
(Increase) in inventories	(2,464,242,980)	(802,635,698)
(Increase) in trade receivables	(326,302,151)	(296,648,961)
Decrease/ (increase) in other receivables	140,415,449	(240,565,455)
(Increase) in advances, deposits and prepayments	(249,277,871)	(56,992,638)
Increase/ (decrease) in trade payables	92,093,638	(109,616,371)
(Decrease) in other payables	(337,741,792)	(193,902,913)
Cash generated by operations	4,610,280,923	6,182,252,095
Finance costs	(271,099,653)	(151,499,311)
Payment of tax	(1,329,841,519)	(1,801,542,908)
Net cash flow from operating activities	3,009,339,751	4,229,209,876

35(a) Consolidated net cash flow from operating activities

Profit before tax	6,122,628,520	6,777,453,733
<i>Adjustments for:</i>		
Depreciation and amortization expenses	1,169,034,360	1,029,225,077
Provision for bad debts & others	46,876,869	7,178,891
Finance costs	434,583,746	168,334,900
(Gain)/ loss on disposal of property, plant and equipment	(24,191,834)	(17,602,471)
Loss on sale of birds	6,404,969	-
Cash generated from operations before changes in working capital	7,755,336,630	7,964,590,130
<i>Adjustments for:</i>		
(Increase) in inventories	(2,464,242,980)	(780,740,076)
(Increase) in trade receivables	(326,302,151)	(304,931,460)
Decrease/ (increase) in other receivables	140,415,449	(237,094,053)
(Increase) in advances, deposits and prepayments	(249,277,871)	(49,207,135)
Increase/ (decrease) in trade payables	92,093,638	(120,489,769)
(Decrease) in other payables	(337,741,792)	(184,888,059)
Cash generated by operations	4,610,280,923	6,287,239,578
Finance costs	(271,136,116)	(155,381,996)
Payment of tax	(1,329,841,519)	(1,811,462,006)
Net cash flow from operating activities	3,009,303,288	4,320,395,576

36 Net operating cash flow per share

The computation of net operating cash flow per share is given below:

Net cash generated from operating activities	3,009,339,751	4,229,209,876
Weighted average number of ordinary shares outstanding during the year	107,192,982	107,192,982
Net operating cash flow per share	28.07	39.45

Last year's net operating cash flow per share has been adjusted due to issuance of bonus shares.

Net operating cash flow per share stood at Taka 28.07 against Taka 39.45 of 2020-2021 due to increase in payment of VAT, payment to suppliers & employees and finance costs during 2021-2022.

36(a) Consolidated net operating cash flow per share

The computation of net operating cash flow per share is given below:

Net cash generated from operating activities	3,009,303,288	4,320,395,576
Weighted average number of ordinary shares outstanding during the year	107,192,982	107,192,982
Net operating cash flow per share	28.07	40.30

Last year's net operating cash flow per share has been adjusted due to issuance of bonus shares.

37 Payments to Directors and officers

The aggregate amount paid (except Directors' fees for attending board meetings) during the year to Directors and officers of the Company is disclosed below as required by the Securities and Exchange Rules-1987:

	Amount in Taka	
	Directors	Officers
Short-term employee benefits		
Remuneration	17,422,850	1,024,675,400
House rent	9,099,450	573,907,709
Bonus	7,009,522	325,046,033
Conveyance allowance and transport	3,580,328	246,401,886
Other welfare expenses	6,527,868	67,234,108
Post-employment benefits		
Contribution to provident fund	1,682,285	73,179,260
Gratuity	2,102,856	43,390,876
	47,425,159	2,353,835,272

37.1 During the year, no payment has been made to any non-executive Directors for any special services rendered.

38 Contingent liabilities

38.1 There are contingent liabilities on account of unresolved disputed corporate income tax assessments involving tax claims by the tax authority amounting to Tk. 3,555,060 for the assessment year 2000-01, Tk. 11,888,503 for the assessment year 2013-14 and Tk. 14,478,424 for the assessment year 2014-2015 which are pending before the Hon'ble High Court Division of the Supreme Court, and Tk. 14,486,696 for the assessment year 2021-2022 has been filed for appeal to the Taxes Appellate Tribunal.

38.2 The Assistant Commissioner of Taxes issued a notice vide letter No. SA-162/2014-2015/82 on 01 September 2014 claiming that during the assessment year 2008-09 (income year 2007), the Company did not deduct VAT on certain accounting heads amounting to Tk. 245,280,917 and tax file reopened accordingly under Section 93 of the Income Tax Ordinance, 1984. Total tax amount was calculated Tk. 73,584,275 on that claimed amount by using the prevailing corporate tax rate 30%. However, the Hon'ble High Court delivered the verdict in favour of the Company on 6 January 2016 but the National Board of Revenue has made leave to appeal to the Supreme Court Appellate Division against the verdict.

39 Claims by the Company not acknowledged as receivable

None as at 30 June 2022.

40 Commitments

On the statement of financial position date, the Company is enjoying unfunded credit facilities from the following banks:

	30 June 2022 Taka	30 June 2021 Taka
Letters of credits (Note-40.1)	3,781,347,125	5,514,021,645
Outstanding guarantees issued by the banks	355,494,006	317,403,717
Capital expenditure commitments	3,951,146,735	8,471,958,113
	8,087,987,866	14,303,383,475

40.1 Letters of credits

	Limit		
Standard Chartered Bank	4,950,000,000	6 639,862,471	1,232,403,959
Eastern Bank Limited	757,300,000	553,655,794	237,884,985
The City Bank Limited	2,200,000,000	533,634,656	607,582,355
Citibank N.A.	2,691,360,000	626,151,072	887,597,616
Commercial Bank of Ceylon PLC	3,250,000,000	132,171,561	1,992,851,519
Bank Asia Limited	2,100,000,000	581,368,432	555,701,211
BRAC Bank Limited	2,500,000,000	714,503,139	-
	18,448,660,000	3,781,347,125	5,514,021,645

41 Dividend paid to non-resident shareholders

Final dividend paid to non-resident shareholder, Business Research International Corp. Inc. for the year 2020-2021 was Tk. 245,793,339.60 equivalent to US\$ 2,799,468.56 for their 21,189,081 shares.

42 Disclosure as per requirement of Schedule XI, Part II of the Companies Act, 1994

42.1 Employee position of Renata Limited as per requirement of schedule XI, part II, Para-3

The company engaged 10,380 (8,957 as at 30 June 2021) employees as at 30 June 2022, of which 6,914 (5,845 as at 30 June 2021) are permanent employees and 3,466 (3,112 as at 30 June 2021) are casual and temporary workers as required. All employees received total salary of above Tk. 36,000 per annum.

42.2 Capacity utilization

Production capacity and current utilization as required by the Companies Act 1994, Schedule-XI, para-7. The Company operates multi-product plants. As a result plant utilization is not comparable with capacity due to variation of product mix. However, actual production and utilization for major product groups are as follows:

Major product group / Unit	Capacity (In '000)	2021-2022		2020-2021	
		Actual production (In '000)	Utilization %	Actual production (In '000)	Utilization %
Sterile dry fill (injectable) / Vials	8,155	10,884	133.46%	10,095	123.79%
Sterile liquid (inj) / Vials / Ampoules	15,350	24,634	160.48%	21,860	142.41%
Ointments / Tubes	1,500	967	64.50%	605	40.33%
Capsules and tablets / Cap / Tab	2,116,800	3,167,868	149.65%	2,981,467	140.85%
Oral liquid & dry syrup / Bottles	19,650	36,928	187.93%	29,527	150.27%
Water for injection / Ampoules	9,400	9,854	104.83%	11,105	118.13%
Premix feed supplement / Kg	6,500	8,233	126.67%	5,912	90.96%
Premix feed supplement / Sachets	11,800	17,378	147.27%	15,009	127.19%
Oral saline / Sachets	540,000	401,991	74.44%	491,147	90.95%
Potent products / Tablets	2,650,000	2,382,056	89.89%	4,189,561	158.10%

43 Payments / receipts in foreign currency

43.1 During the year, the following payments were made in foreign currency for imports, calculated on CIF basis of:

	Foreign currency USD	Local currency Taka
Raw, bulk and packing materials	115,553,235	9,932,956,089
Machinery and spares	62,225,666	5,348,918,264
	177,778,901	15,281,874,353

43.2 Foreign exchange was earned in respect of the following:

Export of goods on FOB	USD	14,069,426
------------------------	-----	-------------------

44 Related party disclosures

During the year the Company carried out a number of transactions with related parties in the normal course of business on an arm's length basis. Name of those related parties, nature of those transactions and their total value have been shown in the table below in accordance with IAS 24 "Related Party Disclosures".

Amount in Taka				
Name of related parties	Relationship	Nature of transactions	Value of Transaction	Balance at year end
1. Sajida Foundation	Parent	Dividend paid	720,624,476	-
2. Renata (UK) Limited	Subsidiary	Advance	-	169,337

45 General

- 1) All the figures in the financial statements represent Bangladesh Taka currency rounded off to the nearest Taka.
- 2) The comparative information have been disclosed in respect of the year 2021-2022 for all numerical information in the financial statements and also the narrative and descriptive information as found relevant for understanding of the current year's financial statements.

46 Events after the reporting period

Amount to be distributed as dividend

The Board of Directors in their meeting held on 22 October 2022 have recommended cash dividend @ 140% per share of Taka 10 each aggregating Taka 1,500,701,748 and stock dividend @ 7% of Taka 10 each aggregating Taka 75,035,087 for the year ended 30 June 2022 subject to approval of the shareholders in the Annual General Meeting scheduled to be held on 17 December 2022. The financial statements for the year ended 30 June 2022 do not include the effects of the above cash dividend and stock dividend which will be accounted for in the period when shareholders' right to receive the payment will be established. The declared dividend is also in compliance with section 16G of Income Tax Ordinance 1984.

Other events

There are no other material events identified after the statement of financial position date which require adjustment or disclosure in these financial statements.



CEO & Managing Director



Director



Chief Financial Officer

Place: Dhaka
Date: 22 October 2022

ANNEXURE-A

FINANCIAL PERFORMANCE OF RENATA LIMITED BY NATURE OF BUSINESS ACTIVITIES FOR THE YEAR ENDED 30 JUNE 2022

	Agro-based products Taka	Other than agro-based products Taka	Total Taka
Turnover	251,123,756	30,819,430,792	31,070,554,548
Cost of sales	(219,856,306)	(16,124,726,190)	(16,344,582,496)
Gross profit	31,267,450	14,694,704,602	14,725,972,052
Administrative expenses	(3,938,398)	(725,558,129)	(729,496,527)
Selling, marketing and distribution expenses	(3,273,232)	(7,466,313,638)	(7,469,586,870)
Operating profit	24,055,820	6,502,832,835	6,526,888,655
Other (loss)/ income	(6,336,513)	342,793,539	336,457,026
Finance costs	(2,640,683)	(431,903,285)	(434,543,968)
Profit before contribution to workers' participation fund	15,078,624	6,413,723,089	6,428,801,713
Contribution to workers' participation and welfare fund	(718,030)	(305,415,385)	(306,133,415)
Profit before tax	14,360,594	6,108,307,704	6,122,668,298
Tax expenses			
Current tax	(2,154,089)	(973,459,133)	(975,613,222)
Deferred tax	(6,088,670)	(30,009,196)	(36,097,866)
	(8,242,759)	(1,003,468,329)	(1,011,711,088)
Net profit after tax for the year	6,117,835	5,104,839,375	5,110,957,210
Other comprehensive income			
Net profit after tax for the year	6,117,835	5,104,839,375	5,110,957,210
Items that will not be reclassified to profit or loss			
Fair value adjustment on investment in shares, net of tax	-	1,793,358	1,793,358
Realised gain on disposal of shares	-	197,467	197,467
Total comprehensive income for the year	6,117,835	5,106,830,200	5,112,948,035

Renata (UK) Limited and Renata Pharmaceutical (Ireland) Limited

EU regulations stipulate that only European corporate entities may conduct medicines business within its borders. Accordingly, we set up Renata UK. However, in the event of Brexit, our UK entity would no longer be sufficient to carry out operations within the EU. Therefore, we established a subsidiary company in the name of Renata Pharmaceutical (Ireland) Limited to fulfill the regulatory requirement. The company has not made any financial transaction yet.

CORPORATE HEADQUARTERS

Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh
PABX: (880 -2) 800 1450-54, Fax: (880 -2) 800 1446
e-mail: renata@renata-ltd.com, Website: www.renata-ltd.com

MANUFACTURING SITES

Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh, PABX: (880 -2) 801 1012-13
Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, Bangladesh, Tel: 06825-55148
Kashor, P.O.: Seed Store, P.S.: Bhaluka, Mymensingh, Bangladesh.

DISTRIBUTION CENTRES

Burigonga Depot

Teghoria (Nuton Raster Moor),
South Keranigonj, Dhaka-1311
Mobile: 01847028891
e-mail: dhaka@renata-ltd.com

Gazipur Depot

E/214, Joorpukurpar
Joydebpur, Gazipur-1700
Mobile: 01817045729
e-mail: gazipur@renata-ltd.com

Bhairab Depot

808, Bhairabpur,
Bhairab-2350
Phone & Fax: 02-9470265
Mobile: 01814651002
e-mail: bhairab@renata-ltd.com

Turag Depot

House-39, Road-06
Block-C, Turag Thana Road
Dhour, Turag, Dhaka-1230
Phone: 02-8981813
Fax: 02-8981898
Mobile: 01833316984
e-mail: turag@renata-ltd.com

Tangail Depot

Holding No.1135, Biswas Betka,
Atpukurpar, Dhaka Road,
Tangail Sadar, Tangail-1900
Phone & Fax: 0921-61158
Mobile: 01847-186614
e-mail: tangail@renata-ltd.com

Brahmaputra Depot

Bypass Mour, Dhaka Road,
Digarkanda, Mymensingh-2200
Mobile: 01817049456
e-mail: mymensingh@renata-ltd.com

Surma Depot

Sylhet Sunamgonj By-pass Road,
Lotipur, Dakshin Surma, Sylhet - 3100
Phone: 0821-718407
Mobile: 01817049367
e-mail: sylhet@renata-ltd.com

Chattogram Depot

Prashanti Tower-3,
Prashanti R/A Road,
Colonel Hat, Pahartali,
Chattogram-4202
Phone: 02-43151450
Fax: 02-43151451
Mobile: 01817049449
e-mail: chittagong@renata-ltd.com

Chokoria Depot

Hospital Road,
Near Khodar Kup,
Chokoria-4740
Phone & Fax: 034-2256251
Mobile: 01817041015
e-mail: chakaria@renata-ltd.com

Gomti Depot

Holding No. 48/01
Ward No. 23,
Batabaria, Sadar Dakhin,
Cumilla-3500
Mobile: 01817049452
e-mail: comilla@renata-ltd.com

Kirtonkhola Depot

Amtola Moor, Band Road,
Barishal-8200
Phone & Fax: 0431-71249
Mobile: 01817049375
e-mail: barisal@renata-ltd.com

Feni Depot

Dhaka Chittagong Highway,
Debipur, Fatepur, Shorshodi,
Feni-3902
Ling 3 No.: +88096877403
Mobile: 01817049531
e-mail: feni@renata-ltd.com

Madhumati Depot

Abd Allah Jahir Uddin Lal Miah
Sarak, Kuthibari-1, Kamalpur,
Faridpur-7800
Phone & Fax: 0631-62174
Mobile: 01817049370
e-mail: faridpur@renata-ltd.com

Khulna Depot

62, KDA, Commercial Area,
Jalil Swaroni,
Rayer Mohol, Boyra,
Khulna-9100
Phone & Fax: 041-720154
Mobile: 01817049382
e-mail: khulna@renata-ltd.com

Jashore Depot

Sarder Vila,
Holding No-1021/B
Airport Road, Arabpur,
Jashore-7400
Phone : 0421-60851
Mobile: 01817049381
e-mail: jessore@renata-ltd.com

Rajshahi Depot

C-212, Laxmipur,
Greater Road,
Rajshahi-6000
Phone : 0721-772893
Mobile: 01817049459
e-mail : rajshahi@renata-ltd.com

Korotoa Depot

Betgari, Dhaka Road,
Banani, Bogura-5800
Phone & Fax: 051-66379
Mobile: 01817049376
e-mail: bogra@renata-ltd.com

Teesta Depot

Holding No. 5836,
Uttam, Hajirhat,
Rangpur-5400
Mobile: 01817049072
e-mail: rangpur@renata-ltd.com

Atrai Depot

Holding No. 1266,
Bhobainagar, Sadar,
Dinajpur-5200
Mobile: 01833-316987
e-mail: dinajpur@renata-ltd.com

PROXY FORM

Revenue Stamp of Taka 20.00
--

I/We, the undersigned, being a member of the above named Company hereby appoint

Mr./Ms. _____

Of (Address) _____

as my/our proxy to vote and act for me/us and on my/our behalf, at the 49th Annual General Meeting of the Company, to be held through Digital Platform on Saturday, December 17, 2022 at 11.30 am and at any adjournment thereof.

Specimen Signature (s) of the Shareholder (s) _____ Date: _____

Name in Block Letters _____

Address _____

Folio/BO No. _____

Date: _____

Signature of the Proxy

Shareholders' Attendance Slip

I/We hereby record my/our attendance at the 49th Annual General Meeting being held on
Saturday, December 17, 2022 through Digital Platform at 11.30 am

Name of Shareholder(s).....

Register Folio/BO No.

holding of Ordinary Shares of Renata Limited.

Signature (s) of Shareholder(s)



Renata Limited

Corporate Headquarters: Plot # 1, Milk Vita Road, Section-7, Mirpur, Dhaka-1216, Bangladesh, GPO Box No. 303
Phone: 8001450, 8001454 (PABX), Fax: 880-2-8001446, Website: www.renata-ltd.com

Find us on **facebook** at <http://www.facebook.com/renatalimited>